

CURRICULUM VITAE**ROY CURTISS III**

Professor, Department of Infectious Diseases and Pathology, College of Veterinary Medicine, University of Florida, Gainesville, FL 32611

BIRTHDATE: May 27, 1934

BIRTHPLACE: New York, NY

NATIONALITY: USA

EDUCATION

B.S.	Agriculture	Cornell University, Ithaca, NY	1956
Ph.D.	Microbiology	University of Chicago, Chicago, IL	1962

PROFESSIONAL CAREER

2015-present Professor, Department of Infectious Diseases and Pathology, College of Veterinary Medicine, University of Florida, Gainesville, FL

2015-present University Professor Emeritus, Arizona State University, Tempe, AZ

2014-2015 University Professor of Microbiology, Arizona State University, Tempe, AZ

2010-2015 Director, Center for Microbial Genetic Engineering, Arizona State University, Tempe, AZ

2007-2015 Director, Center for Infectious Diseases and Vaccinology, Arizona State University, Tempe, AZ

2004-2006 Co-Director, Center for Infectious Diseases and Vaccinology, Arizona State University, Tempe, AZ

2004-2015 Professor of Life Sciences, School of Life Sciences, Arizona State University, Tempe, AZ

2005-Present George William and Irene Koechig Freiberg Professor of Biology Emeritus, Washington University, St. Louis, MO

1984-2005 George William and Irene Koechig Freiberg Professor of Biology, Washington University, St. Louis, MO

1983-2005 Professor, Department of Biology, Washington University, St. Louis, MO

1993-2000 Founder, Member Board of Directors, MEGAN Health, Inc., St. Louis, MO

1998-1999 Vice President of Research, MEGAN Health, Inc., St. Louis, MO

1991-1994 Professor/Collaborator, Iowa State University, Ames, IA

1991-1994 Director, Center for Plant Science & Biotechnology, Washington University, St. Louis, MO

1983-1993 Chairman, Department of Biology, Washington University, St. Louis, MO

1983-1991 Professor, Cellular and Molecular Biology, Washington University School of Dental Medicine, St. Louis, MO

1983-1987 Adjunct Professor, Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL

1982-1983 Acting Chairman, Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL

1981-1982 Vice Chairman, Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL

1981-1983 Founder, Director & Senior Scientist, Cystic Fibrosis Research Center, University of Alabama at Birmingham, Birmingham, AL

1978-1983 Charles H. McCauley Professor of Microbiology, University of Alabama at Birmingham, Birmingham, AL

1972-1983 Senior Scientist, Institute of Dental Research, University of Alabama at Birmingham, Birmingham, AL

1972-1983 Senior Scientist, Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL

1972-1983 Professor, Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL

1971-1972 Interim Director, University of Tennessee - Oak Ridge Graduate School of Biomedical Sciences, Oak Ridge, TN

1970-1972 Associate and Interim Director, University of Tennessee - Oak Ridge Graduate School of Biomedical Sciences, Oak Ridge, TN

1969-1972 Professor, University of Tennessee - Oak Ridge Graduate School of Biomedical Sciences, Oak Ridge, TN

1969-1972 Group Leader, Microbial Genetics and Radiation Microbiology Group, Biology Division, Oak Ridge National Laboratory, Oak Ridge, TN

1967-1969 Lecturer, University of Tennessee - Oak Ridge Graduate School of Biomedical Sciences, Oak Ridge, TN

1965-1972 Lecturer, Department of Microbiology, University of Tennessee, Knoxville, TN

1963-1972 Biologist, Biology Division, Oak Ridge National Laboratory, Oak Ridge, TN

1960-1962 US Public Health Service Predoctoral Fellow, Department of Microbiology, University of Chicago, Chicago, IL

1958-1960 University Fellow, Department of Microbiology, University of Chicago, Chicago, IL
 1956-1958 Junior Technical Specialist, Biology Division, Brookhaven National Laboratory, Upton, NY
 1955-1956 Laboratory Instructor and Research Assistant, Department of Poultry Husbandry, Cornell University, Ithaca, NY

PROFESSIONAL ACTIVITIES

University of Florida, Gainesville, FL

Arizona State University, Tempe, AZ

2011-2014 Member, Research and Collaboration Advancement Team, The Biodesign Institute
 2010-2011 Member, Microbial Ecology Search Committee, SoLS
 2009-2010 Chairman, Microbiology and Immunology Search Committee, SoLS
 2008-2009 Member, Strategic Planning Committee, SoLS
 2008 Member, Septennial Review Committee, SoLS
 2007-2009 Member, Directorate, The Biodesign Institute
 2007-2008 Member, Department of Animal Care and Technologies Director Search Committee
 2006-2007 Member, Graduate School Committee on Interdepartmental Transdisciplinary Graduate Education
 2005-2007 Member, School of Life Sciences Executive Committee
 2005 Member, Neurosciences Search Committee
 2005 Chairman, Bacterial Pathogenesis Search Committee, SoLS
 2004 Member, Mycobacterial Pathogenesis Search Committee, SoLS

Washington University, St. Louis, MO

1998-2004 Member, Center for Infectious Disease Research Advisory Board
 1994-1998 Member, Department of Biology Advisory Committee
 1991-1992 Member, Division Comparative Medicine Chairman Search Committee
 1991-1993 Member, Animal Studies Committee
 1989-1993 Member, Biotechnology Advisory Board
 1989-1991 Member, Committee to Prepare for the 21st Century
 1989-1991 Member, Psychology Chairman Search Committee
 1988-1993 Member, Washington University Committee on AIDS
 1988-1994 Member, Executive Committee, Center for Plant Science and Biotechnology
 1985-1988 Chancellor's Representative to Board of Directors of the Missouri Botanical Garden
 1985-1991 Member, Biosafety Committee
 1984-1986 Member-at-Large, Senate Council
 1984-1993 Chairman, Tyson Research Center Advisory Committee
 1983-1993 Member, Executive Council, Division of Biology and Biomedical Sciences
 1983-1984 Member, Faculty of Arts and Sciences Dean Search Committee

Center for Research in Diagnosis and Discovery, New York, NY

2014-present Member, Scientific Advisory Board

Northeast Biodefense Center (NBC), New York, NY

2011-2013 Member, Scientific Advisory Board

Bacilligen, Inc., Rockville, MD

2007-2011 Board of Advisors

Midwest MRCE Scientific Advisory Committee

2003-2004 Member

American Type Culture Collection, Manassas, VA

2003-Present Presidential Advisor

Missouri Seed Capital Investment Board, Jefferson City, MO

2000-2003 Member

Apovia (EVAX) Technologies, Inc., Munich, Germany

1999-2002 Science Advisor

Whitfield School, St. Louis, MO

2002-2005 Executive Committee of the Board of Directors

1997-2005 Board of Directors

Ajinomoto Company, Inc., Tokyo, Japan

1997-1998 Science Advisor

MEGAN Health Inc., St. Louis, MO

1998-1999 Vice President of Research

1992-1999 Science Advisor

1989-2000 Board of Directors

1989 Founder

Immuno A.G., Vienna, Austria

1991-1994 Science Advisor

Vicam, Cambridge, MA

1991-1993 Science Advisor

Agrigenetics, Madison, WI

1989-1991 Science Advisor

Mycogen Corporation, La Jolla, CA

1988-1989 Science Advisor

Crop Genetics International, Hanover, MD

1987-1990 Science Advisor

Sungene Technologies Corporation, San Jose, CA

1987-1989 Board of Directors

1982-1989 Science Advisor

Praxis Biologics, Inc., Rochester, NY

1985-1988 Science Advisor

Molecular Engineering Associates, Inc., Birmingham, AL

1983-1987 Science Advisor

1981-1984 Board of Directors

1981 Founder

University of Alabama at Birmingham, Birmingham, AL

1981-1982 Member, Biochemistry Chairman Search Committee

1980-1983 Member, Joint Health Sciences Faculty Status Committee

1979-1983 Member, Graduate School Advisory Committee

1979-1981 Member, Comprehensive Cancer Center Review Committee

1977 Member, Graduate School Dean Search Committee

1976-1983 Program Director, Infectious Diseases Postdoctoral Training Program

1976-1983 Member, Promotions Committee, Department of Microbiology

1975-1983 Program Director, Molecular, Cellular and Medical Genetics Postdoctoral Training Program

1974-1983 Member, Biosafety Committee

1973-1982 Program Director, Molecular Cell Biology Graduate Program

1973-1982 Chairman, Molecular Cell Biology Graduate Committee

1973-1975;

1976-1978 Member, Cancer Research and Training Center Review Committee

1973-1983 Member, Graduate School Council

1973-1975 Chairman, Graduate Committee, Department of Microbiology
 1972-1975 Member, Graduate Committee, Department of Microbiology
 1972-1975 Member, Coordinating Council, Department of Microbiology

University of Tennessee, Knoxville, TN

1971-1972 Member, Biomedical Engineering Institute Committee

University of Tennessee-Oak Ridge Graduate School of Biomedical Sciences, Oak Ridge, TN

1971-1972 Program Director, NIGMS Cellular and Molecular Biology Training Grant
 1969-1971 Chairman, Genetics Curriculum Committee
 1969-1971 Member, Postdoctoral Investigatorship Review Committee

Biology Division, Oak Ridge National Laboratory, Oak Ridge, TN

1966-1969 Chairman, Genetics Seminar and Journal Club Committee

NATIONAL AND INTERNATIONAL ACTIVITIES

2015 Member, International Scientific Advisory Committee (ISAC) for the 17th International Congress of Mucosal Immunology (ICMI 2015)
 2014 Member, Scientific Advisory Board, Military Infectious Diseases Research Program (MIDRP)
 2014 Member, NIH-USDA Review Panel for Research in Biomedicine and Agriculture
 2014 Member, NIH Special Emphasis Panel, Cooperative Centers on Human Immunology (U19)
 2013 Member, International Scientific Advisory Committee (ISAC) for the 16th International Congress of Mucosal Immunology (ICMI 2013)
 2013-Present Member, Vaccine Council of 100
 2012-Present Member, External Advisory Committee, Public Health Preparedness for Infectious Diseases Program (PHPID) at the Ohio State University
 2012 Member, NIH Topics in Microbial Diseases Study Section
 2012-Present Member, The American Association of Immunology (AAI)
 2011-2014 Member, Bill and Melinda Gates Foundation, Grand Challenges Explorations Review Panel, Rounds 6-9
 2011-Present Member, National Research Council (NRC) Standing Committee for the Review of Food Safety and Defense Risk Assessments, Analyses and Data
 2011-2014 Member, Scientific Advisory Board, Northeast Biodefense Center (NBC)
 2010 Member, Poultry Pre-Harvest Peer Review Panel, USDA, Office of Scientific Quality Review (OSQR)
 2010-2011 Member, International Scientific Advisory Committee, International Congress of Mucosal Immunology
 2009 Member, NIH Special Emphasis Panel, Immune Defense Mechanisms at the Mucosa
 2009 Member, International Scientific Advisory Committee, International Congress of Mucosal Immunology
 2008-2009 Member, American Society of Microbiology, Culture Collections Colloquium Planning Committee
 2008-2010 Member, Bill and Melinda Gates Foundation, Grand Challenges Explorations Review Panel, Rounds 1-4
 2007 Member, Review Panel, University of Michigan Medical School's Endowment for the Basic Sciences (EBS)
 2006-2009 Member, Steering Committee, International Congress of Mucosal Immunology
 2006 Member, FDA Site Visit, Center for Biologics Evaluation and Research
 2006-2010 Member, Board of Governors, Arizona Arts, Science and Technology Academy
 2005-2008 Alternate, Committee on Election to Fellowship, American Academy of Microbiology
 2004 Member, NIH Vaccine Study Section
 2003 Chairman, NIH Bacterial BioDefense Study Section
 2003-2004 Member, Finance Committee, American Society for Microbiology
 2003 Ad hoc Member, NIH BM-2 Vaccine Study Section
 2002-2003 Member, Nominating Committee, American Society for Microbiology
 2002 Member, NIDCR Scientific Advisory Panel
 2001-Present Member, National Academy of Sciences
 2001-2004 Division Councilor at Large, Council Policy Committee and Council, American Society for Microbiology
 2001-2003 Member, NIH Vaccine Research Study Section

2000-Present	Member, Board of Executive Editors, <u><i>Escherichia coli & Salmonella: Cellular and Molecular Biology</i></u> , The Electronic Edition, ASM Press
2000-2005	Editor-in-Chief and Chairman Board of Executive Editors, <u><i>Escherichia coli & Salmonella: Cellular and Molecular Biology</i></u> , The Electronic Edition, ASM Press
1998-2003	Member, Advisory Committee-Bacteriology Program, American Type Culture Collection
1996-2004	Heiser Trust, Scientific Advisory Board
1999-2001	Division Z Councilor at Large, American Society for Microbiology Council
1999	Chairman, NIH Panel on Leprosy Research in the Post-Genome Era
1998-1999	Member, Compensation Committee, American Type Culture Collection
1996-1999	Member, Molecular Biology Advisory Committee, American Type Culture Collection
1995-1999	Member, Board of Trustees, American Type Culture Collection
1995-1999	Member, Executive Committee of Board of Trustees, American Type Culture Collection
1995-1997	Member, Development and Public Affairs Committee, American Type Culture Collection
1995-1997	Member, Trustees Nominating Committee, American Type Culture Collection
1993-1996	Editor, <u><i>Escherichia coli & Salmonella: Cellular & Molecular Biology</i></u> , 2nd ed., ASM Press
1992-1995	Member, Executive Committee of Board of Directors, American Type Culture Collection
1993-1995	Chairman, Science Committee, American Type Culture Collection
1989-1995	Member, Board of Directors, American Type Culture Collection
1993-1994	Member, American Society for Microbiology Nominating Committee
1991-1994	Division Councilor at Large, Council Policy Committee and Council, American Society for Microbiology
1991	Member, Review Panel, Undergraduate Biological Sciences Education, Howard Hughes Medical Institute
1989-1991	Division B Councilor, American Society for Microbiology Council
1988	Organizer, Workshop on Computerization of Data Bases for Genetic Stock Collections
1987-1999	Member, Editorial Board, <u>ASM News</u>
1987	Member, NIH Research Centers for Oral Biology Review Committee
1987	Ad hoc Member, National Institute of General Medical Sciences Council
1986	Co-organizer, ASM Conference on Streptococcal Genetics
1985-1992	Editor, <u>Infection and Immunity</u>
1984-1989	Member, Cystic Fibrosis Foundation Research Development Program Review Committee
1983-1986	Member, WHO Steering Committee on the Immunology of Tuberculosis
1982	Visiting Professor, University of Oklahoma
1980-1983	Member, NIH Genetic Basis of Disease Review Committee (Chairman 1981-1983)
1978-1981	Vice President, Council for Advancement of Scientific Writing
1977-1980	Branch Councilor at Large, Council Policy Committee and Council, American Society for Microbiology
1977	Southeastern Branch Councilor, Council American Society for Microbiology Council
1976-1981	Member, Board of Directors, Council for Advancement of Scientific Writing
1976	Member, International Council of Scientific Unions Ad Hoc Committee on Recombinant DNA
1975-1978	Member, NSF Genetic Biology Advisory Panel
1974-1977	Member, NIH Recombinant DNA Molecule Advisory Committee
1973	Visiting Professor, Universidad Catolica de Chile, Santiago, Chile
1972	Visiting Professor, University of Puerto Rico, San Juan, PR
1970-1976	Editor, <u>Journal of Bacteriology</u>
1969	Visiting Professor, Instituto Venezolano de Investigaciones Cientificas, Caracas, Venezuela
1966-1970	Editorial Board Member, <u>Journal of Bacteriology</u>

HONORS

2014	University Professor of Microbiology, School of Life Sciences, Arizona State University
2014	Recipient, Arizona BioIndustry Association's Pioneer Award for Lifetime Achievement
2014	Lifetime Achievement Award Laureate, American Society of Microbiology
2014	Recipient, Founders' Day Faculty Research Award, Arizona State University Alumni Association
2013	Keynote Speaker, 4 th ASM Conference on <i>Salmonella</i> : The Bacterium, the Host and the Environment, Boston, MA
2013	Rubbo Orator, Australian Society for Microbiology (ASM), Annual Scientific Meeting, Adelaide
2013	Recipient of the Rubbo Medallion, Australian Society for Microbiology (ASM), Annual Scientific Meeting, Adelaide
2013	Honoree, ASU Faculty Achievement Award, Defining Edge Research and Creative Work – Natural Sciences/Math

- 2012 Recipient of the McLaughlin Medallion, Galveston National Laboratory, University of Texas Medical Branch
- 2012 Faculty of 1000, Kong et al. 2012. PNAS USA, listed below in Publications
- 2012 Invited Speaker, Innovet, International Conference for Veterinary and Food Industries, St. Hyacinthe, Canada
- 2012 Austin and Joan Larsen Distinguished Visiting Lecturer, Washington State University, Pullman
- 2012 Invited Speaker, Special Lecture, Summer School on Infection Research, Helmholtz Centre for Infection Research, Juliusruh, Rügen, Germany
- 2012 Invited Speaker, George B. Saul Lectures, Middlebury College, Middlebury, VT
- 2012 Invited Speaker, College of Veterinary Medicine, University of Minnesota, St. Paul
- 2011 Invited Speaker, International Symposium: Major Emergent Animal Diseases, Public Health and Food Safety, Chengdu, PR China
- 2011 Invited Speaker, International symposium: New Approaches to Animal Disease, Food Safety and Public Health for the 21st Century, Beijing, PR China
- 2011 Maurice Ogur Memorial Lecture, University of Southern Illinois, Carbondale
- 2010 Honorary Diplomate, American College of Veterinary Microbiologists
- 2010 Honorary Professor, East China University of Science and Technology, Shanghai, P.R. China
- 2010 Keynote Speaker, BIT Life Sciences' 2nd Annual World Vaccine Congress-2010, Beijing, P.R. China
- 2010 Invited Speaker, UC Irvine Microbiology and Molecular Genetics Graduate Student Sponsored Seminar Series, Irvine, CA
- 2010 Invited Speaker, South Texas Center for Emerging Infectious Diseases (STCEID) Seminar Series, San Antonio, TX
- 2010 Distinguished Lecturer, Los Alamos National Laboratory Director's Colloquium Series, Los Alamos, NM
- 2009 Cornell University, College of Agriculture and Life Sciences Outstanding Alumni Award, Ithaca, NY
- 2009 Distinguished Lecturer, A Frank N. Nelson Lecture Series, Montana State University, Bozeman, MT
- 2009 Faculty of 1000 Biology, Baek et al. 2009. J. Bacteriology, listed below in Publications
- 2008 Invited Speaker, Infection, Immunology and Vaccine Honored Speaker Program, Louisiana State University Health Sciences Center
- 2008 Invited Speaker, Wellcome Trust Advanced Course Molecular Basis of Bacterial Infection, Sanger Institute
- 2008 Faculty of 1000 Biology, Zhao et al. 2008. PNAS USA, listed below in Publications
- 2007 Ippen-Ihler Memorial Lecture, Texas A&M, Health Science Center
- 2007 Arizona Bioscience Researcher of the Year, Arizona BioIndustry Association
- 2007 Distinguished Lecturer, National Academy of Sciences Lectureship Series, University of Minnesota, Twin Cities
- 2007 Keynote Speaker, Synthetic Biology Engineering Research Center (SynBERC) Annual Retreat
- 2007 Keynote Speaker, Mid-Atlantic Microbial Pathogenesis Meeting
- 2006 Distinguished Lecturer, Centers for Disease Control and Prevention
- 2006 Invited Speaker, Arizona State University Chapter of Sigma Xi Annual Banquet
- 2006 Keynote Speaker, 2nd ASM Conference on *Salmonella*: From Pathogenesis to Therapeutics, Victoria, BC, Canada
- 2005 Recipient of Grant Award from the Bill and Melinda Gates Foundation for the Grand Challenges in Global Health Initiative
- 2005 Keynote Speaker, Annual Meeting Arizona-Nevada Branch of ASM
- 2005 Fellow, Arizona Arts, Science and Technology Academy
- 2005-Present George William and Irene Koechig Freiberg Professor of Biology Emeritus, Washington University
- 2003 Ellison Medical Foundation Global Infectious Disease Senior Scholar
- 2003 Sardinia Science Award, University of Sassari, Alghero, Italy
- 2003 Honorary Doctor of Science, Southern Illinois University, Edwardsville
- 2002 David J. Hentges Lecture on Infectious Disease, Texas Tech
- 2002 Robert P. Williams Memorial Lecturer, Baylor College of Medicine
- 2001 Faculty of 1000 Biology, Daigle et al. 2001. PNAS USA, listed below in Publications
- 2001 Member, National Academy of Sciences
- 2001 Fellow, The Academy of Science of St. Louis
- 2001 Graduate Research Day Colloquium Lecture, Uniformed Services University of the Health Sciences
- 2001 Chancellor's Distinguished Lecturer, Louisiana State University

2000 Animal Health Microbiology Division Lecturer, American Society for Microbiology General Meeting
 2000 Education Division Lecturer, American Society for Microbiology General Meeting
 1999 Keynote Speaker, 4th International Symposium on Typhoid Fever and Other Salmonellosis
 1997 Missouri Inventor of the Year, Bar Association of Metropolitan St. Louis
 1996 Elaine and Arthur Brown Distinguished Lecturer, University of Tennessee-Knoxville
 1994 Chairman, Gordon Research Conference on Microbial Toxins and Pathogenesis
 1994 A. L. Bortree Lecturer, Pennsylvania State University
 1993 Co-Chairman, Gordon Research Conference on Molecular Mechanisms of Microbial Adhesion
 1993 Edwin H. Beachey Memorial Lecturer, Univ. Tenn.-Memphis
 1992 Vice Chairman, Gordon Research Conference on Microbial Toxins and Pathogenesis
 1991 Recipient of \$500,000 Grant Award from Bristol-Myers Squibb to support infectious diseases research
 1990 Fellow, American Association for the Advancement of Science
 1990 Smiley Lecture, Department of Microbiology, University of Kansas
 1990 Distinguished Lecturer in Molecular Biology, Louisiana State University Medical Center
 1990 Stuart Mudd Memorial Lecture, Eastern Pennsylvania Branch of the American Society for Microbiology
 1988 MERIT Award, National Institute of Dental Research
 1988 Herman C. Lichstein Distinguished Lecturer, University of Cincinnati
 1986 Keynote Lecturer, Fiftieth Anniversary of Graduate Dental Education at The University of Rochester
 1984 Seymour J. Kreshover Award, National Institute of Dental Research
 1984-2005 George William and Irene Koechig Freiberg Professor of Biology, Washington University
 1983 Scholar-Leadership Enrichment Program Scholar, University of Oklahoma
 1982 M. F. Shaffer Alumni Lecturer, Tulane University
 1978-1983 Charles H. McCauley Professor of Microbiology, University of Alabama at Birmingham
 1975 Recipient, P. R. Edwards Award of the Southeastern Branch of the American Society for Microbiology
 1974 Fellow, American Academy of Microbiology
 1973 Honorary Member, Asociacion Chilena de Microbiologia
 1969-1970;
 1979-1980;
 1981-1982 Lecturer, American Foundation for Microbiology
 1962 Sigma Xi
 1960-1962 US Public Health Service Predoctoral Fellow, University of Chicago
 1958-1960 University Fellow, University of Chicago
 1955 Danforth Fellowship, Cornell University
 1955 Quill and Dagger, Cornell University
 1955 Ho-Nun-De-Kah, Cornell University
 1953 Alpha Zeta, Cornell University
 1952-1956 New York State Regents Scholarship, Cornell University
 1952-1956 Esso 4-H Scholarship, Cornell University

BIOGRAPHICAL RESUMES

American Men and Women of Science
 Who's Who in the World
 Who's Who in America
 Who's Who in Medicine and Health Care
 Who's Who in Frontier Science and Technology
 Who's Who in American Education
 Who's Who in the Midwest

PROFESSIONAL SOCIETY MEMBERSHIPS

2012-Present The American Association of Immunologists
 2005-Present Arizona Arts, Science and Technology Academy
 Member, Board of Governors 2006-2010
 2001-Present The National Academy of Sciences
 1998-Present The Academy of Science of St. Louis, Fellow 2001
 1997-Present International Society for Vaccines
 1990-Present American Association of Avian Pathologists
 1988-Present Conference of Research Workers on Animal Diseases
 1988-Present International Society of Mucosal Immunology

- 1970-Present Member, Congress of Mucosal Immunology Steering Committee 2006-2015
American Association for the Advancement of Science
Fellow 1990
- 1960-Present Society for General Microbiology
- 1960-Present American Society for Microbiology
Member, American Society of Microbiology, Culture Collections Colloquium Planning Committee
- Committee on Elections, American Academy of Microbiology, Alternate 2005-2008
Finance Committee, 2003-2004
Editor-in-Chief and Chairman, Board of Executive Editors, *Escherichia coli* and *Salmonella: Cellular and Molecular Biology*, 2000-2005
Member, Board of Executive Editors, *Escherichia coli* and *Salmonella: Cellular and Molecular Biology* 2000-2012
Counselor, Division of Animal Health Microbiology, 1999-2001
Organizing Committee for Division of Animal Health Microbiology, 1998-1999
Finance Committee, 1992-1994
Committee on Governance, 1991-1994
Division Councilor At Large to the Council Policy Committee and Council, 1991-1994; 2001-2004
Steering Committee for Undergraduate Faculty-Mentor Enhancement Program, 1989-1992
Representative to the American Type Culture Collection Board of Directors, 1989-1995
Committee on Genetics and Molecular Biology, PSAB, 1988-1993
Counselor, Division of Microbial Pathogenesis, 1989-1991
Alternate Counselor, Division of Microbial Pathogenesis, 1987-1989
Member, Editorial Board, ASM News, 1987-1999
Editor, Infection and Immunity, 1985-1992
Select Committee to Review Governance of ASM, 1981-1983
Headquarters Building Subcommittee, 1979-1980
Constitution and By Laws Committee, 1979
Investment Subcommittee, 1978-1981
Nominating Committee, 1978; 1993-1994; 2002-2003
Ad Hoc Committee on Public and Scientific Affairs, 1978-1979
Committee on Committees, 1977
Branch Counselor At Large to the Council Policy Committee and Council, 1977-1980
Counselor, Southeastern Branch, 1977
Latin American Visiting Professor Program Committee, 1973-1978
Chairman, Division of Genetics and Molecular Biology Nominating Committee, 1973
Membership Committee, 1971-1976
Editor, Journal of Bacteriology, 1970-1976
Parliamentarian, 1970-1975
President, Kentucky and Tennessee Branch, 1968-1969
Vice President, Kentucky and Tennessee Branch, 1967-1968
Editorial Board Member, Journal of Bacteriology, 1966-1970
- 1970-1991 New York Academy of Sciences
- 1960-1991 Genetics Society of America
Nominating Committee, 1983
Committee on Preservation of Germplasm, 1983-1989; Chairman, 1987-1989

TEACHING:

Arizona State University, Tempe, AZ

- BCH 392 Biochemistry Independent Research 2008
BDE 792 Graduate Research 2012-2015
BIO 189 Career Paths In Life 2006-2010; 2012; 2014 (guest lecturer)
BIO 194 Freshman Microbiology Seminar 2006 (guest lecturer)
BIO 311 Biology and Society 2006-2008 (guest lecturer)
BIO 312 Bioethics 2012-2014 (guest lecturer)
BIO 343 Genetic Engineering and Society 2006-2008 (guest lecturer)
BIO 416 Professional Values in Science 2006-2010 (guest lecturer)

BIO 484	Internship 2009, 2010
BIO 495	Undergraduate Research 2011-2013
MIC 191	Freshman Microbiology Seminar 2006; 2007 (two sessions), 2008-2010
MIC 394	Milestones in Microbial Genetics and Phage Biology 2007-2010
MIC 401	Undergraduate Research Paper 2007, 2012, 2013
MIC 420	Immunology: Molecular and Cellular Foundations 2013 (guest lecturer)
MIC 492	Honors Directed Study 2011-2012; 2014-2015
MIC 493	Honors Thesis 2010
MIC 495	Undergraduate Research 2006-2012
MIC 499	Individualized Instruction 2010-2012
MIC 598	Integrative Microbiology 2009 (guest lecturer)
MBB 493	Honors Thesis 2008, 2009, 2010
MBB 484	Internship 2009, 2010
MBB 490	Capstone: Issues In Biotechnology 2008 (guest lecturer)
MBB 499	Internship 2009, 2011

Weekly Journal Club, 2005-2013

Triweekly 2-hour Research Review Sessions, 2005-2013

Biweekly 2-hour Research Review Sessions, 2014-present

Washington University, St. Louis, MO

BIO 3920	Global Impact of Biotechnology 2002-2004
BIO 5011	Ethics and Research Science 2001
BIO 349	Microbiology 1995, 1996, 1997
BIO 349	Microbiology Laboratory 1996, 1997
BIO 445	Microbial Genetics 1984-1987
BIO 181	Freshman Biology Seminar 1983, 1985-1987, 1989-1993
BIO 500	Undergraduate Independent Research 1983-2005

University of Alabama at Birmingham

Molecular Cell Biology	1974-1978, 1979-1983
Medical Microbiology	1973-1978, 1979-1982
Dental Microbiology	1973-1978, 1979-1982
Microbial Genetics	1973
Graduate Seminar	1972, 1974, 1978

University of Tennessee Graduate School of Biomedical Sciences

Advanced Genetics 1967-1972

University of Tennessee at Knoxville

Virology 1965

CURRENT MAIN AREA OF RESEARCH

Design, construction and evaluation of vaccines to elicit protective host immune responses in agriculturally important and companion animals and in humans, mechanisms of bacterial pathogenesis and host immune responses to infections and vaccines. Development of therapeutic vaccines against cancer. Immunological modulation of microbiome. Genetic engineering of cyanobacteria for biofuels production.

PUBLICATIONS

1. Baker, R. C., and R. Curtiss III. 1957. Individual hen differences in eggshell mottling and the relationship of shell mottling to clutch size, internal quality and weight loss. *Poultry Sci.* **36**:904-908
2. Levine, M., and R. Curtiss III. 1958. A genetic test for side-chains in a phage chromosome. *Nature* **182**:126-127.
3. Baker, R. C., and R. Curtiss III. 1958. Strain difference in eggshell mottling, internal quality, shell thickness, specific gravity, and the interrelationships between these factors. *Poultry Sci.* **37**:1086-1090.

4. Levine, M., and R. Curtiss III. 1960. An effect of chloramphenicol on genetic recombination and selection in phage. *Virology* **10**:370-371.
5. Levine, M., and R. Curtiss III. 1961. Genetic fine structure of the *c* region and the linkage map of phage P22. *Genetics* **46**:1573-1580.
6. Curtiss, R. III. 1964. A stable partial diploid strain of *Escherichia coli*. *Genetics* **50**:679-694.
7. Curtiss, R. III. 1965. Chromosomal aberrations associated with mutations to bacteriophage resistance in *Escherichia coli*. *J. Bacteriol.* **89**:28-40.
8. Curtiss, R. III, L. J. Charamella, C. M. Berg, and P. E. Harris. 1965. Kinetic and genetic analyses of D-cycloserine inhibition and resistance in *Escherichia coli*. *J. Bacteriol.* **90**:1238-1250.
9. Berg, C. M. and R. Curtiss III. 1967. Transposition derivatives of an Hfr strain of *Escherichia coli* K-12. *Genetics* **56**:503-525.
10. Curtiss, R. III, and D. R. Stallions. 1967. Energy requirement for specific pair formation during conjugation in *Escherichia coli* K-12. *J. Bacteriol.* **94**:490-492.
11. Curtiss, R. III. 1968. Ultraviolet-induced genetic recombination in a partially diploid strain of *Escherichia coli*. *Genetics* **58**:9-54.
12. Cohen, A., W. D. Fisher, R. Curtiss III, and H. I. Adler. 1968. DNA isolated from *Escherichia coli* minicells mated with F^+ cells. *Proc. Natl. Acad. Sci. USA* **61**:61-68.
13. Curtiss, R. III, L. J. Charamella, D. R. Stallions, and J. A. Mays. 1968. Parental functions during conjugation in *Escherichia coli* K-12. *Bacteriol. Rev.* **32**:320-348.
14. Cohen, A., W. D. Fisher, R. Curtiss III, and H. I. Adler. 1968. The properties of DNA transferred to minicells during conjugation. *Cold Spring Harbor Symp. Quant. Biol.* **33**:635-641.
15. Curtiss, R. III, and J. Renshaw. 1969. F^+ strains of *Escherichia coli* K-12 defective in Hfr formation. *Genetics* **63**:7-26.
16. Curtiss, R. III, and D. R. Stallions. 1969. Probability of F integration and frequency of stable Hfr donors in F^+ populations of *Escherichia coli* K-12. *Genetics* **63**:27-38.
17. Curtiss, R. III, and J. Renshaw. 1969. Kinetics of F transfer and recombinant production in $F^+ \times F^-$ matings in *Escherichia coli* K-12. *Genetics* **63**:39-52.
18. Curtiss, R. III. 1969. Bacterial conjugation. *Annu. Rev. Microbiol.* **23**:69-136.
19. Curtiss, R. III, L. G. Caro, D. P. Allison, and D. R. Stallions. 1969. Early stages of conjugation in *Escherichia coli* K-12. *J. Bacteriol.* **100**:1091-1104.
20. Jones, R. T., and R. Curtiss III. 1970. Genetic exchange between *Escherichia coli* strains in the mouse intestine. *J. Bacteriol.* **103**:71-80.
21. Roozen, K. J., R. G. Fenwick, Jr., and R. Curtiss III. 1971. Isolation of plasmids and specific chromosomal segments from *Escherichia coli* K-12, p. 249-264. *In* L. Ledoux (ed.), *Informative Molecules in Biological Systems*. North Holland, Amsterdam.
22. Stallions, D. R., and R. Curtiss III. 1971. Chromosome transfer and recombinant formation with deoxyribonucleic acid temperature-sensitive strains of *Escherichia coli*. *J. Bacteriol.* **105**:886-895.

23. Roozen, K. J., R. G. Fenwick, Jr., and R. Curtiss III. 1971. Synthesis of ribonucleic acid and protein in plasmid-containing minicells of *Escherichia coli* K-12. *J. Bacteriol.* **107**:21-33.
24. Stallions, D. R., and R. Curtiss III. 1972. Bacterial conjugation under anaerobic conditions. *J. Bacteriol.* **111**:294-295.
25. Sheehy, R. J., C. Orr, and R. Curtiss III. 1972. Molecular studies on entry exclusion in *Escherichia coli* minicells. *J. Bacteriol.* **112**:861-869.
26. Sheehy, R. J., D. P. Allison, and R. Curtiss III. 1973. Cryptic plasmids in a minicell-producing strain of *Salmonella typhimurium*. *J. Bacteriol.* **114**:439-442.
27. Frazer, A. C., and R. Curtiss III. 1973. Derepression of anthranilate synthase in purified minicells of *Escherichia coli* containing the Col-trp plasmid. *J. Bacteriol.* **114**:615-622.
28. Sheehy, R. J., A. Perry, D. P. Allison, and R. Curtiss III. 1973. Molecular nature of R-factor deoxyribonucleic acid isolated from *Salmonella typhimurium* minicells. *J. Bacteriol.* **114**:1328-1335.
29. Fenwick, R. G., Jr., and R. Curtiss III. 1973. Conjugal DNA replication by *Escherichia coli* K-12: stimulation in *dnaB*(TS) donors by minicells. *J. Bacteriol.* **116**:1212-1223.
30. Fenwick, R. G., Jr., and R. Curtiss III. 1973. Conjugal DNA replication by *Escherichia coli* K-12: effect of chloramphenicol and rifampin. *J. Bacteriol.* **116**:1224-1235.
31. Fenwick, R. G., Jr., and R. Curtiss III. 1973. Conjugal DNA replication by *Escherichia coli* K-12: effect of nalidixic acid. *J. Bacteriol.* **116**:1236-1246.
32. Curtiss, R. III, F. L. Macrina, and J. O. Falkinham III. 1974. *Escherichia coli* - An overview, p. 115-133. In R. C. King (ed.), *Handbook of Genetics*, Vol. I. Plenum Publishing Corp., NY.
33. Khachatourians, G. G., R. J. Sheehy, and R. Curtiss III. 1974. Fate of conjugally transferred DNA in minicells of *Escherichia coli* K-12. *Molec. Gen. Genet.* **128**:23-42.
34. Macrina, F. L., G. C. Weatherly, and R. Curtiss III. 1974. R6K plasmid replication: influence of chromosomal genotype in minicell-producing strains of *Escherichia coli* K-12. *J. Bacteriol.* **120**:1387-1400.
35. Frazer, A. C., and R. Curtiss III. 1975. Production, properties and utility of bacterial minicells. *Curr. Top. Microbiol. Immunol.* **69**:1-84.
36. Curtiss, R. III, and R. G. Fenwick, Jr. 1975. Mechanism of conjugal plasmid transfer, p. 156-165. In D. Schlessinger (ed.), *Microbiology - 1974*. American Society for Microbiology, Washington, DC.
37. Curtiss, R. III. 1975. Research on bacterial conjugation with minicells and minicell-producing *E. coli* strains, p. 169-183. In S. Mitsuhashi and H. Hashimoto (eds.), *Microbial Drug Resistance*. University of Tokyo Press, Tokyo.
38. Curtiss, R. III, W. Szybalski, D. R. Helsinki, and S. Falkow. 1976. Workshop on design and testing of safer prokaryotic vehicles and bacterial hosts for research on recombinant DNA molecules. *ASM News* **42**:134-138.
39. Novick, R. P., R. C. Clowes, S. N. Cohen, R. Curtiss III, N. Datta, and S. Falkow. 1976. A proposed uniform nomenclature for bacterial plasmids. *Bacteriol. Rev.* **40**:168-189.
40. Falkinham, J. O. III, and R. Curtiss III. 1976. Isolation and characterization of conjugation-deficient mutants of *Escherichia coli* K-12. *J. Bacteriol.* **126**:1194-1206.
41. Curtiss, R. III. 1976. Genetic manipulation of microorganisms: potential benefits and biohazards. *Annu. Rev. Microbiol.* **30**:507-533.

42. Curtiss, R. III, D. A. Pereira, J. C. Hsu, S. C. Hull, J. E. Clark, L. J. Maturin, Sr., R. Goldschmidt, R. Moody, M. Inoue, and L. Alexander. 1977. Biological containment: the subordination of *Escherichia coli* K-12, p. 45-56. In R.F. Beers, Jr. and E.G. Bassett (eds.), *Recombinant Molecules: Impact on Science and Society*. Raven Press, NY.
43. Curtiss, R. III, R. G. Fenwick, Jr., R. Goldschmidt, and J. O. Falkinham, III. 1977. Mechanism of conjugation, p. 109-134. In S. Mitsuhashi (ed.), *R. Factor Drug Resistance Plasmid*. University of Tokyo Press, Tokyo.
44. Curtiss, R. III, J. E. Clark, R. Goldschmidt, J. C. Hsu, S. C. Hull, M. Inoue, L. J. Maturin, Sr., R. Moody, and D. A. Pereira. 1977. Biohazard assessment of recombinant DNA molecule research, p. 375-387. In S. Mitsuhashi, L. Rosival, and V. Krcmery (eds.), *Plasmids - Medical and Theoretical Aspects*. Avicenum, Czechoslovak Medical Press, Prague.
45. Maturin, L. Sr., and R. Curtiss III. 1977. Degradation of DNA by nucleases in intestinal tracts of rats. *Science* **196**:216-218.
46. Curtiss, R. III, M. Inoue, D. Pereira, J. C. Hsu, L. Alexander, and L. Rock. 1977. Construction and use of safer bacterial host strains for recombinant DNA research, p. 99-114. In W.A. Scott and R.A. Werner (eds.), *Molecular Cloning of Recombinant DNA*. Academic Press, Inc., NY.
47. Curtiss, R. III, and J. Clark-Curtiss. 1977. Effectiveness of physical and biological containment, p. 198-202. In *Research with Recombinant DNA*. National Academy of Sciences, Washington, DC.
48. Curtiss, R. III. 1978. Biological containment and cloning vector transmissibility. *J. Infect. Dis.* **137**:668-675.
49. Hull, R. A., G. S. Gill, and R. Curtiss III. 1978. Genetic characterization of the Mu-like bacteriophage D108. *J. Virol.* **27**:513-518.
50. Curtiss, R. III. 1978. A scientist's perspective on regulation of recombinant DNA activities, pp. 242-250. In O.K. Sebek and A.I. Laskin (eds.), *Genetics of Industrial Microorganisms*. American Society for Microbiology, Washington, DC.
51. Curtiss, R. III. 1978. Comments on Callahan, p. 149-155. In John Richards (ed.), *Recombinant DNA: Science, Ethics, and Politics*. Academic Press, Inc., NY.
52. Robeson, J. P., R. M. Goldschmidt, and R. Curtiss III. 1980. Potential of *Escherichia coli* isolated from nature to propagate cloning vectors. *Nature* **283**:104-106.
53. Hirasawa, M., H. Kiyono, T. Shiota, R. Hull, R. Curtiss III, S. M. Michalek, and J. McGhee. 1980. Virulence of *Streptococcus mutans*: restoration of pathogenesis of a glucosyltransferase (GTF) defective mutant (C4). *Infect. Immun.* **287**:915-921.
54. Alexander, W. J., L. S. Alexander, and R. Curtiss III. 1980. Bactericidal activity of human serum against *Escherichia coli* □1776. *Infect. Immun.* **28**:837-841.
55. Alexander, W. J., C. G. Cobbs, and R. Curtiss III. 1980. Modification of bacterial serum susceptibility by rifampicin. *Infect. Immun.* **28**:923-926.
56. Curtiss, R. III. 1980. Recombinant DNA: technology, application, ethics. *Ala. J. Med. Sci.* **17**:191-196.
57. Gill, G. S., R. C. Hull, and R. Curtiss III. 1981. Mutator bacteriophage D108 and its DNA: an electron microscopic characterization. *J. Virol.* **37**:420-430.
58. Hansen, J. B., Y. Abiko, and R. Curtiss III. 1981. Characterization of the *Streptococcus mutans* plasmid pVA318 cloned into *Escherichia coli*. *Infect. Immun.* **31**:1034-1043.

59. Curtiss, R. III. 1981. Gene transfer, p. 243-265. *In* P. Gerhardt, R.G.E. Murray, R.N. Costilow, E.W. Nester, W.A. Wood, N.R. Krieg, and G.B. Phillips (eds.), *Manual of Methods for General Microbiology*. American Society for Microbiology, Washington, DC.
60. Maturin, L. J. Sr., and R. Curtiss III. 1981. Role of ribonucleic acid synthesis in conjugational transfer of chromosomal and plasmid deoxyribonucleic acids. *J. Bacteriol.* **146**:552-563.
61. Murchison, H., S. Larrimore, and R. Curtiss III. 1981. Isolation and characterization of *Streptococcus mutans* mutants defective in adherence and aggregation. *Infect. Immun.* **34**:1044-1055.
62. Jagusztyn-Krynicka, E. K., M. Smorawska, and R. Curtiss III. 1982. Expression of *Streptococcus mutans* aspartate semialdehyde dehydrogenase gene cloned into plasmid pBR322. *J. Gen. Microbiol.* **128**:1135-1145.
63. Curtiss, R. III, J. P. Robeson, R. Barletta, Y. Abiko, and M. Smorawska. 1982. Synthesis and function of *Streptococcus mutans* cell-surface proteins in *Escherichia coli*, p. 253-257. *In* D. Schlessinger (ed.), *Microbiology-1982*. American Society for Microbiology, Washington, DC.
64. Curtiss, R. III, E. K. Jagusztyn-Krynicka, J. B. Hansen, M. Smorawska, Y. Abiko, and G. Cardineau. 1982. Expression of *Streptococcus mutans* plasmid and chromosomal genes in *Escherichia coli* K-12, Vol. 3, p. 15-27. *In* S. Mitsuhashi (ed.), *Microbial Drug Resistance*. University Park Press, Baltimore.
65. Shaw, D. R., A. T. Maurelli, J. D. Goguen, S. C. Straley, and R. Curtiss III. 1982. Use of UV-irradiated bacteriophage T6 to kill extracellular bacteria in tissue culture infectivity assays. *J. Immunol. Methods* **56**:75-83.
66. Holt, R. G., Y. Abiko, S. Saito, M. Smorawska, J. B. Hansen, and R. Curtiss III. 1982. *Streptococcus mutans* genes that code for extra-cellular proteins in *Escherichia coli* K-12. *Infect. Immun.* **38**:147-156.
67. Murchison, H., S. Larrimore, S. Hull, and R. Curtiss III. 1982. Isolation and characterization of *Streptococcus mutans* mutants with altered cellular morphology or chain length. *Infect. Immun.* **38**:282-291.
68. Curtiss, R. III, R. G. Holt, R. G. Barletta, J. P. Robeson, and S. Saito. 1983. *Escherichia coli* strains producing *Streptococcus mutans* proteins responsible for colonization and virulence. *In* J.R. McGhee and J. Mestecky (eds.), *The Secretory Immune System*. Ann. N.Y. Acad. Sci. **409**:688-696.
69. Clark-Curtiss, J. E., and R. Curtiss III. 1983. Analysis of recombinant DNA using *Escherichia coli* minicells. *Meth. Enzymol.* **101**:347-362.
70. Robeson, J. P., R. G. Barletta, and R. Curtiss III. 1983. Expression of a *Streptococcus mutans* glucosyltransferase gene in *Escherichia coli*. *J. Bacteriol.* **153**:211-221.
71. Smorawska, M., J. C. Hsu, J. B. Hansen, E. K. Jagusztyn-Krynicka, Y. Abiko, and R. Curtiss III. 1983. Clustered genes for galactose metabolism from *Streptococcus mutans* cloned in *Escherichia coli* K-12. *J. Bacteriol.* **153**:1095-1097.
72. Curtiss, R. III, S. A. Larrimore, R. G. Holt, J. F. Barrett, R. Barletta, H. H. Murchison, S. M. Michalek, and S. Saito. 1983. Analysis of *Streptococcus mutans* virulence attributes using recombinant DNA and immunological techniques, p. 95-104. *In* R.J. Doyle and J.E. Ciardi (eds.), *Glucosyltransferases, Glucans, Sucrose and Dental Caries*. Sp. Supp. Chemical Senses.
73. Curtiss, R. III. 1983. Technology of recombinant DNA techniques. *Ala. J. Med. Sci.* **20**:60-63.
74. Curtiss, R. III. 1983. The creation of the cystic fibrosis research center - from research lab to the clinic. *Ala. J. Med. Sci.* **20**:219-222.
75. Larrimore, S., H. Murchison, T. Shiota, S. Michalek, and R. Curtiss III. 1983. *In vitro* and *in vivo* complementation of *Streptococcus mutans* mutants defective in adherence. *Infect. Immun.* **42**:558-566.

76. Jacobs, W. R., J. E. Clark-Curtiss, L. R. Ritchie, and R. Curtiss III. 1983. Construction and partial characterization of *Mycobacterium leprae* genomic libraries using an *in vivo* cosmid cloning system. *Int. J. Lepr.* **51**:667-668.
77. Maurelli, A. T., B. Blackmon, and R. Curtiss III. 1984. Temperature-dependent expression of virulence genes in *Shigella* species. *Infect. Immun.* **43**:195-201.
78. Maurelli, A. T., B. Blackmon, and R. Curtiss III. 1984. Loss of pigmentation in *Shigella flexneri* 2a is correlated with loss of virulence and virulence-associated plasmid. *Infect. Immun.* **43**:397-401.
79. Maurelli, A. T., and R. Curtiss III. 1984. Bacteriophage MudI(Ap^rlac) generates *vir-lac* operon fusions in *Shigella flexneri* 2a. *Infect. Immun.* **45**:642-648.
80. Michalek, S. M., R. L. Gregory, M. Scholler-Guinard, S. Kimura, J. Mestecky, R. Curtiss III, and J. R. McGhee. 1984. Immunity to dental caries: induction of protective salivary IgA antibodies to *Streptococcus mutans*, p. 99-105. *In* J. -P. Revillard, C. Voisin, and N. Wierzbicki (eds.), *Mucosal Immunity IgA and Polymorphonuclear Neutrophils*. Fondation Franco-Allemande, Suresnes, France.
81. Curtiss, R. III, H. H. Murchison, W. E. Nesbitt, J. F. Barrett, and S. M. Michalek. 1985. Use of mutants and gene cloning to identify and characterize colonization mechanisms of *Streptococcus mutans*, p. 187-193. *In* S. Mergenhagen and B. Rosan (eds.), *Molecular Basis for Oral Microbial Adhesion*. American Society for Microbiology, Washington, DC.
82. Murchison, H., S. Larrimore, and R. Curtiss III. 1985. *In vitro* inhibition of adherence of *Streptococcus mutans* strains by nonadherent mutants of *S. mutans* 6715. *Infect. Immun.* **50**:826-832.
83. Curtiss, R. III. 1985. Genetic analysis of *Streptococcus mutans* virulence. *Curr. Top. Microbiol. Immun.* **118**:253-277.
84. Clark-Curtiss, J. E., W. R. Jacobs, M. A. Docherty, L. R. Ritchie, and R. Curtiss III. 1985. Molecular analysis of DNA and construction of genomic libraries of *Mycobacterium leprae*. *J. Bacteriol.* **161**:1093-1102.
85. Takada, K., T. Shiota, R. Curtiss III, and S. M. Michalek. 1985. Inhibition of plaque and caries formation by a glucan produced by *Streptococcus mutans* mutant UAB108. *Infect. Immun.* **50**:833-843.
86. Jacobs, W. R., J. F. Barrett, J. E. Clark-Curtiss, and R. Curtiss III. 1986. *In vivo* repackaging of recombinant cosmid molecules for analyses of *Salmonella typhimurium*, *Streptococcus mutans* and mycobacterial genomic libraries. *Infect. Immun.* **52**:101-109.
87. Jacobs, W. R., M. A. Docherty, R. Curtiss III, and J. E. Clark-Curtiss. 1986. Expression of *Mycobacterium leprae* genes from a *Streptococcus mutans* promoter in *Escherichia coli* K-12. *Proc. Natl. Acad. Sci. USA* **83**:1926-1930.
88. Curtiss, R. III, R. Goldschmidt, R. Pastian, M. Lyons, S. M. Michalek, and J. Mestecky. 1986. Cloning virulence determinants from *Streptococcus mutans* and the use of recombinant clones to construct bivalent oral vaccine strains to confer protective immunity against *S. mutans*-induced dental caries, p. 173-180. *In* S. Hamada, S.M. Michalek, H. Kiyono, L. Menaker, and J.R. McGhee (eds.), *Molecular Microbiology and Immunobiology of Streptococcus mutans*. Elsevier Science Publishing, Inc., NY.
89. Barrett, J. F., T. A. Barrett, and R. Curtiss III. 1986. Biochemistry and genetics of dextranase from *Streptococcus mutans* 6715, p. 205-215. *In* S. Hamada, S.M. Michalek, H. Kiyono, L. Menaker, and J.R. McGhee (eds.), *Molecular Microbiology and Immunobiology of Streptococcus mutans*. Elsevier Science Publishing, Inc., NY.
90. Michalek, S. M., I. Morisaki, S. Kimura, S. Hamada, R. Curtiss III, and J. R. McGhee. 1986. Effective immunity to *Streptococcus mutans*-induced dental caries, p. 269-278. *In* S. Hamada, S.M. Michalek, H. Kiyono, L. Menaker, and J.R. McGhee (eds.), *Molecular Microbiology and Immunobiology of Streptococcus mutans*. Elsevier Science Publishing, Inc., NY.

91. Curtiss, R. III. 1986. Genetic analysis of *Streptococcus mutans* virulence and prospects for an anticaries vaccine. *J. Dent. Res.* **65**:1034-1045.
92. Murchison, H. H., J. F. Barrett, G. A. Cardineau, and R. Curtiss III. 1986. Transformation of *Streptococcus mutans* with chromosomal and shuttle plasmid (pYA629) DNAs. *Infect. Immun.* **54**:273-282.
93. Barrett, J. F., and R. Curtiss III. 1986. Renaturation of dextranase activity from culture supernatant fluids of *Streptococcus sobrinus* after sodium dodecyl sulfate polyacrylamide gel electrophoresis. *Anal. Biochem.* **158**:365-370.
94. Barrett, J. F., T. A. Barrett, and R. Curtiss III. 1987. Purification and partial characterization of the multicomponent dextranase complex of *Streptococcus sobrinus* and cloning of the dextranase gene. *Infect. Immun.* **55**:792-802.
95. Switalski, L. M., H. Murchison, R. Timpl, R. Curtiss III, and M. Hook. 1987. Binding of laminin to oral and endocarditis strains of viridans streptococci. *J. Bacteriol.* **169**:1095-1101.
96. Cardineau, G. A., and R. Curtiss III. 1987. Nucleotide sequence of the *asd* gene of *Streptococcus mutans*: identification of the promoter region and evidence for attenuator like sequences preceding the structural gene. *J. Biol. Chem.* **262**:3344-3353.
97. Ferretti, J. J., and R. Curtiss III. 1987. *Streptococcal Genetics*. American Society for Microbiology, Washington, DC.
98. Curtiss, R. III, R. Goldschmidt, J. Barrett, M. Thoren-Gordon, D. J. Salzberg, H. H. Murchison, and S. M. Michalek. 1987. Genetic analysis of surface proteins essential for virulence of *Streptococcus sobrinus*, p. 212-216. *In* J.J. Ferretti and R. Curtiss III (eds.), *Streptococcal Genetics*. American Society for Microbiology, Washington, DC.
99. Curtiss, R. III, R. Goldschmidt, S. Kelly, M. Lyons, S. M. Michalek, R. Pastian, and S. Stein. 1987. Recombinant avirulent *Salmonella* for oral immunization to induce mucosal immunity to bacterial pathogens, p. 261-271. *In* H. Kohler and P.T. LoVerde (eds.), *Vaccines: New Concepts and Developments - Proceedings of the Tenth International Convocation on Immunology*. Longman Scientific and Technical, Harlow, Essex, Great Britain.
100. Gulig, P. A., and R. Curtiss III. 1987. Plasmid-associated virulence of *Salmonella typhimurium*. *Infect. Immun.* **55**:2891-2901.
101. Curtiss, R. III, and S. M. Kelly. 1987. *Salmonella typhimurium* deletion mutants lacking adenylate cyclase and cyclic AMP receptor protein are avirulent and immunogenic. *Infect. Immun.* **55**:3035-3043.
102. Curtiss, R. III, C. Pearce, J. Pollack, and H. M. Murchison. 1987. Isolation and characterization of mutants of *Streptococcus mutans* using selective removal of wild-type cells by agglutination with an agglutinin from *Persea americana*. *Acta Microbiol. Polonica* **36**:3-15.
103. Katz, J., S. M. Michalek, R. Curtiss III, C. Harmon, G. Richardson, and J. Mestecky. 1987. Novel oral vaccines: The effectiveness of cloned gene products on inducing secretory immune responses, p. 1741-1747. *In* J. Mestecky, J.R. McGhee, J. Bienenstock, and P.L. Orga (eds.), *Recent Advances in Mucosal Immunology, Part B*.
104. Michalek, S. M., N. K. Childers, J. Katz, and R. Curtiss III. 1987. Oral vaccines and the secretory immune system. *Clin. Immunol. News.* **8**:158-159.
105. Barletta, R. G., S. M. Michalek, and R. Curtiss III. 1988. Analysis of the virulence of *Streptococcus mutans* serotype *c gtfA* mutants in the rat model system. *Infect. Immun.* **56**:322-330.
106. Curtiss, R. III, S. M. Kelly, P. A. Gulig, C. R. Gentry-Weeks, and J. E. Galan. 1988. Avirulent *Salmonella* expressing virulence antigens from other pathogens for use as orally-administered vaccines, p. 311-328. *In* J.A. Roth (ed.), *Virulence Mechanisms of Bacterial Pathogens*. American Society for Microbiology, Washington, DC.

107. Curtiss, R. III, R. M. Goldschmidt, N. B. Fletchall, and S. M. Kelly. 1988. Avirulent *Salmonella typhimurium* Δ *cya* Δ *crp* oral vaccine strains expressing a streptococcal colonization and virulence antigen. *Vaccine* **6**:155-160.
108. Nakayama, K., S. M. Kelly, and R. Curtiss III. 1988. Construction of an Asd⁺ expression-cloning vector: Stable maintenance and high level expression of cloned genes in a *Salmonella* vaccine strain. *Bio/Tech.* **6**:693-697.
109. Gentry-Weeks, C. R., B. T. Cookson, W. E. Goldman, R. B. Rimler, S. Porter, and R. Curtiss III. 1988. Dermonecrotic toxin and tracheal cytotoxin - putative virulence factors of *Bordetella avium*. *Infect. Immun.* **56**:1698-1707.
110. Curtiss, R. III. 1988. Engineering organisms for safety: What is necessary?, p. 7-20. *In* M. Sussman, C.H. Collins, F. A. Skinner, and D. E. Stewart-Tull (eds.), *The Release of Genetically-Engineered Micro-Organisms*. Academic Press, London.
111. Curtiss, R. III, A. T. Maurelli, and P. A. Gulig. 1988. Genetic analysis of pathogenesis of enteric bacteria, p. 69-84. *In* P. Owen and T.J. Foster (eds.), *Immunochemical and Molecular Genetic Analysis of Bacterial Pathogens*. Elsevier Science Publishing, Inc., NY.
112. Gulig, P. A., and R. Curtiss III. 1988. Cloning and transposon insertion mutagenesis of virulence genes of the 100-kilobase plasmid of *Salmonella typhimurium*. *Infect. Immun.* **56**:3262-3271.
113. Curtiss, R. III. 1988. Use of genetically-engineered microorganisms and viruses as vaccines, p. 72-88. *In* P. DeForest, M.S. Frankel, J. Poindexter, and V. Weil (eds.), *Biotechnology: Professional Issues & Social Concerns*. American Association for the Advancement of Science, Washington, DC.
114. James, L. C., T. A. Hughes, and R. Curtiss III. 1988. Nucleotide sequence of the *gtfA* gene from *S. mutans* GS-5. *Nucleic Acids Res.* **16**:10398.
115. Galan, J. E., J. F. Timoney, and R. Curtiss III. 1989. Expression and localization of the *Streptococcus equi* M protein in *Escherichia coli* and *Salmonella typhimurium*, p. 34-40. *In* D.G. Powell (ed.), *Equine Infectious Diseases V, Proceedings of the Fifth International Congress*. The University Press of Kentucky, Lexington, KY.
116. Barletta, R. G., and R. Curtiss III. 1989. Impairment of melibiose utilization in *Streptococcus mutans* serotype c *gtfA* mutants. *Infect. Immun.* **57**:992-995.
117. Curtiss, R. III, S. M. Kelly, P. A. Gulig, and K. Nakayama. 1989. Selective delivery of antigens by recombinant bacteria. *Curr. Top. Microbiol. Immun.* **146**:35-49.
118. Michalek, S. M., N. K. Childers, J. Katz, F. R. Denys, A. K. Berry, J. H. Eldridge, J. R. McGhee, and R. Curtiss III. 1989. Liposomes as oral adjuvants. *Curr. Top. Microbiol. Immun.* **146**:51-58.
119. Curtiss, R. III, K. Nakayama, and S. M. Kelly. 1989. Recombinant avirulent *Salmonella* vaccine strains with stable maintenance and high level expression of cloned genes *in vivo*. *Immunol. Invest.* **18**:583-596.
120. Galan, J. E., and R. Curtiss III. 1989. Cloning and molecular characterization of genes whose products allow *Salmonella typhimurium* to penetrate tissue culture cells. *Proc. Natl. Acad. Sci. USA* **86**:6383-6387.
121. Galan, J. E., and R. Curtiss III. 1989. Virulence and vaccine potential of *phoP* mutants of *Salmonella typhimurium*. *Microb. Pathog.* **6**:433-443.
122. Curtiss, R. III, S. M. Kelly, P. A. Gulig, and K. Nakayama. 1989. Stable recombinant avirulent *Salmonella* vaccine strains. *Adv. Exp. Med. Biol.* **251**:33-47.
123. Poppe, C., R. Curtiss III, P. A. Gulig, and C. L. Gyles. 1989. Hybridization studies with a DNA probe derived from the virulence region of the 60 Mdal plasmid of *Salmonella typhimurium*. *Can. J. Vet. Res.* **53**:378-384.
124. Curtiss, R. III. 1989. Computerization of data bases for genetic stock collections. *Genome* **31**:1102-1103.

125. Lockman, H. A., and R. Curtiss III. 1990. *Salmonella typhimurium* mutants lacking flagella or motility remain virulent in BALB/c mice. *Infect. Immun.* **58**:137-143.
126. Hudson, M. C., and R. Curtiss III. 1990. Regulation of expression of *Streptococcus mutans* genes important to virulence. *Infect. Immun.* **58**:464-470.
127. Galan, J. E., and R. Curtiss III. 1990. Expression of *Salmonella typhimurium* genes required for invasion is regulated by changes in DNA supercoiling. *Infect. Immun.* **58**:1879-1885.
128. Goldschmidt, R. M., and R. Curtiss III. 1990. Cross-reactivity between the immunodominant determinant of the antigen I component of *Streptococcus sobrinus* SpaA protein and surface antigens from other members of the *Streptococcus mutans* group. *Infect. Immun.* **58**:2276-2282.
129. Goldschmidt, R. M., M. Thoren-Gordon, and R. Curtiss III. 1990. Regions of the *Streptococcus sobrinus spaA* gene encoding major determinants of antigen I. *J. Bacteriol.* **172**:3988-4001.
130. Tinge, S. A., and R. Curtiss III. 1990. Isolation of the replication and partitioning regions of the *Salmonella typhimurium* virulence plasmid and stabilization of heterologous replicons. *J. Bacteriol.* **172**:5266-5277.
131. Tinge, S. A., and R. Curtiss III. 1990. Conservation of *Salmonella typhimurium* virulence plasmid maintenance regions among *Salmonella* serovars as a basis for plasmid curing. *Infect. Immun.* **58**:3084-3092.
132. Galan, J. E., K. Nakayama, and R. Curtiss III. 1990. Cloning and characterization of the *asd* gene of *Salmonella typhimurium*: use in stable maintenance of recombinant plasmids in *Salmonella* vaccine strains. *Gene* **94**:29-35.
133. Lockman, H. A., and R. Curtiss III. 1990. Occurrence of secondary attenuating mutations in avirulent *Salmonella typhimurium* vaccine strains. *J. Infect. Dis.* **162**:1397-1400.
134. Curtiss, R. III. 1990. Attenuated *Salmonella* strains as live vectors for the expression of foreign antigens, pp. 161-188. *In* G.C. Woodrow and M.M. Levine (eds.), *New Generation Vaccines*. Marcel Dekker, Inc., NY.
135. Curtiss, R. III, and S. M. Michalek. 1990. Vaccines against dental caries due to *Streptococcus mutans*, p. 715-740. *In* G. C. Woodrow and M. M. Levine (eds.), *New Generation Vaccines*. Marcel Dekker, Inc., NY.
136. Curtiss, R. III. 1990. Antigen delivery systems for analyzing host immune responses and for vaccine development. *Trends Biotechnol.* **8**:237-240.
137. Curtiss, R. III, S. B. Porter, M. Munson, S. A. Tinge, J. O. Hassan, C. Gentry-Weeks, and S. M. Kelly. 1991. Nonrecombinant and recombinant avirulent *Salmonella* live vaccines for poultry, p. 169-198. *In* L. C. Blankenship, J. S. Bailey, N. A. Cox, N. J. Stern, and R. J. Meinersmann (eds.), *Colonization Control of Human Bacterial Enteropathogens in Poultry*. Academic Press, NY.
138. Curtiss, R. III, J. E. Galan, K. Nakayama, and S. M. Kelly. 1990. Stabilization of recombinant avirulent vaccine strains *in vivo*. *Res. Microbiol.* **141**:797-805.
139. Hassan, J. O., and R. Curtiss III. 1990. Control of colonization by virulent *Salmonella typhimurium* by oral immunization of chickens with avirulent $\Delta cya \Delta crp$ *S. typhimurium*. *Res. Microbiol.* **141**:839-850.
140. Parker, C., N. C. Molina, S. M. Kelly, R. Curtiss III, and J. Yu. 1990. Live oral attenuated *Salmonella typhimurium* vaccine vectors which induce formation of antibody to *Bordetella pertussis*, p. 189-195. *In* C.R. Manclark (ed.), *Proceedings of the Sixth International Symposium on Pertussis*, Department of Health and Human Service, Bethesda, MD. DHHS Publication No. (FDA) 90-1164.
141. Hudson, M. C., and R. Curtiss III. 1991. Use of operon fusions to study gene expression in *Streptococcus mutans*. p. 261-266. *In* G. M. Dunny, P. P. Cleary, and L. McKay (eds.), *Genetics and Molecular Biology of Streptococci, Lactococci and Enterococci*. American Society for Microbiology, Washington, DC.

142. Gentry-Weeks, C. R., D. L. Provence, J. M. Keith, and R. Curtiss III. 1991. Isolation and characterization of *Bordetella avium* phase variants. *Infect. Immun.* **59**:4026-4033.
143. Galan, J. E., and R. Curtiss III. 1991. Distribution of the *InvA*, *-B*, *-C*, and *-D* genes of *Salmonella typhimurium* among other *Salmonella* serovars: *invA* mutants of *Salmonella typhi* are deficient for entry into mammalian cells. *Infect. Immun.* **59**:2901-2908.
144. Curtiss, R. III, and J. Galan. 1991. Colonization of the murine gastrointestinal tract by *Salmonella typhimurium*, p. 197-206. *In* T. Wädström, P. H. Mäkelä, A-M. Svennerholm, and H. Wolf-Watz (eds.), *Molecular Pathogenesis of Gastrointestinal Infections*. Plenum Publishing Corporation, London, England.
145. Singh, V., and R. Curtiss III. 1991. Hormonotoxins: abrogation of ribosome inactivating property of gelonin in the disulfide linked ovine luteinizing hormone-gelonin conjugates. *Biochem. Int.* **25**:531-536.
146. Lockman, H. A., and R. Curtiss III. 1992. Virulence of non-type 1-fimbriated and nonfimbriated nonflagellated *Salmonella typhimurium* mutants in murine typhoid fever. *Infect. Immun.* **60**:491-496.
147. Tacket, C. O., D. Hone, R. Curtiss III, S. Kelly, G. Losonsky, L. Guers, A. M. Harris, R. Edelman, and M. Levine, 1992. Comparison of the safety and immunogenicity of Δ *arpC* Δ *aroD* and Δ *lya* Δ *crp* *Salmonella typhi* strains in adult volunteers. *Infect. Immun.* **60**:536-541.
148. Toth, T. E., R. Curtiss III, H. Veit, R. H. Pyle, and P. B. Siegel. 1992. Reaction of the avian respiratory system to intratracheally administered avirulent *Salmonella typhimurium*. *Avian Dis.* **36**:24-29.
149. Honeyman, A. L., and R. Curtiss III. 1992. Isolation, characterization, and nucleotide sequence of the *Streptococcus mutans* mannitol-phosphate dehydrogenase gene and the mannitol-specific factor III gene of the phosphoenolpyruvate phosphotransferase system. *Infect. Immun.* **60**:3369-3375.
150. Lottenberg, R, C. C. Broder, M. D. P. Boyle, S. J. Kain, B. L. Schroeder, and R. Curtiss III. 1992. Cloning, sequence analysis, and expression in *Escherichia coli* of a streptococcal plasmin receptor. *J. Bacteriol.* **174**:5204-5210.
151. Rahn, K., S. A. DeGrandis, R. C. Clarke, S. A. McEwen, J. E. Galan, C. Ginocchio, R. Curtiss III, and C. L. Gyles. 1992. Amplification of an *invA* gene sequence of *Salmonella typhimurium* by polymerase chain reaction as a specific method of detection of *Salmonella*. *Mol. Cell. Probes* **6**:271-279.
152. Lockman, H. A., and R. Curtiss III. 1992. Isolation and characterization of conditional adherent and non-type 1 fimbriated *Salmonella typhimurium* mutants. *Mol. Microbiol.* **6**:933-945.
153. Spatafora-Harris, G., S. M. Michalek, and R. Curtiss III. 1992. Cloning of a locus involved in *Streptococcus mutans* intracellular polysaccharide accumulation and virulence-testing of an intracellular polysaccharide-deficient mutant. *Infect. Immun.* **60**:3175-3185.
154. Kelly, S. M., B. A. Bosecker, and R. Curtiss III. 1992. Characterization and protective properties of attenuated mutants of *Salmonella choleraesuis*. *Infect. Immun.* **60**:4881-4890.
155. Gentry-Weeks, C. R., A-L Hultsch, S. M. Kelly, J. M. Keith, and R. Curtiss III. 1992. Cloning and sequencing of a 21 kDa outer membrane protein gene from *Bordetella avium*: expression in *Salmonella typhimurium*. *J. Bacteriol.* **174**:7729-7742.
156. Jagusztyn-Krynicka, E. K., J. B. Hansen, V. L. Crow, T. D. Thomas, A. L. Honeyman, and R. Curtiss III. 1992. *Streptococcus mutans* serotype c tagatose 6-phosphate pathway gene cluster. *J. Bacteriol.* **174**:6152-6158.
157. Doggett, T., and R. Curtiss III. 1992. Delivery of antigens by recombinant avirulent *Salmonella* strains, p. 165-173, *In* J. E. Ciardi, J. R. McGhee, and Jerry M. Keith (eds.), *Genetically engineered vaccines*. Plenum Press, NY.

158. Provence, D. L., and R. Curtiss III. 1992. Role of *crl* in avian pathogenic *Escherichia coli*: a knock-out mutation of *crl* does not affect hemagglutination activity, fibronectin binding, or curli production. *Infect. Immun.* **60**:4460-4467.
159. Curtiss, R. III, and S. A. Tinge. 1993. Recombinant avirulent *Salmonella* vaccines and prospects for an antifertility vaccine, p. 459-476, *In* P.D. Griffin & P.M. Johnson (eds.), *Proceedings of the Symposium on Local Immunity in Reproduction Tract Tissues*, New Delhi, India, Nov. 1990. Oxford University Press.
160. Hassan, O., S. Porter, and R. Curtiss III. 1993. Effect of infective dose on humoral immune responses and colonization in chickens experimentally infected with *Salmonella typhimurium*. *Avian Dis.* **37**:19-26.
161. Jagusztyn-Krynicka, E. K., J. E. Clark-Curtiss, and R. Curtiss III. 1993. *Escherichia coli* heat-labile toxin subunit B fusions with *Streptococcus sobrinus* antigens expressed by *Salmonella typhimurium* oral vaccine strain: importance of the linker for antigenicity and biological activities of the hybrid proteins. *Infect. Immun.* **61**:1004-1015.
162. Doggett, T., E. K. Jagusztyn-Krynicka, and R. Curtiss III. 1993. Immune responses to *Streptococcus sobrinus* surface protein antigen A expressed by recombinant *Salmonella typhimurium*. *Infect. Immun.* **61**:1859-1866.
163. Porter, S. B., S. A. Tinge, and R. Curtiss III. 1993. Virulence of *Salmonella typhimurium* mutants for white leghorn chicks. *Avian Dis.* **37**:265-273.
164. Curtiss, R. III, S. M. Kelly, and J. O. Hassan. 1993. Live oral avirulent *Salmonella* vaccines. *Vet. Microbiol.* **37**:397-405.
165. Provence, D. L., and R. Curtiss III. 1993. Gene transfer in gram negative bacteria, p 317-347, *In* P. Gerhardt, (ed.), *Methods for General and Molecular Bacteriology*. American Society for Microbiology, Washington, D.C.
166. Curtiss, R. III, D. L. MacLeod, H. A. Lockman, J. E. Galan, S. M. Kelly, and G. G. Mahairas. 1993. Colonization and invasion of the intestinal tract by *Salmonella*, p. 191-198, *In* F. Cabello (ed.), *Biology of Salmonella*. Plenum Press, NY.
167. Singh, V., and R. Curtiss III. 1993. Disulfide linked \square_{GelB} in conjugate failed to recombine with \square_{oLH} subunit to generate bioeffective hormonotoxin. *Molec. Cell. Biochem.* **120**:95-102.
168. Levine, M. M., D. M. Hone, C.O. Tacket, M. Sztein, G. Losonsky, J. P. Nataro, C. Gonzalez, G. Dougan, S. Chatfield, S. Cryz, R. Curtiss III, and S. Kelley (sic). 1993. Attenuated *Salmonella typhi* as live oral vaccines to prevent typhoid fever and as carrier vaccines to express foreign antigens, p. 343-346, *In* F. Cabello (ed.), *Biology of Salmonella*. Plenum Press, NY.
169. Honeyman, A. L., and R. Curtiss III. 1993. Isolation, characterization, and nucleotide sequence of the *Streptococcus mutans* lactose-specific enzyme II (*lacE*) gene of the PTS and the phospho-beta-galactosidase (*lacG*) gene. *J. Gen. Microbiol.* **139**:2685-2694.
170. Michalek, S. M., J. H. Eldridge, R. Curtiss III, and K. L. Rosenthal. 1994. Antigen delivery systems: new approaches to mucosal immunization, p. 373-390, *In* P. L. Ogra, J. Mestecky, M. Lamm, W. Strober, J. McGhee, and J. Bienenstock (eds.), *Handbook of Mucosal Immunology*. Academic Press, San Diego, CA.
171. Wanda, S. -Y., and R. Curtiss III. 1994. Purification and characterization of *Streptococcus sobrinus* dextranase produced in recombinant *Escherichia coli* and sequence analysis of the dextranase gene. *J. Bacteriol.* **176**:3839-3850.
172. Singh, V., and R. Curtiss III. 1994. Effect of amino group modification of ovine luteinizing hormone (oLH) by M-succinimidyl 6-[3-(2-pyridyldithio)propionate]hexanoate, a long chain M-succinimidyl-3-(2-pyridyldithio)propionate (SPDP) on immunological and biological properties: a comparative study with SPDP modified oLH. *Molec. Cell. Biochem.* **130**:83-90.

173. Singh, V., and R. Curtiss III. 1994. Hormonotoxins: The role of positive charge of lysine residue on the immunological, biological and cytotoxic properties of ovine lutropin-S-S-gelonin conjugates. *Molec. Cell. Biochem.* **130**:91-101.
174. Curtiss, R. III, J. O. Hassan, J. Herr, S. M. Kelly, M. Levine, G. G. Mahairas, D. Milich, D. Peterson, F. Schodel, J. Srinivasan, C. Tacket, S. A. Tinge, and R. Wright. 1994. Nonrecombinant and recombinant avirulent *Salmonella* vaccines, p. 340-351, *In* G. P. Talwar, K. V. S. Rao, and V. S. Chauhan (eds.), *Recombinant and Synthetic Vaccines*. Narosa Publishing House, New Delhi, India.
175. Hassan, J. O., and R. Curtiss III. 1994. Virulent *Salmonella typhimurium* induced lymphocyte depletion and immunosuppression in chickens. *Infect. Immun.* **62**:2027-2036.
176. Provence, D. L., and R. Curtiss III. 1994. Isolation and characterization of a gene involved in hemagglutination by an avian pathogenic *Escherichia coli* strain. *Infect. Immun.* **62**:1369-1380.
177. Hassan, J. O., and R. Curtiss III. 1994. Development and evaluation of an experimental vaccination program using live avirulent *Salmonella typhimurium* to protect immunized chickens against challenge with homologous and heterologous *Salmonella* serotypes. *Infect. Immun.* **62**:5519-5527.
178. Curtiss, R. III, S. M. Kelly, S. A. Tinge, C. O. Tacket, M. Levine, J. Srinivasan, and M. Koopman. 1994. Recombinant *Salmonella* vectors in vaccine development, p. 23-33, Vol. 82, *In* F. Brown (ed.), *Recombinant Vectors in Vaccine Development*. Dev. Biol. Stand. Basel, Switzerland.
179. Schodel, F., S. M. Kelly, D. Peterson, D. Milich, J. Hughes, S. Tinge, R. Wirtz, and R. Curtiss III. 1994. Development of recombinant *Salmonellae* expressing hybrid hepatitis B virus core particles as candidate oral vaccines, p. 151-158, Vol. 82, *In* F. Brown (ed.), *Recombinant Vectors in Vaccine Development*. Dev. Biol. Stand. Basel, Switzerland.
180. Schodel, F., S. M. Kelly, D. L. Peterson, D. R. Milich, and R. Curtiss III. 1994. Hybrid hepatitis B virus core/pre-S proteins synthesized in avirulent *Salmonella typhimurium* and *Salmonella typhi* for oral vaccination. *Infect. Immun.* **62**:1669-1676.
181. Wanda, S. -Y., A. Camilli, H. M. Murchison, and R. Curtiss III. 1994. Overproduction of a dextranase inhibitor by *Streptococcus sobrinus* mutants. *J. Bacteriol.* **176**:7206-7212.
182. Sun, J. -W., S. -Y. Wanda, A. Camilli, and R. Curtiss III. 1994. Cloning and DNA sequencing of the dextranase inhibitor gene (*dei*) from *Streptococcus sobrinus*. *J. Bacteriol.* **176**:7213-7222.
183. Sun, J. -W., S. -Y. Wanda, and R. Curtiss III. 1995. Purification, characterization and function of dextranase inhibitor (Dei) expressed from *Streptococcus sobrinus* UAB108 gene cloned in *Escherichia coli*. *J. Bacteriol.* **177**:1703-1711.
184. Srinivasan, J., A. Nayak, R. Curtiss III, and S. Rubino. 1995. Effect of the route of immunization using recombinant *Salmonella* on mucosal and humoral immune responses, p. 273-280, *In* R. M. Chanock, F. Brown, H. S. Ginsberg, and E. Norrby (eds.), *Vaccines 95: Molecular approaches to the control of infectious diseases*, Cold Spring Harbor Laboratory Press, Plainview, N.Y.
185. Srinivasan, J., S. Tinge, R. Wright, J. C. Herr, and R. Curtiss III. 1995. Oral immunization with attenuated *Salmonella* expressing human sperm antigen induces antibodies in serum and the reproductive tract. *Biol. Reprod.* **53**:462-471.
186. Stone, G. G., R. D. Oberst, M. P. Hays, S. McVey, J. C. Galland, R. Curtiss III, S. M. Kelly, and M. M. Chengappa. 1995. Detection of *Salmonella typhimurium* from rectal swabs of experimentally infected beagles by short cultivation and PCR-hybridization. *J. Clin. Microbiol.* **33**:1292-1295.
187. Zhang, X., and R. Curtiss III. 1995. Contraceptive vaccine development: attenuated *Salmonella* vaccine expressing a sperm-specific antigen induced antibody response. (Manuscript in Chinese.) p. 444-450, *In*

Proceedings of the Second Academic Conference of Young Scientists. China Association for Science and Technology, Beijing, China.

188. Schodel, F., and R. Curtiss III. 1995. *Salmonella* as oral vaccine carriers. *Dev. Biol. Stand.* **84**:245-253.
189. Honeyman, A. L., and R. Curtiss III. 1995. Analysis of the promoter region of the *S. mutans* mannitol PTS operon, p. 383-386, *In* J. J. Ferretti, M. S. Gilmore, T. R. Klaenhammer, and F. Brown, (eds.), *Genetics of Streptococci, Enterococci and Lactococci*. *Dev. Biol. Stand.* Basel, Switzerland.
190. Enjuanes, L., C. Smerdou, C. M. Sanchez, C. Sune, S. Kelly, R. Curtiss III, and J. M. Torres. 1995. Induction of transmissible gastroenteritis coronavirus specific immune responses using vectors with enteric tropism. *Adv. Exp. Med. Biol.* **371B**:1535-1541.
191. Curtiss, R. III, and J. O. Hassan. 1996. Nonrecombinant and recombinant avirulent *Salmonella* vaccines for poultry. *Vet. Immunol. Immunopath.* **54**:365-372.
192. Lee, M. D., R. Curtiss III, and T. Peay. 1996. The effect of bacterial surface structures on the pathogenesis of *Salmonella typhimurium* infection in chickens. *Avian Dis.* **40**:28-36.
193. Wilmes-Riesenberg, M. R., J. W. Foster, B. Bearson, and R. Curtiss III. 1996. Role of the acid tolerance response in virulence of *Salmonella typhimurium*. *Infect. Immun.* **64**:1085-1092.
194. Hassan, J. O., and R. Curtiss III. 1996. Effect of vaccination of hens with an avirulent strain of *Salmonella typhimurium* on immunity of progeny challenged with wild-type *Salmonella* strains. *Infect. Immun.* **64**:938-944.
195. Curtiss, R. III, T. Doggett, A. Nayak, and J. Srinivasan. 1996. Strategies for the use of live recombinant avirulent bacterial vaccines for mucosal immunization, p. 499-511, *In* H. Kiyono and M.F. Kagnoff, (eds.), *Essentials of Mucosal Immunology*. Academic Press, San Diego, CA.
196. Neidhardt, F. C., R. Curtiss III, J. L. Ingraham, E.C.C. Lin, K. B. Low, B. Magasanik, W. S. Reznikoff, M. Riley, M. Schaechter, and H. E. Umbarger. 1996. *Escherichia coli* and *Salmonella*. *Cellular and Molecular Biology*, 2nd ed., ASM Press, Washington, D.C.
197. Schaechter, M., R. Curtiss III, J. L. Ingraham, E. C. C. Lin, K. B. Low, B. Magasanik, F. C. Neidhardt, W.S. Reznikoff, M. Riley, and H. E. Umbarger. 1996. Epilog: The view from here, p. 2817-2822, *In* F. C. Neidhardt et al., (ed.) *Escherichia coli* and *Salmonella*. *Cellular and Molecular Biology*, 2nd ed., ASM Press, Washington, D.C.
198. Smerdou C., A. Urniza, R. Curtiss III, and L. Enjuanes. 1996. Characterization of transmissible gastroenteritis coronavirus S protein expression products in virulent *S. typhimurium* Δ *gya* Δ *grp*: persistence, stability and immune response in swine. *Vet. Microbiol.* **48**:87-100.
199. Smerdou, C., I. M. Anton, J. Plana, R. Curtiss III, and L. Enjuanes. 1996. A continuous epitope from transmissible gastroenteritis virus S protein fused to *E. coli* heat-labile toxin B subunit expressed by attenuated *Salmonella* induces serum and secretory immunity. *Virus Res.* **41**:1-9.
200. Brown, P. K., and R. Curtiss III. 1996. Unique chromosomal regions associated with virulence of an avian pathogenic *Escherichia coli* strain. *Proc. Natl. Acad. Sci. USA* **93**:11149-11154.
201. Saltzman, D. A., C. P. Heise, D. E. Hasz, M. Zebede, S. M. Kelly, R. Curtiss III, A. S. Leonard, and P. M. Anderson. 1996. Attenuated *Salmonella typhimurium* containing interleukin-2 decreases MC-38 hepatic metastases: a novel anti-tumor agent. *Cancer Biother. Radiopharm.* **11**:145-153.
202. Nardelli-Haefliger, D., J. -P. Kraehenbuhl, R. Curtiss III, F. Schodel, A. Potts, S. Kelly, and P. De Grandi. 1996. Oral and rectal immunization of adult female volunteers with a recombinant attenuated *Salmonella typhi* vaccine strain. *Infect. Immun.* **64**:5219-5224.
203. Schodel, F., S. Kelly, S. Tinge, S. Hopkins, D. Peterson, D. Milich, and R. Curtiss III. 1996. Hybrid hepatitis B virus core antigen as a vaccine carrier moiety II. Expression in avirulent *Salmonella spp* for mucosal

- immunization. p.15-21 *In* S. Cohen and A. Shafferman (eds.) *Novel Strategies in Design and Production of Vaccines*. Plenum Press, N.Y.
204. Curtiss, R. III, L. L. Burns-Keliher, B. J. Morrow, C. A. Nickerson, and M. R. Wilmes-Riesenberg. 1996. Toward an understanding of *Salmonella* pathogenicity. *Acta. Microbiol. Polonica* **44**:189-203.
 205. Zhang, X., Y. Lou, M. Koopman, T. Doggett, K. S. K. Tung, and R. Curtiss III. 1997. Antibody responses and infertility in mice following oral immunization with attenuated *Salmonella typhimurium* expressing recombinant murine ZP3. *Biol. Reprod.* **56**:33-41.
 206. Wilmes-Riesenberg, M. R., J. W. Foster, and R. Curtiss III. 1997. An altered *rpoS* allele contributes to the avirulence of *Salmonella typhimurium* LT2. *Infect. Immun.* **65**:203-210.
 207. Georgiou, G., C. Stathopoulos, P. S. Daugherty, A. R. Nayak, B. L. Iverson, and R. Curtiss III. 1997. Display of heterologous proteins on the surface of microorganisms: from the screening of combinatorial libraries to live recombinant vaccines. *Nature Biotech.* **15**:29-34.
 208. Porter, S. B., and R. Curtiss III. 1997. Effect of *inv* mutations on *Salmonella* virulence and colonization in one-day-old white leghorn chicks. *Avian Dis.* **41**:45-57.
 209. Saltzman, D. A., E. Katsanis, C. P. Heise, D. Hasz, S. M. Kelly, R. Curtiss III, A. S. Leonard, and P. M. Anderson. 1997. Patterns of hepatic and splenic colonization by an attenuated strain of *Salmonella typhimurium* containing the gene for human interleukin-2: A novel anti-tumor agent. *Cancer Biother. Radiopharm.* **12**:37-45.
 210. Nickerson, C. A., and R. Curtiss III. 1997. Role of sigma factor RpoS in initial stages of *Salmonella typhimurium* infection. *Infect. Immun.* **65**:1814-1823.
 211. Grey, W. T., R. Curtiss III, and M. C. Hudson. 1997. Expression of the *Streptococcus mutans* fructosyltransferase gene within a mammalian host. *Infect. Immun.* **65**:2488-2490.
 212. Burns-Keliher, L., A. Portteus, and R. Curtiss III. 1997. Specific detection of *Salmonella typhimurium* proteins synthesized intracellularly. *J. Bacteriol.* **179**:3604-3612.
 213. Tacket, C. O., S. M. Kelly, F. Schodel, G. Losonsky, J. P. Nataro, R. Edelman, M. M. Levine, and R. Curtiss III. 1997. Safety and immunogenicity in humans of an attenuated *Salmonella typhi* vaccine vector strain expressing plasmid-encoded Hepatitis B antigens stabilized by the Asd-balanced lethal vector system. *Infect. Immun.* **65**:3381-3385.
 214. Saltzman, D. A., E. Katsanis, C. P. Heise, D. E. Hasz, V. Vigdorovich, S. M. Kelly, R. Curtiss III, A. S. Leonard, and P. M. Anderson. 1997. Antitumor mechanisms of attenuated *Salmonella typhimurium* containing the gene for human interleukin-2: a novel antitumor agent? *J. Pediatr. Surg.* **32**:301-306.
 215. Zhang, X., S. M. Kelly, W. S. Bollen, and R. Curtiss III. 1997. Characterization and immunogenicity of *Salmonella typhimurium* SL1344 and UK-1 Δ *crp* and Δ *cdt* deletion mutants. *Infect. Immun.* **65**:5381-5387.
 216. Hassan, J. O., and R. Curtiss III. 1997. Efficacy of a live avirulent *Salmonella typhimurium* vaccine in preventing colonization and invasion of laying hens by *Salmonella typhimurium* and *Salmonella enteritidis*. *Avian Dis.* **41**:783-791.
 217. Meyer, P. N., M. R. Wilmes-Riesenberg, C. Stathopoulos, and R. Curtiss III. 1998. Virulence of a *Salmonella typhimurium* *OmpD* mutant. *Infect. Immun.* **66**:387-390.
 218. Burns-Keliher, L. L., C. A. Nickerson, B. Morrow, and R. Curtiss III. 1998. Cell-specific proteins synthesized by *Salmonella typhimurium*. *Infect. Immun.* **66**:856-861.

219. Nayak, A. R., S. A. Tinge, R. C. Tart, L. S. McDaniel, D. E. Briles, and R. Curtiss III. 1998. A live recombinant avirulent oral *Salmonella* vaccine expressing pneumococcal surface protein A (PspA) induced protective responses against *Streptococcus pneumoniae*. *Infect. Immun.* **66**:3744-3751.
220. Kaniga, K., M. S. Compton, R. Curtiss III, and P. Sundaram. 1998. Molecular and functional characterization of *Salmonella enterica* serovar Typhimurium *poxA* gene: effect on attenuation of virulence and protection. *Infect. Immun.* **66**:5599-5606.
221. Grey, W. T., J. D. Lasker, R. Curtiss III, and M. C. Hudson. 1998. Examination of streptococcal gene expression in the mammalian environment. *Meth. Cell Sci.* **20**:137-142.
222. Zhang, X., S. M. Kelly, W. Bollen, and R. Curtiss III. 1999. Protection and immune responses induced by attenuated *Salmonella typhimurium* UK-1 strains. *Microb. Pathog.* **26**:121-130.
223. Stathopoulos, C., D. L. Provence, and R. Curtiss III. 1999. Characterization of the avian pathogenic *Escherichia coli* hemagglutinin Tsh, a member of the immunoglobulin A protease-type family of autotransporters. *Infect. Immun.* **67**:772-781.
224. Thankavel, K., A. H. Shah, M. S. Cohen, T. Ikeda, R. G. Lorenz, R. Curtiss III, and S. N. Abraham. 1999. Molecular basis for the enterocyte tropism exhibited by *Salmonella typhimurium* type 1 fimbriae. *J. Biol. Chem.* **274**:5797-5809.
225. Dozois, C. M., and R. Curtiss III. 1999. Pathogenic diversity of *Escherichia coli* and the emergence of 'exotic' islands in the gene stream. *Vet. Res.* **30**:157-179.
226. Curtiss, R. III. 1999. Genetically modified plants for use as oral immunogens. *Mucosal Immunol. Update* **7**:10-12.
227. Hassan, J. O., and R. Curtiss III. 1999. Control of *Salmonella enterica* serovar Enteritidis infection in chickens by using live avirulent *Salmonella typhimurium* vaccine strain, p. 405-412, *In* A. M. Saeed, R. K. Gast, M. E. Potter, and P. G. Wall (eds.), *Salmonella enterica* Serovar Enteritidis in Humans and Animals. Iowa State University Press, Ames, IA.
228. Kennedy, M. J., R. J. Yancey, Jr., M. S. Sanchez, R. A. Rzepkowski, S. M. Kelly, and R. Curtiss III. 1999. Attenuation and immunogenicity of $\Delta cya \Delta crp$ derivatives of *Salmonella choleraesuis* in pigs. *Infect. Immun.* **67**:4628-4636.
229. Roland, K., R. Curtiss III, and D. Sizemore. 1999. Construction and evaluation of a $\Delta cya \Delta crp$ *Salmonella typhimurium* strain expressing avian pathogenic *Escherichia coli* O78 LPS as a vaccine to prevent air sacculitis in chickens. *Avian Dis.* **43**:429-441. *Received the P. P. Levine Award from American Association of Avian Pathologists for best manuscript published in 1999.
230. Morrow, B. J., J. E. Graham, and R. Curtiss III. 1999. Genomic subtractive hybridization and selective capture of transcribed sequences identify a novel *Salmonella typhimurium* fimbrial operon and putative transcriptional regulator that are absent from the *Salmonella typhi* genome. *Infect. Immun.* **67**:5106-5116.
231. Webb, C., M. Moreno, M. Wilmes-Riesenberg, R. Curtiss III, and J. W. Foster. 1999. Effects of DksA and ClpP protease on sigma S production and virulence in *Salmonella typhimurium*. *Mol. Microbiol.* **34**:112-123.
232. Benyacoub, J., S. Hopkins, A. Potts, S. Kelly, J. P. Kraehenbuhl, R. Curtiss III, P. DeGrandi, and D. Nardelli-Haefliger. 1999. The nature of the attenuation of *Salmonella typhimurium* strains expressing human papillomavirus type 16 virus-like particles determines the systemic and mucosal antibody responses in nasally immunized mice. *Infect. Immun.* **67**:3674-3679.
233. Honeyman, A. L., and R. Curtiss III. 2000. The mannitol-specific enzyme II $\Delta mtIA$ gene and the *mtIR* gene of the PTS of *Streptococcus mutans*. *Microbiology* **146**:1565-1572.

234. Dozois, C. M., M. Dho-Moulin, A. Brée, J. M. Fairbrother, C. Desautels, and R. Curtiss III. 2000. Relationship between the Tsh autotransporter and pathogenicity of avian *Escherichia coli*, and localization and analysis of the *tsh* genetic region. *Infect. Immun.* **68**:4145-4154.
235. Stathopoulos, C., D. R. Hendrixson, D. G. Thanassi, S. J. Hultgren, J. W. St. Geme III, and R. Curtiss III. 2000. Secretion of virulence determinants by the general secretory pathway in Gram-negative pathogens: an evolving story. *Microbes Infect.* **2**:1061-1072.
236. Maurer, J. J., T. A. Doggett, L. Burns-Keliker, and R. Curtiss III. 2000. Expression of the *rfa*, LPS biosynthesis promoter in *Salmonella typhimurium* during invasion of intestinal epithelial cells. *Curr. Microbiol.* **41**:172-176.
237. Curtiss, R. III, S. Blower, K. Cooper, D. Russell, S. Silverstein, and L. Young. 2000. Leprosy research in the post-genome era: Workshop. *Int. J. Lepr.* **68**:492-503.
238. Schaechter, M., and The View From Here Group (J. Beckwith, R. Curtiss III, W. Hatfield, J. Ingraham, K. B. Low, B. Magasanik, F. Neidhardt, W. Reznikoff, and M. Riley). 2001. *Escherichia coli* and *Salmonella* 2000: The view from here. *Microbiol. Mol. Biol. Rev.* **65**:119-130.
239. Sheoran, A. S., J. F. Timoney, S. A. Tinge, P. Sundaram, and R. Curtiss III. 2001. Intranasal immunogenicity of a Δ *cya* Δ *crp-pabA* mutant of *Salmonella enterica* serovar Typhimurium for the horse. *Vaccine.* **19**:3591-3599.
240. Sheoran, A. S., J. F. Timoney, S. A. Tinge, P. Sundaram, and R. Curtiss III. 2001. Intranasal immunogenicity of a Δ *cya* Δ *crp-pabA* mutant of *Salmonella enterica* serovar Typhimurium for the horse. *Vaccine.* **19**:3787-3795.
241. Brown, P. K., C. M. Dozois, C. A. Nickerson, A. Zuppardo, J. Terlonge, and R. Curtiss III. 2001. MlrA a novel regulator of curli (Agf) synthesis and aggregation by *Escherichia coli* and *Salmonella enterica* serovar Typhimurium. *Mol. Microbiol.* **41**:349-363.
242. Curtiss, R. III, S. Blower, K. Cooper, D. Russell, S. Silverstein, and L. Young. 2001. Leprosy research in the post-genome era. *Lepr. Rev.* **72**:8-22.
243. Daigle, F., J. E. Graham, and R. Curtiss III. 2001. Identification of *Salmonella typhi* genes expressed within macrophages by selective capture of transcribed sequences (SCOTS). *Mol. Microbiol.* **41**:1211-1222.
*Recommended by Faculty of 1000 Biology
244. Frey, S. E., W. Bollen, D. Sizemore, M. Campbell, and R. Curtiss III. 2001. Bacteremia associated with live attenuated (8110 *Salmonella enterica* serovar Typhi ISP1820 in healthy adult volunteers. *Clin. Immunol.* **101**:32-37.
245. Curtiss, R. III. 2001. Vaccines and vaccine technology to prevent typhoid and *Salmonella* diarrheal diseases, p. 1-24. *In* Typhoid Fever and other Salmonellosis. Proceedings of the 4th International Symposium. Jeou-Chou Book Co., LTD, Taipei, Taiwan, R.O.C.
246. Kang, H. Y., C. M. Dozois, S. A. Tinge, T. H. Lee, and R. Curtiss III. 2002. Transduction-mediated transfer of unmarked deletion and point mutations through use of counterselectable suicide vectors. *J. Bacteriol.* **184**:307-312.
247. Kang, H. Y., J. Srinivasan, and R. Curtiss III. 2002. Immune responses to recombinant pneumococcal PspA antigen delivered by live attenuated *Salmonella enterica* serovar typhimurium vaccine. *Infect. Immun.* **70**:1739-1749.
248. Honeyman, A. L., C. K. Cote, and R. Curtiss III. 2002. Construction of transcriptional and translational *lacZ* gene reporter plasmids for use in *Streptococcus mutans*. *J. Microbiol. Meth.* **49**:163-171.
249. McVey, D. S., M. M. Chengappa, D. E. Mosier, G. G. Stone, R. D. Oberst, M. J. Sylte, N. M. Gabbert, S. M. Kelly-Aehle, and R. Curtiss III. 2002. Immunogenicity of (⁴¹²⁷ *phoP* – *Salmonella enterica* serovar Typhimurium in dogs. *Vaccine.* **20**:1618-1623.

250. Schnapp, A. R., C. S. Eickhoff, D. Sizemore, R. Curtiss III, and D. F. Hoft. 2002. Cruzipain induces both mucosal and systemic protection against *Trypanosoma cruzi* in mice. *Infect. Immun.* **70**:5065-5074.
251. Curtiss, R. III. 2002. Perspective: Bacterial infectious disease control by vaccine development. *J. Clin. Invest.* **110**:1061-1066.
252. Curtiss, R. III. 2002. Bacterial biotechnology and development of recombinant attenuated vaccines, p. 21-38. *In Proceedings of the International Conference "Genetically Modified Organisms: Doubts and certainties"*, Porto Conte Ricerche Center, Alghero, Italy. Vol. 3.
253. Mellata, M., M. Dho-Moulin, C. M. Dozois, R. Curtiss III, B. Lehoux, and J. M. Fairbrother. 2003. Role of avian pathogenic *Escherichia coli* virulence factors in bacterial interaction with chicken heterophils and macrophages. *Infect. Immun.* **71**:494-503.
254. Mellata, M., M. Dho-Moulin, C. M. Dozois, R. Curtiss III, P. Brown, P. Arne, A. Bree, C. Desautels, and J. M. Fairbrother. 2003. Role of virulence factors in resistance of avian pathogenic *Escherichia coli* to serum and in pathogenicity. *Infect. Immun.* **71**:536-540.
255. Dozois, C. M., F. Daigle, and R. Curtiss III. 2003. Identification of pathogen-specific and conserved genes expressed in vivo by an avian pathogenic *Escherichia coli* strain. *Proc. Natl. Acad. Sci. USA.* **100**:247-252.
256. Kang, H. Y., and R. Curtiss III. 2003. Immune responses dependent on antigen location in recombinant attenuated *Salmonella typhimurium* vaccines following oral immunization. *FEMS Immunol. Med. Microbiol. Lett.* **37**:99-104.
257. Baud, D., J. Benyacoub, V. Revaz, M. Kok, F. Ponci, M. Bobst, R. Curtiss III, P. De Grandi, and D. Nardelli-Haefliger. 2004. Immunogenicity against human papillomavirus type 16 virus-like particles is strongly enhanced by the PhoP^c phenotype in *Salmonella enterica* serovar Typhimurium. *Infect. Immun.* **72**:750-756.
258. Abromaitis, S., S. Faucher, M. Beland, R. Curtiss III, and F. Daigle. 2005. The presence of the *tet* gene from cloning vectors impairs *Salmonella* survival in macrophages. *FEMS Microbiol. Lett.* **242**:305-312.
259. Curtiss, R. III. 2005. Antigen delivery systems I: Development of live recombinant attenuated bacterial antigen and DNA vaccine delivery vector vaccines, p. 1009-1037, Vol. I. *In* J. Mestecky, M.E. Lamm, W. Strober, J. Bienenstock, J.R. McGhee, and L. Mayer (eds.). *Mucosal Immunology*, 3rd ed., Elsevier Academic Press.
260. Lamarche, M. G., C. M. Dozois, F. Daigle, M. Caza, R. Curtiss III, J. D. Dubreuil, and J. Harel. 2005. Inactivation of the Pst system reduces the virulence of an avian pathogenic *Escherichia coli* O78 strain. *Infect. Immun.* **73**:4138-4145.
261. Uzzau, S., G. Marogna, G. S. Leori, R. Curtiss III, G. Schianchi, B. A. D. Stocker, and S. Rubino. 2005. Virulence attenuation and live vaccine potential of *aroA*, *crp* *cdt cya*, and plasmid-cured mutants of *Salmonella enterica* serovar Abortusovis in mice and sheep. *Infect. Immun.* **73**:4302-4308.
262. Faucher, S. P., R. Curtiss III, and F. Daigle. 2005. Selective capture of *Salmonella enterica* serovar typhi genes expressed in macrophages that are absent from the *Salmonella enterica* serovar Typhimurium genome. *Infect. Immun.* **73**:5217-5221.
263. Konjufca, V., S. Y. Wanda, M. C. Jenkins, and R. Curtiss III. 2006. A recombinant attenuated *Salmonella enterica* serovar Typhimurium vaccine encoding *Eimeria acervulina* antigen offers protection against *E. acervulina* challenge. *Infect. Immun.* **74**:6785-6796.
264. Loessner, H., A. Endmann, M. Rohde, R. Curtiss III, and S. Weiss. 2006. Differential effect of auxotrophies on the release of macromolecules by *Salmonella enterica* vaccine strains. *FEMS Microbiol. Lett.* **265**:81-88.
265. Santander, J., S. Y. Wanda, C. Nickerson, and R. Curtiss III. 2007. Role of RpoS in fine-tuning the synthesis of Vi capsular polysaccharide in *Salmonella enterica* serotype Typhi. *Infect. Immun.* **75**:1382-1392.

266. Mahoney, R. T., A. Krattiger, A., J. D. Clemens, and R. Curtiss III. 2007. The introduction of new vaccines into developing countries IV: global access strategies. *Vaccine* **25**:4003-4011.
267. Curtiss, R. III, X. Zhang, S. Y. Wanda, H. Y. Kang, V. Konjufca, Y. Li, B. Gunn, S. Wang, G. Scarpellini, and I. S. Lee. 2007. Induction of host immune responses using *Salmonella*-vectored vaccines, p. 297-313. In K. A. Brogden, F. C. Minion, N. Cornick, T. B. Stanton, Q. Zhang, L. K. Nolan, and M. J. Wannemuehler (eds.). *Virulence Mechanisms of Bacterial Pathogens*, 4th ed., ASM Press, Washington, D.C.
268. Branger, C., J. Fetherston, R. Perry, and R. Curtiss III. 2007. Oral vaccination with different antigens from *Yersinia pestis* KIM delivered by live attenuated *Salmonella* Typhimurium elicits a protective immune response against plague. *Adv. Exp. Med. Biol.* **603**:387-399.
269. Sabri, M., M. Caza, J. Proulx, M. H. Lymberopoulos, A. Brée, M. Moulin-Schouleur, R. Curtiss III, and C. M. Dozois. 2008. Contribution of the SitABCD, MntH, and FeoB metal transporters to the virulence of avian pathogenic *Escherichia coli* O78 strain χ 7122. *Infect. Immun.* **76**:601-611. PMID: [PMC2223448](#)
270. Zekarias, B., H. Mo, and R. Curtiss III. 2008. Recombinant attenuated *Salmonella enterica* serovar Typhimurium expressing the carboxy-terminal domain from δ toxin from *Clostridium perfringens* induces protective responses against necrotic enteritis in chickens. *Clin. Vaccine Immunol.* **15**:805-816. PMID: [PMC2394831](#)
271. Xin, W., S. Y. Wanda, Y. Li, S. Wang, H. Mo, and R. Curtiss III. 2008. Analysis of type II secretion of recombinant pneumococcal PspA and PspC in a *Salmonella enterica* serovar Typhimurium vaccine with regulated delayed antigen synthesis. *Infect. Immun.* **76**:3241-3254. PMID: [PMC2446722](#)
272. Bollen, W., B. M. Gunn, H. Mo, M. K. Lay, and R. Curtiss III. 2008. Presence of wild-type and attenuated *Salmonella enterica* strains in brain tissues following inoculation of mice by different routes. *Infect. Immun.* **76**:3268-3272. PMID: [PMC2446729](#)
273. Sun, W., S. Wang, and R. Curtiss III. 2008. Highly efficient method for introducing successive multiple scarless gene deletions and markerless gene insertions into the *Yersinia pestis* chromosome. *Appl. Environ. Microbiol.* **74**:4241-4245. PMID: [PMC2446500](#)
274. Kong, W., S. Y. Wanda, X. Zhang, W. Bollen, S. A. Tinge, K. L. Roland, and R. Curtiss III. 2008. Regulated programmed lysis of recombinant *Salmonella* in host tissues to release protective antigens and confer biological containment. *Proc. Natl. Acad. Sci. USA* **105**:9361-9366. PMID: [PMC2453710](#)
275. Smith, J. N., J. L. Dyszel, J. A. Soares, C. D. Ellermeier, C. Altier, S. D. Lawhon, L. G. Adams, V. Konjufca, R. Curtiss III, J. M. Slauch, and B. M. M. Ahmer. 2008. SdiA, an *N*-acylhomoserine lactone receptor, becomes active during the transit of *Salmonella enterica* through the gastrointestinal tract of turtles. *PLoS ONE* **3**:e2826. PMID: [PMC2475663](#)
276. Song, H., W. Kong, N. Weatherspoon, G. Qin, W. Tyler, J. Turk, R. Curtiss III, and Y. Shi. 2008. Modulation of the regulatory activity of bacterial two-component systems by SlyA. *J. Biol. Chem.* **283**:28158-28168. PMID: [PMC2661387](#)
277. Li, Y., S. Wang, W. Xin, G. Scarpellini, Z. Shi, B. Gunn, K. L. Roland, and R. Curtiss III. 2008. A *sopB* deletion mutation enhances the immunogenicity and protective efficacy of a heterologous antigen delivered by live attenuated *Salmonella enterica* vaccines. *Infect. Immun.* **76**:5238-5246. PMID: [PMC2573344](#)
278. Park, S. M., H. J. Ko, D. H. Shim, J. Y. Yang, Y. H. Park, R. Curtiss III, and M. N. Kweon. 2008. MyD88 signaling is not essential for induction of antigen-specific B cell responses but is indispensable for protection against *Streptococcus pneumoniae* infection following oral vaccination with attenuated *Salmonella* expressing PspA antigen. *J. Immunol.* **181**:6447-6455. PMID: [PMC4063294](#)
279. Konjufca, V., M. Jenkins, S. Wang, M. D. Juarez-Rodriguez, and R. Curtiss III. 2008. Immunogenicity of recombinant attenuated *Salmonella enterica* serovar Typhimurium vaccine strains carrying a gene that encodes *Eimeria tenella* antigen SO7. *Infect. Immun.* **76**:5745-5753. PMID: [PMC2583560](#)

280. Zhao, G., N. Weatherspoon, W. Kong, R. Curtiss, and Y. Shi. 2008. A dual-signal regulatory circuit activates transcription of a set of divergent operons in *Salmonella typhimurium*. Proc. Natl. Acad. Sci. USA **105**:20924-20929. PMID: [PMC2634881](#) *Recommended by Faculty of 1000 Biology
281. Santander, J., K. Roland, and R. Curtiss III. 2008. Regulation of Vi capsular polysaccharide synthesis in *Salmonella enterica* serotype Typhi. J. Infect. Developing Countries **2**:412-420. PMID: [PMC4100779](#)
282. Li, Y., S. Wang, G. Scarpellini, B. Gunn, W. Xin, S. Y. Wanda, K. L. Roland, and R. Curtiss III. 2009. Evaluation of new generation *Salmonella enterica* serovar Typhimurium vaccines with regulated delayed attenuation to induce immune responses against PspA. Proc. Natl. Acad. Sci. USA **106**:593-598. PMID: [PMC2626748](#)
283. Dieye, Y., K. Ameiss, M. Mellata, and R. Curtiss III. 2009. The *Salmonella* pathogenicity island (SPI) 1 contributes more than SPI2 to the colonization of the chicken by *Salmonella enterica* serovar Typhimurium. BMC Microbiol. **9**:3. PMID: [PMC2630912](#)
284. Mellata, M., J. W. Touchman, and R. Curtiss III. 2009. Full sequence and comparative analysis of the plasmid pAPEC-1 of avian pathogenic *E. coli* χ 7122 (O78:K80:H9). PLoS ONE **4**:e4232. PMID: [PMC2626276](#)
285. Baek, C., S. Wang, and R. Curtiss III. 2009. Leucine-responsive regulatory protein (Lrp) acts as a virulence repressor in *Salmonella enterica* serovar Typhimurium. J. Bacteriol. **191**:1278-1292. PMID: [PMC2631999](#)
*Recommended by Faculty of 1000 Biology
286. Ko, H. J., J. Y. Yang, D. H. Shim, H. Yang, S. M. Park, R. Curtiss III, and M. N. Kweon. 2009. Innate immunity mediated by MyD88 signal is not essential for induction of lipopolysaccharide-specific B cell responses but is indispensable for protection against *Salmonella enterica* serovar Typhimurium infection. J. Immunol. **182**:2305-2312. PMID: [PMC4049229](#)
287. Curtiss, R. III, S. Y. Wanda, B. M. Gunn, X. Zhang, S. A. Tinge, V. Ananthnarayan, H. Mo, S. Wang, and W. Kong. 2009. *Salmonella enterica* serovar Typhimurium strains with regulated delayed attenuation in vivo. Infect. Immun. **77**:1071-1082. PMID: [PMC2643627](#)
288. Branger, C. G., A. Torres-Escobar, W. Sun, R. Perry, J. Fetherston, K. L. Roland, and R. Curtiss III. 2009. Oral Vaccination with LcrV from *Yersinia pestis* KIM delivered by live attenuated *Salmonella enterica* serovar Typhimurium elicits a protective immune response against challenge with *Yersinia pseudotuberculosis* and *Yersinia enterocolitica*. Vaccine **27**:5363-5370.
289. Zhang, X., W. Kong, S. Ashraf, and R. Curtiss III. 2009. A "one-plasmid" system to generate influenza virus in cultured chicken cells for potential use in influenza vaccine. J. Virol. **83**:9296-9303.
290. Sun, W., K. L. Roland, C. G. Branger, X. Kuang, and R. Curtiss III. 2009. The role of *relA* and *spoT* in *Yersinia pestis* KIM5⁺ pathogenicity. PLoS One **4**:e6720. PMID: [PMC2726946](#)
291. Xin, W., Y. Li, H. Mo, K. L. Roland, and R. Curtiss III. 2009. PspA family fusion proteins delivered by attenuated *Salmonella enterica* serovar Typhimurium extend and enhance protection against *Streptococcus pneumoniae*. Infect. Immun. **77**:4518-4528. PMID: [PMC2747926](#)
292. Kong, Q., Q. Liu, K. L. Roland, and R. Curtiss III. 2009. Regulated delayed expression of *rfaH* in an attenuated *Salmonella enterica* serovar Typhimurium vaccine enhances immunogenicity of outer membrane proteins and a heterologous antigen. Infect. Immun. **77**:5572-5582. PMID: [PMC2786485](#)
293. Liu, X., and R. Curtiss III. 2009. Nickel-inducible lysis system in *Synechocystis* sp. PCC 6803. Proc. Natl. Acad. Sci. USA **106**:21550-21554.
294. Torres-Escobar, A., M. Juárez-Rodríguez, and R. Curtiss III. 2010. Biogenesis of *Yersinia pestis* PsaA in recombinant attenuated *Salmonella* Typhimurium vaccine (RASV) strain. FEMS Microbiol. Lett. **302**:106-113. PMID: [PMC2818566](#)

295. Sun, W., K. Roland, X. Kuang, C. G. Branger, and R. Curtiss III. 2010. *Yersinia pestis* with regulated delayed attenuation as a vaccine candidate to induce protective immunity against plague. *Infect. Immun.* **78**:1304-1313. PMID: [PMC2825917](#)
296. Gunn, B. M., S. Y. Wanda, D. Burshell, C. Wang, and R. Curtiss III. 2010. Construction of recombinant attenuated *Salmonella enterica* serovar Typhimurium vaccine vector strains for safety in newborn and infant mice. *Clin. Vaccine Immunol.* **17**:354-362. PMID: [PMC2837962](#)
297. Shi, H., S. Wang, K. L. Roland, B. M. Gunn, and R. Curtiss III. 2010. Immunogenicity of a live recombinant *Salmonella enterica* serovar Typhimurium vaccine expressing *pspA* in neonates and infant mice born from naïve and immunized mothers. *Clin. Vaccine Immunol.* **17**:363-371. PMID: [PMC2837964](#)
298. Mellata, M., K. Ameiss, H. Mo, and R. Curtiss III. 2010. Characterization of the contribution to virulence of three large plasmids of avian pathogenic *E. coli* χ 7122 (O78:K80:H9). *Infect. Immun.* **78**:1528-1541. PMID: [PMC2849417](#)
299. Curtiss, R. III, W. Xin, Y. Li, W. Kong, S. Y. Wanda, B. M. Gunn, and S. Wang. 2010. New technologies in using recombinant attenuated *Salmonella* vaccine vectors. *Crit. Rev. Immunol.* **30**:255-270. PMID: [PMC3970581](#)
300. Torres-Escobar, A., M. D. Juarez-Rodriguez, B. M. Gunn, C. G. Branger, S. A. Tinge, and R. Curtiss III. 2010. Fine-tuning synthesis of *Yersinia pestis* LcrV from runaway-like replication balanced-lethal plasmid in a *Salmonella enterica* serovar Typhimurium vaccine induces protection against a lethal *Y. pestis* challenge in mice. *Infect. Immun.* **78**:2529-2543. PMID: [PMC2876574](#)
301. Chow, K. C., X. Wang, R. Curtiss III, and C. Castillo-Chavez. 2010. Evaluating the efficacy of antimicrobial cycling programs and patient isolation on dual resistance in hospitals. *J. Biol. Dyn.* **5**:27-43.
302. Shi, H., J. Santander, K. Brennenman, S. Y. Wanda, S. Wang, P. Senechal, W. Sun, K. Roland, and R. Curtiss III. 2010. Live recombinant *Salmonella* Typhi vaccines constructed to investigate the role of *rpoS* in eliciting immunity to a heterologous antigen. *PLoS ONE* **8**:e11142. PMID: [PMC2887840](#)
303. Hapfelmeier, S., M. A. Lawson, E. Slack, J. K. Kirundi, M. Stoel, M. Heikenwalder, J. Cahenzli, Y. Velykoredko, M. L. Balmer, K. Endt, M. B. Geuking, R. Curtiss III, K. D. McCoy, and A. J. Macpherson. 2010. Reversible microbial colonization of germ-free mice reveals the dynamics IgA immune responses. *Science* **328**:1705-1709. PMID: [PMC3923373](#)
304. Wang, S., Y. Li, H. Shi, G. Scarpellini, A. Torres-Escobar, K. L. Roland, and R. Curtiss III. 2010. Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated *Salmonella* vaccine. *Infect. Immun.* **78**:3258-3271. PMID: [PMC2897375](#)
305. Torres-Escobar, A., M. D. Juarez-Rodriguez, C. G. Branger, and R. Curtiss III. 2010. Evaluation of the humoral immune response in mice orally vaccinated with live recombinant attenuated *Salmonella enterica* delivering a secreted form of *Yersinia pestis* PsaA. *Vaccine* **28**:5810-5816. PMID: [PMC2921469](#)
306. Kong, Q., Q. Liu, A. M. Jansen, and R. Curtiss III. 2010. Regulated delayed expression of *rfc* enhances the immunogenicity and protective efficacy of a heterologous antigen delivered by live attenuated *Salmonella enterica* vaccines. *Vaccine* **28**:6094-6103. PMID: [PMC3956130](#)
307. Wang, S., Y. Li, G. Scarpellini, W. Kong, H. Shi, C. Baek, B. Gunn, S. Y. Wanda, K. L. Roland, X. Zhang, P. Senechal-Willis, and R. Curtiss III. 2010. *Salmonella* vaccine vectors displaying delayed antigen synthesis in vivo to enhance immunogenicity. *Infect. Immun.* **78**:3969-3980. PMID: [PMC2937466](#)
308. Ameiss, K., S. Ashraf, W. Kong, A. Pekosz, W. H. Wu, D. Milich, J. N. Billaud, and Roy Curtiss III. 2010. Delivery of woodchuck hepatitis virus-like particle presented influenza M2e by recombinant attenuated *Salmonella* displaying a delayed lysis phenotype. *Vaccine* **28**:6704-6713. PMID: [PMC2939226](#)

309. Branger, C. G., W. Sun, A. Torres-Escobar, R. Perry, K. L. Roland, J. Fetherston, and R. Curtiss III. 2010. Evaluation of Psn, HmuR and a modified LcrV protein delivered to mice by live attenuated *Salmonella* as a vaccine against bubonic and pneumonic *Yersinia pestis* challenge. *Vaccine* **29**:274-282. PMID: [PMC3014047](#)
310. Santander, J., and R. Curtiss III. 2010. *Salmonella enterica* serovars Typhi and Paratyphi A are avirulent in newborn and infant mice even when expressing virulence plasmid genes of *S. Typhimurium*. *J. Infect. Dev. Countries* **4**:723-731. PMID: [PMC4059606](#)
311. Santander, J., W. Xin, Z. Yang, and R. Curtiss III. 2010. Aspartate-semialdehyde dehydrogenase (*asdA*) gene of *Edwardsiella ictaluri* and its use to develop a balanced-lethal vector-host system for construction of antibiotic-sensitive live attenuated recombinant vaccines for the catfish aquaculture industry. *PLoS ONE* **5**:e15944.
312. Curtiss, R. III. 2011. The impact of vaccines and vaccinations: challenges and opportunities for modelers. *Math. Biosci. Eng.* **8**:81-97.
313. Muralinath, M., M. J. Kuehn, K. L. Roland, and R. Curtiss III. 2011. Immunization with *Salmonella enterica* serovar Typhimurium-derived outer membrane vesicles delivering the pneumococcal protein PspA confers protection against challenge with *Streptococcus pneumoniae*. *Infect. Immun.* **79**:887-894. PMID: [PMC3028854](#)
314. Wang, S., Y. Li, H. Shi, W. Sun, K. L. Roland, and R. Curtiss III. 2011. Comparison of a regulated delayed antigen synthesis system with in vivo-inducible promoters for antigen delivery by live attenuated *Salmonella* vaccines. *Infect. Immun.* **79**:937-949. PMID: [PMC3028866](#)
315. Zhang X, S. Y. Wanda, K. Brenneman, W. Kong, X. Zhang, K. Roland, and R. Curtiss III. 2011. Improving *Salmonella* vector with *rec* mutation to stabilize the DNA cargoes. *BMC Microbiol.* **11**:31. PMID: [PMC3047425](#)
316. Sun, W, D. Six, X. Kuang, K. L. Roland, C. R. Raetz, and R. Curtiss III. 2011. A live attenuated strain of *Yersinia pestis* KIM as a vaccine against plague. *Vaccine* **29**:2986-2998. PMID: [PMC3073832](#)
317. Liu, X., J. Sheng, and R. Curtiss III. 2011. Fatty acid production in genetically modified cyanobacteria. *Proc. Natl. Acad. Sci. USA* **108**:6899-6904.
318. Liu, X., S. Fallon, J. Sheng, and R. Curtiss III. 2011. CO₂ limitation inducible green recovery of fatty acids from cyanobacterial biomass. *Proc. Natl. Acad. Sci. USA* **108**:6905-6908.
319. Ashraf, S., W. Kong, S. Wang, J. Yang, and R. Curtiss III. 2011. Protective cellular responses elicited by vaccination with influenza nucleoprotein delivered by a live recombinant attenuated *Salmonella* vaccine. *Vaccine* **29**:3990-4002. PMID: [PMC3092860](#)
320. Kong, Q., D. A. Six, K. L. Roland, Q. Liu, L. Gu, C. M. Reynolds, X. Wang, C. R. H. Raetz, and R. Curtiss III. 2011. *Salmonella* synthesizing 1-dephosphorylated lipopolysaccharide exhibits low endotoxic activity while retaining its immunogenicity. *J. Immunol.* **187**:412-423. PMID: [PMC3119770](#) *Featured on the Cover of July 2011 issue. Selected for "In This Issue"
321. Luo, Y., Q. Kong, J. Yang, G. Golden, S. Y. Wanda, R. V. Jensen, P. B. Ernst, and R. Curtiss III. 2011. Complete genome sequence of the universal killer, *Salmonella enterica* serovar Typhimurium UK-1 (ATCC 68169). *J. Bacteriol.* **193**:4035-4036. PMID: [PMC3147501](#)
322. Sun, W., K. L. Roland, and R. Curtiss III. 2011. Developing live vaccines against plague. *J. Infect. Dev. Countries* **5**:614-627. PMID: [PMC3932668](#)
323. Kong, Q., J. Yang, Q. Liu, P. Alamuri, K. L. Roland, and R. Curtiss III. 2011. Effect of deletion of genes involved in lipopolysaccharide core and O-antigen synthesis on virulence and immunogenicity of *Salmonella enterica* serovar Typhimurium. *Infect. Immun.* **79**:4227-4239. PMID: [PMC3187260](#) *Featured in Journal Highlights section of *Microbe*, ASM
324. Baek, C., H. Y. Kang, K. L. Roland, and R. Curtiss III. 2011. Lrp acts as both a positive and negative regulator for type 1 fimbriae production in *Salmonella enterica* serovar Typhimurium. *PLoS ONE* **6**:e26896.

325. Curtiss, R. III. 2011. Vaccine design: Innovative approaches and novel strategies. *Expert Rev. Vaccines* **10**:1385.
326. Jenikova, G., P. Hruz, M. K. Andersson, N. Tejman-Yarden, P. C. D. Ferreira, Y. S. Andersen, B. J. Davids, F. D. Gillin, S. G. Svård, R. Curtiss III, and L. Eckmann. 2011. *Giardin* based live heterologous vaccine protects against *Giardia lamblia* infection in a murine model. *Vaccine* **29**:9529-9537. PMID: [PMC4045459](#)
327. Kong, Q., D. A. Six, Q. Liu, L. Gu, K. L. Roland, C. R. H. Raetz, and R. Curtiss III. 2011. Palmitoylation state impacts innate and acquired immunity in the *Salmonella enterica* serovar Typhimurium *msbB* mutant. *Infect. Immun.* **79**:5027-5038. PMID: [PMC3232669](#) *Featured in Journal Highlights section of *Microbe*, ASM
328. Santander, J., A. Mitra, and R. Curtiss III. 2011. Phenotype, virulence and immunogenicity of *Edwardsiella ictaluri* cyclic adenosine 3',5'-monophosphate receptor protein (Crp) mutants in catfish host. *Fish and Shellfish Immunology* **31**:1142-1153.
329. Mellata, M., J. T. Maddux, T. Nam, N. Thomson, H. Hauser, M. P. Stevens, S. Mukhopadhyay, S. Sarker, A. Crabbe, C. A. Nickerson, J. Santander, and R. Curtiss III. 2012. New Insights into the bacterial fitness-associated mechanisms revealed by the characterization of large plasmids of an avian pathogenic *E. coli*. *PLoS ONE* **7**:e29481. PMID: [PMC3251573](#)
330. Juárez-Rodríguez, M. D., L. T. Arteaga-Cortés, R. Kader, R. Curtiss III, and J. E. Clark-Curtiss. 2012. Live attenuated *Salmonella* Vaccines against *Mycobacterium tuberculosis* with antigen delivery via the type III secretion system. *Infect. Immun.* **80**:798-814. PMID: [PMC3264309](#)
331. Juárez-Rodríguez, M. D., J. Yang, R. Kader, P. Alamuri, R. Curtiss III, and J. E. Clark-Curtiss. 2012. Live attenuated *Salmonella* vaccines displaying regulated delayed lysis and delayed antigen synthesis to confer protection against *Mycobacterium tuberculosis*. *Infect. Immun.* **80**:815-831. PMID: [PMC3264310](#)
332. Kupz, A., G. Guarda, T. Gebhardt, L. E. Sander, K. R. Short, D. A. Diavatopoulos, O. L. C. Wijburg, H. Cao, J. C. Waithman, W. Chen, D. Fernandez-Ruiz, P. G. Whitney, W. R. Heath, R. Curtiss III, J. Tschopp, R. A. Strugnell, and S. Bedoui. 2012. NLRC4 inflammasomes in dendritic cells regulate noncognate effector function by memory CD8⁺ T cells. *Nat. Immunol.* **13**:162-169.
333. Brenneman, K. E., C. McDonald, S. M. Kelly, K. L. Roland, and R. Curtiss III. 2012. Use of RapidChek® SELECT™ *Salmonella* to detect shedding of live attenuated *Salmonella enterica* serovar Typhi vaccine strains. *J. Microbiol. Methods* **89**:137-147.
334. Luo, Y., Q. Kong, J. Yang, A. Mitra, G. Golden, S. Y. Wanda, K. L. Roland, R. V. Jensen, P. B. Ernst, and R. Curtiss III. 2012. Comparative genome analysis of the high pathogenicity *Salmonella* Typhimurium strain UK-1. *PLoS One.* **7**:e40645. PMID: [PMC3391293](#)
335. Santander, J., G. Golden, S. Y. Wanda, and R. Curtiss III. 2012. The Fur-regulated iron uptake system of *Edwardsiella ictaluri* and its influence on pathogenesis and immunogenicity in the catfish host. *Infect. Immun.* **80**:2689-2703. PMID: [PMC3434582](#)
336. Kong, Q., D. Six, Q. Liu, L. Gu, S. Wang, P. Alamuri, C. R. H. Raetz, and R. Curtiss III. 2012. Phosphate groups of lipid A are essential for *Salmonella enterica* serovar Typhimurium virulence and affect innate and adaptive immunity. *Infect. Immun.* **80**:3215-3224. PMID: [PMC3418755](#)
337. Theoret, J. R., K. K. Cooper, B. Zekarias, K. L. Roland, B. F. Law, R. Curtiss III, and L. A. Joens. 2012. The *Campylobacter jejuni* Dps homologue is important for in vitro biofilm formation and cecal colonization of poultry, and may serve as a protective antigen for vaccination. *Clin. Vaccine Immunol.* **19**:1426-1431. PMID: [PMC3428391](#)
338. Liu, X and R. Curtiss III. 2012. Thermorecovery of cyanobacterial fatty acids at elevated temperatures. *J. Biotechnol.* **161**:445-449.

339. Xin, W., S. Y. Wanda, X. Zhang, J. Santander, G. Scarpellini, K. Ellis, P. Alamuri, and R. Curtiss III. 2012. The Asd⁺-DadB⁺ dual-plasmid system offers novel means to deliver multiple protective antigens by a recombinant attenuated *Salmonella* vaccine. *Infect. Immun.* **80**:3621-3633. PMID: [PMC3457550](#)
340. Sun, W. and R. Curtiss III. 2012. Amino acid substitutions in LcrV at putative sites of interaction with toll-like receptor II do not affect the virulence of *Yersinia pestis*. *Microb. Pathog.* **53**:198-206. PMID: [PMC3470733](#)
341. Kong, W., M. Brovold, B. A. Koneneman, J. Clark-Curtiss, and R. Curtiss III. 2012. Turning self-destructing *Salmonella* into a universal DNA vaccine delivery platform. *Proc. Natl. Acad. USA* **109**:19414-19419. PMID: [PMC3511069](#) *Recommended by Faculty of 1000 Biology and Recommended by F1000 Prime
342. León, M., J. Santander, R. Curtiss III, and J. Robeson. 2012. Natural lysogenization and transduction in *Salmonella enterica* serovar Choleraesuis by bacteriophage P1. *Res. Microbiol.* **164**:1-5. PMID: [PMC3790573](#)
343. Seo, S., J. Kim, H. Yang, H. Kwon, J. Yang, R. Curtiss III, and M. Kweon. 2012. Effective protection against secondary pneumococcal pneumonia by oral vaccination with attenuated *Salmonella* delivering PspA antigen in mice. *Vaccine.* **30**:6816-6823.
344. Mitra, A., A. Loh, A. Gonzales, P. Łaniewski, C. Willingham, R. Curtiss III and K. L. Roland. 2013. Safety and protective efficacy of live attenuated *Salmonella* Gallinarum mutants in Rhode Island Red chickens. *Vaccine* **31**:1094-1099. PMID: [23261043](#)
345. Kupz, A., T. A. Scott, G. T. Belz, D. M. Andrews, M. Greyer, A. M. Lew, A. G. Brooks, M. J. Smyth, R. Curtiss III, S. Bedoui, and R. Strugnell. 2013. Contribution of Thy1+ NK cells to protective IFN- γ production during *Salmonella* Typhimurium infections. *Proc. Natl. Acad. USA* **110**:2252-2257. PMID: [PMC3568339](#). Recommended by F1000 Prime
346. Dziva, F., H. Hauser, T. Connor, P. M. van Diemen, G. Prescott, G. C. Langridge, S. Eckert, R. R. Chaudhuri, C. Ewers, M. Mellata, S. Mukhopadhyay, R. Curtiss III, G. Dougan, L. H. Wieler, N. R. Thomson, D. J. Pickard, and M. P. Stevens. 2013. Sequencing and functional annotation of avian pathogenic *Escherichia coli* serogroup O78 strains reveal the evolution of *E. coli* lineages pathogenic for poultry via distinct mechanisms. *Infect. Immun.* **81**:838-849. PMID: [PMC3584874](#)
347. Sun, W., D. A. Six, C. M. Reynolds, H. S. Chung, C. R. H. Raetz, and R. Curtiss III. 2013. Pathogenicity of *Yersinia pestis* synthesis of 1-dephosphorylated lipid A. *Infect. Immun.* **81**:1172-1185. PMID: [PMC3639600](#)
348. Kong, W., J. Clark-Curtiss, and R. Curtiss III. 2013. Utilizing *Salmonella* for antigen delivery: the aims and benefits of bacterial delivered vaccination. *Expert Review of Vaccines.* **12**:345-347. PMID: [23560914](#)
349. Wang, S., Q. Kong, and R. Curtiss III. 2013. New technologies in developing recombinant attenuated *Salmonella* vaccine vectors. *Microbial. Pathog.* **58**:17-28. PMID: [PMC3587120](#)
350. Shi, H., S. Wang, and R. Curtiss III. 2013. Evaluation of regulated delayed attenuation strategies for *Salmonella enterica* serovar Typhi vaccine vectors in neonatal and infant mice. *Clin. Vaccine Immunol.* **20**:931-944. PMID: [PMC3675971](#)
351. Brennenman, K. E., C. Willingham, W. Kong, R. Curtiss III, and K. L. Roland. 2013. Low-pH rescue of acid-sensitive *Salmonella enterica* Serovar Typhi strains by a rhamnose-regulated arginine decarboxylase system. *J. Bacteriol.* **195**:3062-3072.
352. Santander, J., T. Martin, A. Loh, C. Pohlenz, D. M. Gatlin 3rd, and R. Curtiss III. 2013. Mechanisms of intrinsic resistance to antimicrobial peptides of *Edwardsiella ictaluri* and its influence on fish gut inflammation and virulence. *Microbiology* **159**:1471-1486. PMID: [PMC4085987](#)
353. Wang, S., H. Shi, Y. Li, Z. Shi, X. Zhang, C. H. Baek, T. Mothershead, and R. Curtiss III. 2013. A colanic acid operon deletion mutation enhances induction of early antibody responses by live attenuated *Salmonella* vaccines. *Infect. Immun.* **81**:3148-3162. PMID: [PMC3754205](#)

354. Lottenbach, K. R., S. M. Kelly-Aehle, K. E. Brenneman, R. Curtiss III, and S. E. Frey. 2013. Rapid, sensitive recovery of recombinant attenuated *Salmonella enterica* serovar Typhi vaccine strains from human blood. *Clin. Vaccine Immunol.* **20**:1473-1478.
355. Fisher, M. L., R. Allen, Y. Luo, and R. Curtiss III. 2013. Export of extracellular polysaccharides modulates adherence of the cyanobacterium *Synechocystis*. *PLoS One.* **8**:e74514. PMID: [PMC3769361](#)
356. Frey, S. E., K. R. Lottenbach, H. Hill, T. P. Blevins, Y. Yu, Y. Zhang, K. E. Brenneman, S. M. Kelly-Aehle, C. McDonald, A. Jansen, and R. Curtiss III. 2013. A Phase I, dose-escalation trial in adults of three recombinant attenuated *Salmonella* Typhi vaccine vectors producing *Streptococcus pneumoniae* surface protein antigen PspA. *Vaccine* **31**:4874-4880.
357. Guan, L., J. Santander, M. Mellata, Y. Zhang, and R. Curtiss III. 2013. Identification of an iron acquisition machinery in *Flavobacterium columnare*. *Dis. Aquat. Organ.* **106**:129-138.
358. Pei, Y., V. R. Parreira, K. L. Roland, R. Curtiss III, and J. F. Prescott. 2014. Assessment of attenuated *Salmonella* vaccine strains in controlling experimental *Salmonella* Typhimurium infection in chickens. *Can. Vet. J. Res.* **78**:23-30. PMID: [PMC3878005](#)
359. Sun, W. and R. Curtiss III. 2014. Rational considerations about development of live attenuated *Yersinia pestis* vaccines. *Curr. Pharm. Biotechnol.* **14**:878-886. PMID: [PMC3977779](#)
360. Stacy, A. K., N. M. Mitchell, J. T. Maddux, M. A. De la Cruz, L. Durán, J. A. Girón, R. Curtiss III, and M. Mellata. 2014. Evaluation of the prevalence and production of *Escherichia coli* common pilus among avian pathogenic *E. coli* and its role in virulence. *PLoS ONE.* **9**:86565. PMID: [PMC3900561](#)
361. Brenneman, K. E., C. Willingham, J. A. Kilbourne, R. Curtiss III, and K. L. Roland. 2014. A low gastric pH mouse model to evaluate live attenuated bacterial vaccines. *PLoS ONE.* **9**:e87411. PMID: [PMC3906194](#)
362. Wang, S., and R. Curtiss III. 2014. Development of *Streptococcus pneumoniae* vaccines using live vectors. *Vaccines (Bassel).* **2**:49-88. PMID: [PMC4192125](#)
363. Fisher, M., W. Sun, and R. Curtiss III. 2014. The route less taken: pulmonary models of enteric Gram-negative infection. *Pathog. Dis.* **70**:99-109. PMID: [PMC3959565](#)
364. Sun, W., J. Olinzock, S. Wang, S. Sanapala, and R. Curtiss III. 2014. Evaluation of YadC protein delivered by live attenuated *Salmonella* as a vaccine against plague. *Pathog. Dis.* **70**:119-131. PMID: [PMC4028040](#)
365. Jiang, Y., Q. Kong, K. Roland, A. Wolf, and R. Curtiss III. 2014. Multiple effects of *Escherichia coli* Nissle 1917 on growth, biofilm formation and inflammation cytokines profile of *Clostridium perfringens* type A strain CP4. *Pathog. Dis.* **70**:390-400. PMID: [PMC4038294](#)
366. Jiang, Y., Q. Kong, K. L. Roland, and R. Curtiss III. 2014. Membrane vesicles of *Clostridium perfringens* type A strains induce innate and adaptive immunity. *Int. J. Med. Microbiol.* **304**:431-443. PMID: [PMC4285460](#)
367. Kupz, A., R. Curtiss III, S. Bedoui, and R. A. Strugnell. 2014. In vivo IFN- γ secretion by NK cells in response to *Salmonella* Typhimurium requires NLRC4 inflammasomes. *PLoS One.* **9**:e97418. PMID: [PMC4020851](#)
368. Santander, J. Kilbourne, J. Y. Park, T. Martin, A. Loh, I. Diaz, R. Rojas, C. Segovai, D. DeNardo and R. Curtiss III. 2014. Inflammatory effects of *Edwardsiella ictaluri* lipopolysaccharide modifications in catfish gut. *Infect. Immun.* **82**:3394-3404. PMID: [PMC4136215](#)
369. Galen, J.E., and R. Curtiss III. 2014. The delicate balance in genetically engineering live vaccines. *Vaccine.* **32**:4316-4385. PMID: [PMC4069233](#)
370. Laniewski, P., A. Mitra, K. Karaca, A. Khan, R. Prasad, R. Curtiss III, and K. L. Roland. 2014. Evaluation of protective efficacy of live attenuated *Salmonella enterica* serovar Gallinarum vaccine strains against fowl typhoid in chickens. *Clin. Vaccine Immunol.* **21**:1267-1276. PMID: [PMC4178578](#)

371. Dankel, D. J., K. L. Roland, M. Fisher, K. Brenneman, A. Delgado, J. Santander, C. H. Baek, J. Clark-Curtiss, R. Strand and R. Curtiss III. 2014. Making common sense of vaccines: An example of discussing the Recombinant Attenuated *Salmonella* Vaccine with the public. *Nanoethics*. **8**:179-185. PMID: PMC4129221.
372. Sun, W., S. Sanapala, J. C. Henderson, S. Sam, J. Olinzock, M. S. Trent, and R. Curtiss III. 2014. LcrV delivered via Type III secretion system of live attenuated *Yersinia pseudotuberculosis* enhances immunogenicity against pneumonic plague. *Infect. Immun.* **82**:4390-4404. PMID: [PMC4187879](#)
373. Mitchell, N., J. Johnson, B. Johnston, and R. Curtiss III, and M. Mellata. 2015. Zoonotic potential of *Escherichia coli* isolates from retail chicken meat products and eggs. *Appl. Environ. Microbiol.* **81**:117-1187. PMID: [PMC4292506](#)
374. Zhang, X., W. Kong, S. Y. Wanda, W. Xin, P. Alamuri, and R. Curtiss III. 2015. Generation of influenza virus from avian cells infected by *Salmonella* carrying the viral genome. *PLoS One*. **10**:e0119041. PMID: [PMC4351096](#)
375. Mitra, A., P. Landowski, R. Curtiss III. 2015. A live oral fowl typhoid vaccine with reversible O-antigen production. *Avian Dis.* **59**:52-56.
376. Brenneman, K. E., A. Gonzales, K. L. Roland, and R. Curtiss III. 2015. Use of Ensure® nutrition shakes as an alternative formulation method for live recombinant attenuated *Salmonella* Typhi vaccines. *BMC Microbiol.* **15**:76.
377. Frahm, M., S. Felgner, D. Kocijancic, M. Rode, M. Hensel, R. Curtiss III, M. Erhardt, and S. Weiss. 2015. Efficiency of conditionally attenuated *Salmonella enterica* serovar Typhimurium in bacterium-mediated tumor therapy. *MBio*. **6**:e00254-15.
378. Curtiss, R. III. 2015. Antigen delivery system II: Development of live recombinant attenuated bacterial vectors, p. 1233-1269, Vol. I. *In* J. Mestecky *In* J. Mestecky, W. Strober, M.W. Russell, H. Cheroutre, B.N. Lambrecht, and B. Kelsall (eds.) *Mucosal Immunology*, 4th ed., Elsevier Academic Press.

Publications in Press/Accepted

- Castillo-Chavez, C., R. Curtiss III, P. Daszak, S. Levin, O. Patterson, C. Perrings, G. Poste, and S. Towers. 2015. Beyond Ebola: Lessons for mitigating pandemics. *Lancet Glob Health*. Accepted

PATENTS

1. Curtiss, R. III. Modified Microorganisms and Method of Preparing and Using Same. Filed Sep. 30, 1976. (Patent on biological containment and EK2 host-vector systems.)

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	APPL. NO./ SERIAL NO.	EXPIRATION	DOCKET NO.
Germany	Issued	2,644,432	12/29/88			
United Kingdom	Issued	1,146,458	9/30/78			
United States	Issued	4,190,495	2/26/80			
United States	Issued	4,968,619	11/27/90			

2. Curtiss, R. III. Vaccines Obtained From Antigenic Gene Products of Recombinant Genes. Filed Oct. 22, 1981. (Patent on use of recombinant avirulent *Salmonella*, *Escherichia* and *Salmonella-Escherichia* hybrids as antigen delivery vectors to induce mucosal, systemic and cellular immunity.)

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	APPL. NO./ SERIAL NO.	EXPIRATION	DOCKET NO.
Greece	Issued	76,769	9/03/84		10/22/97	
Canada	Issued	1,338,705	11/12/96		11/12/13	
Germany	Issued	P3279824.5	7/19/89		10/22/02	
Ireland	Issued	55478	1/09/91		10/21/98	
Japan, 10/22/82	Pending			57-185912		
Japan, 5/25/93	Pending			5-144230		

EPO, 7/19/89, entitled "Live Vaccine and Its Method of Production"

Austria	Issued	080,806	7/19/89	10/22/02
Belgium	Issued	080,806	7/19/89	10/22/02
France	Issued	080,806	7/19/89	10/22/02
United Kingdom	Issued	080,806	7/19/89	10/22/02
Italy	Issued	080,806	7/19/89	10/22/02
Luxembourg	Issued	080,806	7/19/89	10/22/02
Netherlands	Issued	080,806	7/19/89	10/22/02
Sweden	Issued	080,806	7/19/89	10/22/02
Switzerland	Issued	080,806	7/19/89	10/22/02

CIP filed Sep. 9, 1985, refiled Nov. 13, 1989 and Dec. 6, 1991

United States	Issued	4,888,170	12/19/89	12/19/06
---------------	--------	-----------	----------	----------

Continuation Filed 5/2/94

Curtiss, R. III. Recombinant Avirulent Bacterial Antigen Delivery System.

United States	Issued	5,888,799	3/30/99	3/30/16
---------------	--------	-----------	---------	---------

3. Curtiss, R. III. Avirulent Microbes and Uses Therefor. Filed Jun. 4, 1987; First CIP filed Jun. 1, 1988. (Patent on Δcya and Δcrp attenuation mutations.)

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	APPL. NO./ SERIAL NO.	EXPIRATION	DOCKET NO.
Australia	Issued	623599	9/22/92		6/01/04	
Canada	Issued	1,338,957			3/04/14	
China	Issued	88104317.6			6/04/03	
Denmark	Pending					937950
Ireland	Issued	63905	5/31/95		1/06/08	
Israel	Issued	86583			5/31/08	
Japan	Issued	2640525	5/02/97		6/01/08	
New Zealand	Issued	224884			6/02/04	
Rep. of South Korea	Issued	139950			3/07/98	3/07/13
Singapore	Pending					
South Africa	Issued	88/3954	2/22/89		6/03/08	
United States	Issued	5,389,368	2/14/95		2/07/12	
EPO 0315682B1, 6/1/08						
Austria	Issued	E98870	12/22/93		6/01/08	
Belgium	Issued	BE0315682	12/22/93		6/01/08	
France	Issued	FR0315682	12/22/93		6/01/08	
Germany	Issued	DE3886506 T2	12/22/93		6/01/08	
United Kingdom	Issued	GB0315682	12/22/93		6/01/08	
Italy	Issued	IT0315682	12/22/93		6/01/08	
Luxembourg	Issued	2U0315682	12/22/93		6/01/08	
Netherlands	Issued	NL0315682	12/22/93		6/01/08	
Sweden	Issued	88905542.2	12/22/93		6/01/08	
Switzerland	Issued	CH0315682	12/22/93		6/01/08	

4. Curtiss, R. III. Avirulent Microbes and Uses Therefor: *Salmonella choleraesuis*. Second CIP filed Mar. 31, 1989. (Patent on Δcya and Δcrp attenuation mutations in *S. choleraesuis*.)

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	APPL. NO./ SERIAL NO.	EXPIRATION	DOCKET NO.
Canada	Pending					937960
Japan	Pending					937965
United States	Issued	5,468,485	11/21/95		11/21/12	

5. Curtiss, R. III, and S. M. Kelly. Avirulent Microbes and Uses Therefor: *cdt*. Third CIP filed Nov. 7, 1990. (Patent on Δcdt attenuation mutation alone and in combination with *cya* and *crp* mutations.) Divisional patent EP0556333

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	APPL. NO./ SERIAL NO.	EXPIRATION	DOCKET NO.
EPO		92901722.6-210	3/19/03			3116-8419
Austria	Issued	03006123.8	9/05/03			
Belgium	Issued	03006123.8	9/05/03			
Denmark	Issued	03006123.8	9/05/03			
France	Issued	03006123.8	9/05/03			
Germany	Issued	03006123.8	9/05/03			
United Kingdom	Issued	03006123.8	9/05/03			
Italy	Issued	03006123.8	9/05/03			
Luxembourg	Issued	03006123.8	9/05/03			
Liechtenstein	Issued	03006123.8	9/05/03			
Netherlands	Issued	03006123.8	9/05/03			
Spain	Issued	03006123.8	9/05/03			
Sweden	Issued	03006123.8	9/05/03			
Switzerland	Issued	03006123.8	9/05/03			
Australia	Issued	666108	5/20/96		11/08/11	
Canada, 11/8/91	Issued	2,095,534	9/17/02		11/08/11	53116-8421
Ireland	Pending					937955
Israel	Issued	100010	5/18/98		11/08/11	
Japan	Issued	502265/1992	10/1/04		11/08/11	MEG-200.49JP
New Zealand	Issued	240538	6/14/94		11/11/07	
South Africa	Issued	91/8876	11/08/91		11/08/11	
United States	Issued	5,387,744	2/07/95		2/07/12	

6. Curtiss, R. III. Avirulent Microbes and Uses Therefor: *Salmonella typhi*. Fourth CIP filed Nov. 7, 1991. (Patent on Δcya and Δcrp attenuation mutations in *S. typhi*.)

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	APPL. NO./ SERIAL NO.	EXPIRATION	DOCKET NO.
United States	Issued	5,294,441	3/15/94		3/15/11	

7. Curtiss, R. III. Avirulent Microbes and Uses Therefore: *crp*. Continuation and divisional filed Jul. 7, 1993. (Patent on Δcrp attenuation mutation.)

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	APPL. NO./ SERIAL NO.	EXPIRATION	DOCKET NO.
United States	Issued	5,855,879	1/5/99		1/05/16	

8. Curtiss, R. III. Avirulent Microbes and Uses Therefor: *cya*. Divisional filed Feb. 6, 1996. filed 1/4/99. (Patent on Δcya attenuation mutation.)

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	APPL. NO./ SERIAL NO.	EXPIRATION	DOCKET NO.
United States	Issued	5,855,880	1/5/99		10/07/07	

9. Curtiss, R. III. A Method of Maintaining a Desired Recombinant Gene in a Genetic Population of Cells. Filed Oct. 7, 1987; CIP Filed Oct. 3, 1988. Continuation filed 3/10/95, 6/7/95, and 11/20/98. (Patent on balanced-lethal host-vector systems for stable high-level expression of foreign antigens.)

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	APPL. NO./ SERIAL NO.	EXPIRATION	DOCKET NO.
Australia	Issued	637969	10/6/88		10/06/04	
Canada	Issued	1,339,412	9/2/97		9/02/14	
Japan, 10/6/88	Pending			1-500124		3116-7932
Japan (Divisional filed)	Pending	10-358165				3116-6480
United States	Issued	5,672,345	9/30/97	10/35865	9/30/14	

United States	Pending	09/196,057			3116-7655
EPO	Issued	0381706 B1		10/06/08	
Austria	Issued	E 121785	4/26/95	10/06/08	
Belgium	Issued	0381706	4/26/95	10/06/08	
France	Issued	0381706	4/26/95	10/06/08	
Germany	Issued	DE 3853683.8	4/26/95	10/06/08	
Italy	Issued	0381706	4/26/95	10/06/08	
Luxembourg	Abandoned	0381706	4/26/95	10/06/08	
Netherlands	Issued	0381706	4/26/95	10/06/08	
Sweden	Issued	0381706	4/26/95	10/06/08	
Switzerland	Issued	0381706	4/26/95	10/06/08	
United Kingdom	Issued	0381706	4/26/95	10/06/08	
United States	Issued	5,840,483	11/24/98	11/24/15	
(patent on vector claims)					

10. Curtiss, R. III, and G. A. Cardineau. Oral Immunization by Transgenic Plants. Filed Sep. 6, 1988; CIP filed Aug. 29, 1989; continuation and two divisionals filed Jun. 1, 1995. (Patent on immunization by oral feeding of transgenic plants expressing colonization and virulence antigens of microbial pathogens.)

PCT, 9/5/89, PCT/US89/03799, 3/22/90 WO 90/02484. Filed nationally in Australia, Denmark, EPO, Japan, and Korea.

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	APPL. NO./ SERIAL NO.	EXPIRATION	DOCKET NO.
Australia	Issued	634178	6/25/93	43172/89		MPS (2570)
Brazil, 5/14/97	Pending			PI 1101003-7		MPS (2570)
Canada	Issued	1,339,307	8/19/97	610,249		MPS SG-59
Hong Kong, 12/22/98,	Pending			98114604.2		
Japan, 9/5/89	Pending	4-501801	(Pub. 4/2/92)	1-509842		MPS SG-59
Japan, 9/5/89	Pending	11-200841				
Mexico, 9/6/89	Pending	17593				
New Zealand	Issued	230,576	9/22/92			
United States, 8/29/89	Pending		Appeal #93-434107/398,520			MPS SG-59 C1
United States	Issued	5,686,079	11/11/97		11/11/14	
United States	Issued	5,679,880	10/21/97		10/21/14	
United States	Issued	5,654,184	8/5/97		8/5/14	
EPO, 9/5/89, filed		0433372	6/12/03	89910552.2	09/15/09	MPS SG-59
Austria	Issued	AT218797				
Belgium	Issued	BE433372				
France	Issued	FR433372				
Germany	Issued	6892405.0				
United Kingdom	Issued	GB433372				
Greece	Pending					
Italy	Issued	IT433372				
Luxembourg	Issued	LU433372				
Netherlands	Issued	NL433372				
Spain	Pending					
Sweden	Issued	SE433372				
Switzerland (Liechtenstein)	Issued	P433372				

PCT, 9/5/89, WO 90/02484, 3/22/90

US89/03799

11. Curtiss, R. III, and J.E. Galan. Vaccines Containing Avirulent *phoP* Microorganisms. Filed Mar. 31, 1989. (Patent on *phoP* mutation rendering bacteria avirulent and immunogenic.) European Patent Filed Mar. 23, 1990. PCT filed Mar. 23, 1990.

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	APPL. NO./ SERIAL NO.	EXPIRATION	DOCKET NO.
---------	--------	----------	------------	--------------------------	------------	------------

Australia	Issued	645,489	5/6/94		3/23/06
Canada	Issued	0500699	6/10/98		3/20/10
Finland	Pending				
Hungary	Pending				
Japan	Issued	3004049	11/19/99		3/23/10
Norway	Pending				
United States	Issued	5,424,065	6/13/95	981,935	6/13/12
PCT		WO 90/11687		PCT/US90/01573	
EPO	Issued	0465560	6/5/96		3/23/10
(opposition filed and rejected)					
Austria	Issued	AT E 138784	6/5/96		3/23/10
Belgium	Issued	0465560	6/5/96		3/23/10
Denmark	Issued	0465560	6/5/96		3/23/10
France	Issued	0465560	6/5/96		3/23/10
Germany	Issued	DE69027313 T2	6/5/96		3/23/10
United Kingdom	Issued	0465560	6/5/96		3/23/10
Italy	Issued	0465560	6/5/96		3/23/10
Luxembourg	Issued	0465560	6/5/96		3/23/10
Netherlands	Issued	0465560	6/5/96		3/23/10
Spain	Issued	0465560	6/5/96		3/23/10
Sweden	Issued	0465560	6/5/96		3/23/10
Switzerland	Issued	0465560	6/5/96		3/23/10

12. Curtiss, R. III. Cross Protective *Salmonella* Vaccines. Filed Nov. 3, 1989. (Patent on using *pmi*, *galE* and *fur* mutations in conjunction with other attenuating mutations to enhance induction of cross protective immunity.)

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	APPL. NO./ SERIAL NO.	EXPIRATION	DOCKET NO.
Europe	Issued	0500699	6/10/98		11/20/10	
Austria	Issued	0500699	6/10/98		11/20/10	
Belgium	Issued	0500699	6/10/98		11/20/10	
Denmark	Issued	0500699	6/10/98		11/20/10	
France	Issued	0500699	6/10/98		11/20/10	
Germany	Issued	DE69032408T2	6/10/98		11/20/10	
Greece	Issued	0500699	6/10/98		11/20/10	
Italy	Issued	0500699	6/10/98		11/20/10	
Luxembourg	Issued	0500699	6/10/98		11/20/10	
Netherlands	Issued	0500699	6/10/98		11/20/10	
Spain	Issued	0500699	6/10/98		11/20/10	
Sweden	Issued	0500699	6/10/98		11/20/10	
Switzerland	Issued	0500699	6/10/98		11/20/10	
United Kingdom	Issued	0500699	6/10/98		11/20/10	

13. Curtiss, R. III. Recombinant Avirulent *Salmonella* Antifertility Vaccines. Filed Nov. 21, 1990; CIP filed Nov. 20, 1991 with R. Curtiss III and K. S. K. Tung as inventors. (Patent on using recombinant avirulent *Salmonella* expressing gamete-specific antigens to induce immunity to prevent fertilization.)

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	APPL. NO./ SERIAL NO.	EXPIRATION	DOCKET NO.
Canada	Pending			2,096,529		938461
Israel	Pending	100121				937967;3116-7967
South Africa	Issued	91/9213	11/21/91			
United States	Issued	5,656,488	8/12/97		8/12/14	
United States, 6/7/95; Pending				08/478,504		952997
Europe	Issued	0558631	3/17/99	92901072.6	11/20/11	
Belgium	Issued	0558631	3/17/99	92901072.6	11/20/11	
France	Issued	0558631	3/17/99	92901072.6	11/20/11	

Germany	Issued	69131014.9-08	3/17/99	92901072.6	11/20/11
United Kingdom	Issued	0558631	3/17/99	92901072.6	11/20/11
Netherlands	Issued	0558631	3/17/99	92901072.6	11/20/11
Spain	Issued	0558631	3/17/99	92901072.6	11/20/11
Switzerland	Issued	0558631	3/17/99	92901072.6	11/20/11

14. Curtiss, R. III, and S. A. Tinge. Recombinant Bacterial Vaccine System with Environmentally Limited Viability. Filed Jun. 7, 1995. PCT filed Jun. 7, 1996. (Patent on methods to cause viability of live bacterial vaccines to be restricted to specific environments or to temperatures of immunized warm-blooded vertebrate hosts with death of such vaccines resulting from exposure to defined environments or to temperatures for growth below body temperatures.)

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	APPL. NO./ SERIAL NO.	EXPIRATION	DOCKET NO.
United States	Abandoned			08/473,789		3116-1780
United States	Issued	6,610,529	8/26/03	08/761,769		3116-1772
United States	Issued	7,871,604	1/18/11	09/120/970	8/22/19	
PCT		WO 96/40947		PCT/US96/09774		
Australia	Issued	711618	2/3/00	61664/96	6/7/16	
Canada	Pending			2,222,761		3116-1760
Japan	Issued	11-507532	7/6/99	S/N 9-501998		
Europe	Issued	0832255	12/14/05	96919292.1	3116-1761	
Austria	Issued	0832255	12/14/05	96919292.1		
Belgium	Issued	0832255	12/14/05	96919292.1		
Switzerland	Issued	0832255	12/14/05	96919292.1		
Germany	Issued	0832255	12/14/05	96919292.1		
Denmark	Issued	0832255	12/14/05	96919292.1		
Spain	Issued	0832255	12/14/05	96919292.1		
Finland	Issued	0832255	12/14/05	96919292.1		
France	Issued	0832255	12/14/05	96919292.1		
United Kingdom	Issued	0832255	12/14/05	96919292.1		
Ireland	Issued	0832255	12/14/05	96919292.1		
Italy	Issued	0832255	12/14/05	96919292.1		
Liechtenstein	Issued	0832255	12/14/05	96919292.1		
Luxembourg	Issued	0832255	12/14/05	96919292.1		
Monaco	Issued	0832255	12/14/05	96919292.1		
Netherlands	Issued	0832255	12/14/05	96919292.1		
Portugal	Issued	0832255	12/14/05	96919292.1		
Sweden	Issued	0832255	12/14/05	96919292.1		

15. Curtiss, R. III, and C. A. Nickerson. Recombinant Vaccines Comprising Avirulent Immunogenic *S. typhi* Having RpoS Positive Phenotype. Filed November 14, 1997. PCT filed Nov. 13, 1998. (Patent on novel avirulent *Salmonella enterica* serotype Typhi having an RpoS⁺ phenotype for use as vaccines and delivery vehicles for gene products and to methods for their preparation.)

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	APPL. NO./ SERIAL NO.	EXPIRATION	DOCKET NO.
United States	Issued	6,024,961	2/15/00	08/970,789	11/14/17	3116-6059
PCT		WO99/25387		PCT/US98/24295		3116-7471
Israel, 5/14/00				136131		3116-4688
Japan						3116-4689
S. Korea, 5/15/00		7005297/2000				3116-4690

CIP filed 5/18/99

Recombinant Vaccines Comprising Immunogenic Attenuated Bacteria Having RpoS Positive Phenotype. Continuation filed 5/3/02

United States	Issued	6,383,496	5/7/02	09/314,062		3116-9419
Continuation		7,083,794	8/1/06	10/138,329		3116-33076
Australia	Issued	736242	11/8/01	14595/99		3116-4685

Canada	Issued	2,309,925	6/1/10	2,309,925	11/13/18	56029-4686
Europe	Issued	1030690	7/3/02	98958581.5	11/13/18	3116-4687
Austria	Issued	1030690	7/3/02	98958581.5	11/13/18	3116-4687
Belgium	Issued	1030690	7/3/02	98958581.5	11/13/18	3116-4687
Switzerland	Issued	1030690	7/3/02	98958581.5	11/13/18	3116-4687
Cyprus	Issued	1030690	7/3/02	98958581.5	11/13/18	3116-4687
Germany	Issued	1030690	7/3/02	98958581.5	11/13/18	3116-4687
Denmark	Issued	1030690	7/3/02	98958581.5	11/13/18	3116-4687
Spain	Issued	1030690	7/3/02	98958581.5	11/13/18	3116-4687
Finland	Issued	1030690	7/3/02	98958581.5	11/13/18	3116-4687
France	Issued	1030690	7/3/02	98958581.5	11/13/18	3116-4687
United Kingdom	Issued	1030690	7/3/02	98958581.5	11/13/18	3116-4687
Greece	Issued	1030690	7/3/02	98958581.5	11/13/18	3116-4687
Ireland	Issued	1030690	7/3/02	98958581.5	11/13/18	3116-4687
Italy	Issued	1030690	7/3/02	98958581.5	11/13/18	3116-4687
Liechtenstein	Issued	1030690	7/3/02	98958581.5	11/13/18	3116-4687
Luxembourg	Issued	1030690	7/3/02	98958581.5	11/13/18	3116-4687
Monaco	Issued	1030690	7/3/02	98958581.5	11/13/18	3116-4687
Netherlands	Issued	1030690	7/3/02	98958581.5	11/13/18	3116-4687
Portugal	Issued	1030690	7/3/02	98958581.5	11/13/18	3116-4687
Sweden	Issued	1030690	7/3/02	98958581.5	11/13/18	3116-4687

16. Curtiss, R. III, and Steven Tinge. Regulated Antigen Delivery System. Filed April 28, 2000. PCT filed April 30, 2001.

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	APPL. NO./ SERIAL NO.	EXPIRATION	DOCKET NO.
United States	Issued	6,780,405	8/24/04	09/560,539		
United States	Issued	7,341,860	3/11/08	10/924,574		3116-4355
PCT		WO 01/083785		PCT/US01/13915		3116-7781
Regulated Antigen Delivery System (RADS) Involving Bacteria						
Europe	Issued	1292687	8/16/06	01944119.5		
Austria	Issued	1292687	8/16/06	01944119.5		
Belgium	Issued	1292687	8/16/06	01944119.5		
Switzerland	Issued	1292687	8/16/06	01944119.5		
Cyprus	Issued	1292687	8/16/06	01944119.5		
Germany	Issued	1292687	8/16/06	01944119.5		
Denmark	Issued	1292687	8/16/06	01944119.5		
Spain	Issued	1292687	8/16/06	01944119.5		
Finland	Issued	1292687	8/16/06	01944119.5		
France	Issued	1292687	8/16/06	01944119.5		
United Kingdom	Issued	1292687	8/16/06	01944119.5		
Greece	Issued	1292687	8/16/06	01944119.5		
Ireland	Issued	1292687	8/16/06	01944119.5		
Italy	Issued	1292687	8/16/06	01944119.5		
Liechtenstein	Issued	1292687	8/16/06	01944119.5		
Luxembourg	Issued	1292687	8/16/06	01944119.5		
Monaco	Issued	1292687	8/16/06	01944119.5		
Netherlands	Issued	1292687	8/16/06	01944119.5		
Portugal	Issued	1292687	8/16/06	01944119.5		
Sweden	Issued	1292687	8/16/06	01944119.5		
Turkey	Issued	1292687	8/16/06	01944119.5		
New Zealand	Issued	522433	8/12/04		4/30/21	MEG-213.0P

17. Curtiss, R. III. Functional Balanced-Lethal Host-Vector Systems. Filed October 11, 2000. PCT filed October 5, 2001.

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	APPL. NO./ SERIAL NO.	EXPIRATION	DOCKET NO.
United States	Issued	6,872,547	3/29/05	09/686,499	56029-1192	
PCT				PCT/US01/42527		
Guatemala		Pending				3116-8517

Thailand

Pending

3116-8521

18. Curtiss, R. III, and Steven Tinge. Microbes Having an Attenuating Mutation Comprising a Transcription Terminator. Filed Oct. 12, 2000. PCT filed Nov. 10, 2001.

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	APPL. NO./ SERIAL NO.	EXPIRATION	DOCKET NO.
United States	Abandoned			09/689,123		15060-00005
PCT		WO 02/30457		PCT/US01/31606		15060-7
Canada				2,463,482		15060-32
Argentina				010104792		15060-8
Chilean				2442-01		15060-9
Europe	Issued	1326960	7/16/03	01979646.5		15060-33
France	Issued	1326960	7/16/03	01979646.5		15060-33
Great Britain	Issued	1326960	7/16/03	01979646.5		15060-33
Germany	Issued	60107707.5	8/12/05	01979646.5		

19. Curtiss, R. III, and H. Y. Kang. Improved Immunogenic Compositions and Vaccines Comprising Carrier Bacteria that Secrete Antigens. Provisional filed April 15, 2002. Formal filed April 15, 2003. (WITHDRAWN)

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	APPL. NO./ SERIAL NO.	EXPIRATION	DOCKET NO.
United States	Provisional			60/372,710		56029-31238
United States	Pending			10/414,532		56029-40437

20. Curtiss, R. III. Regulated Attenuation of Live Vaccines to Enhance Cross-Protective Immunogenicity. Provisional filed April 15, 2002 and April 18, 2002. Formal filed April 15, 2003. PCT filed April 15, 2003. Divisional EP 2 380 440 A1, filed Sept. 28, 2010.

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	APPL. NO./ SERIAL NO.	EXPIRATION	DOCKET NO.
United States	Provisional			60/372,616		56029-31335
				60/373,626		56029-32858
United States	Issued	8,133,493	3/13/12	10/511,616		56029-51044
PCT		WO 03/096812		PCT/US03/11802		56029-40434
Australia				2003235457		56029-51047
Canada				2,526,895		
Europe	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
Austria	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
Belgium	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
Bulgaria	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
Switzerland	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
Cyprus	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
Czech Republic	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
Germany	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
Denmark	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
Estonia	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
Spain	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
Finland	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
France	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
United Kingdom	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
Greece	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
Hungary	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
Ireland	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
Italy	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
Liechtenstein	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
Luxemburg	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
Monaco	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
Netherlands	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
Portugal	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
Romania	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045

Sweden	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
Slovenia	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
Slovak Republic	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045
Turkey	Issued	1499191	5/9/12	03721711.4	4/15/23	56029-51045

21. Curtiss, R. III, and H. Y. Kang. Modulation of Immune Responses to Foreign Antigens Expressed by Recombinant Attenuated Bacterial Vectors. Provisional filed April 15, 2002 and April 18, 2002. Formal filed April 15, 2003.

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	APPL. NO./	EXPIRATION	DOCKET NO.
				SERIAL NO.		
United States	Provisional			60/372,676		56029-31336
				60/373,669		56029-32859
United States	Issued	7,195,757	3/27/07	10/414,533		56029-40420

22. Curtiss, R. III, and W. Kong. Regulated Bacterial Lysis for Gene Vaccine Vector Delivery and Antigen Release. Provisional filed Sept.1, 2002. PCT filed Aug. 29, 2003.

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	APPL. NO./	EXPIRATION	DOCKET NO.
				SERIAL NO.		
United States	Pending			10/526,365		
United States	Provisional			60/407,522		56029-35347
PCT		WO 2004/020643		PCT/US03/26883		56029-42524
Australia				2003278729		
Europe	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Austria	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Belgium	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Bulgaria	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Switzerland	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Cyprus	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Czech Republic	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Germany	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Denmark	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Estonia	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Spain	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Finland	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
France	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
United Kingdom	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Greece	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Hungary	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Ireland	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Italy	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Liechtenstein	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Luxemburg	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Monaco	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Netherlands	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Portugal	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Romania	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Sweden	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Slovenia	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Slovak Republic	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711
Turkey	Issued	1537214	3/1/06	03770256.0	8/29/23	56029-53711

23. Curtiss, R. III. Recombinant bacteria comprising vectors for expression of nucleic acid sequences encoding antigens. U.S. Provisional Patent Application No. 60/917,306, filed 5/10/07. PCT/US08/63303, filed 5/9/08. Publication No. WO 2008/141226. Europe Nationalized Application No. 08825819.9, Publication No. EP2152883, filed 5/9/08. (Internal Tech ID M7-012L)

24. Curtiss, R. III, S. Wang, S.Y. Wanda, and W. Kong. Regulated expression of antigen and/or regulated attenuation to enhance vaccine immunogenicity and/or safety. Provisional filed 05/10/07. PCT filed 05/09/08. Europe Nationalized

Application No. 08827622.5, Publication No. EP2150616, filed 05/9/08.

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	APPL. NO./ SERIAL NO.	EXPIRATION	INTERNAL TECH ID
United States	Issued	8,445,254	5/21/13	12/615,872		M7-011L
United States	Provisional			60/917,313		M7-011L
PCT	WO 2009/025888			PCT/US08/063293		M7-011L

25. Curtiss, R. III, M. Mellata, B. Zekarias, Z. Shi, C. Branger, and K. Roland. Recombinant bacterium capable of eliciting an immune response against enteric pathogens. *Salmonella* vaccine against bacterial enteric pathogens. Provisional filed 10/5/07. PCT filed 10/6/08.

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	APPL. NO./ SERIAL NO.	EXPIRATION	INTERNAL TECH ID
United States	issued	8,465,755	7/18/13	12/681,721		M8-025L
United States	Provisional			60/978,084		M8-025L
PCT	WO 2009/046449			PCT/US08/078991		

26. Curtiss, R. III, B. Zekarias, and K. Roland. Recombinant bacterium capable of eliciting a protective immune response against *C. perfringens*. U.S. Provisional Application No. 60/978,084, filed. 10/5/07. PCT/US08/78993, filed 10/6/08. Publication No. WO 2009/046451. (Internal Tech ID M8-062L) Claims allowed.

27. Curtiss, R. III, and X. Liu. Nucleic acids, bacteria, and methods for degrading the peptidoglycan layer of a cell wall. (Patent on regulated lysis of cyanobacteria) U.S. Provisional Application No. 61/073/299, filed 06/17/08. PCT/US09/47681, filed 6/17/09. Publication No. WO 2009/155357. (Internal Tech ID M8-060L)

28. Curtiss, R. III, J. Santander Morales, S.Y. Wanda, and S. Wang, K. Brenneman, H. Shi, W. Xin, and Q. Kong. Recombinant bacterium capable of eliciting an immune response against *Streptococcus pneumoniae*. U.S. Provisional Application No. 61/106,367, filed 10/17/2008. PCT/US09/61100, filed 10/16/09. Publication No. WO 2010/045620. Nationalized PCT US13/088,141, filed 4/15/11. (Internal Tech ID M8-061L) Claims allowed.

29. Curtiss, R. III, and X. Liu. Neutral lipid producing cyanobacterial. U.S. Provisional Application No. 61/142,551, filed 1/5/09. PCT/US10/20137, filed 1/5/10. Publication No. WO 2010/078584 (Internal Tech ID M9-017L)

30. Curtiss, R. III, and X. Zhang. A Single Expression Vector for Generation of a Virus with a Segmented Genome. U.S. Provisional Patent Application 61/168,996, filed 4/14/9. PCT/US12/759,842, filed 4/14/10. (Internal Tech ID M9-088L) Claims allowed.

31. Curtiss, R. III, and J. Santander Morales. Recombinant *Edwardsiella* Bacterium. U.S. Provisional Application No. 61/182,569, filed 05/29/09. U.S. Patent Application 12/789,869, filed 5/28/10. PCT/US12/789,869, filed 5/28/10. (Internal Tech ID M9-119L) Claims allowed.

32. Curtiss, R. III, and W. Kong. Recombinant bacterium for delivering plasmid DNA. U.S. Provisional Patent Application No. 61/180,620, filed 5/22/09. Recombinant bacterium and methods of antigen delivery. U.S. Provisional Application No. 61/222,306, filed 7/1/09. Recombinant bacterium and methods of antigen and nucleic acid delivery. PCT/US10/35630, filed 05/20/10. Publication No. WO 2010/135563. (Internal Tech ID M9-141L)

33. Curtiss, R. III, and X. Liu. Bacterium for production of fatty acids. U.S. Provisional Patent Application 61/255,729, filed 10/28/09; 61/307,185, filed 02/23/10, 61/382/156, filed 9/13/10. PCT/US10/54494, filed 10/28/10. Publication No. WO 2011/059745. U.S. Application 13/459,774, filed 4/30/12. (Internal Tech ID M10-056L; M10-122L; M11-015L).

34. Curtiss, R. III, and W. Sun. *Yersinia pestis* vaccine. U.S. Provisional Application No. 61/294,727, filed 1/13/10. Non-Provisional 13/006,072, filed 1/13/11. U.S. Publication No. US2011/0256177 A1. (Internal Tech ID M10-055L) Claims allowed.

35. Curtiss, R. III, and Q. Kong. Bacterium comprising a regulated *rfaH* nucleic acid. (Induction of cross-protective immunity by over exposure and expression of cross-protective antigens) Provisional filed 1/22/10. PCT filed 1/21/11.

APPL. NO./

INTERNAL

COUNTRY	STATUS	PAT. NO.	ISSUE DATE	SERIAL NO.	EXPIRATION	TECH ID
United States	Issued	8,889,121	11/18/14	13/574,729		M10-037L
United States	Provisional			61/297,315		M8-025L
PCT	WO 2011/091291			PCT/US11/22110		

36. Curtiss, R. III, and W. Kong Engineering self-destructing *Salmonella* as a cancer cure (Recombinant bacterium to decrease tumor growth). U.S. Provisional Application No. 61/349,425, filed 5/28/10. PCT/US2011/038588, filed 4/25/11. Publication No. WO 2011/150421 A2. U.S. Patent Application 13/700,591, filed 4/15/13. (Internal Tech ID M10-154L)

37. Curtiss, R. III, and X. Liu. Cyanobacterium that produces neutral lipids (Compositions and methods for bacterial lysis and neutral lipid production). U.S. Provisional Application No. 61/361,116, filed 7/2/10. PCT/US2011/042821, filed 1/20/11. Publication No. WO 2012/003460 A2. U.S. Patent Application 13/805,733, filed 12/20/12. (Internal Tech ID M10-180L)

38. Curtiss, R. III, and S. Ashraf. Recombinant bacterium for induction of cellular immune responses. U.S. Provisional Application No. 61/619,307, filed 4/02/12. PCT/US13/31592, filed 3/14/13. Publication No. WO 2013/15173 A1. U.S. Patent Application 14/390,306, filed 10/02/14. (Internal Tech ID M10-133L)

39. Curtiss, R. III, and X. Liu. Photosynthetic microorganisms expressing thermostable lipase. U.S. Provisional Application No. 61/648,820 filed 5/18/12. U.S. Patent Application 13/898,241, filed 5/20/2013. (Internal Tech ID M12-068L)

40. Curtiss, R. III, M. Fisher, and R. Allen. Microbes with controlled adhesive properties. U.S. Provisional Application No. 61/657,242, filed 06/08/12 and U.S. Provisional Application No. 61/707,427, filed 9/28/12. PCT/US13/44978, filed 6/10/13. U.S. Patent Application 14/406,461, filed 12/08/14. (Internal Tech ID M12-149L)

41. Curtiss, R. III, K. Brenneman, and K. Roland. Attenuated live bacteria with increased acid resistance and methods of use thereof. U.S. Provisional Application No. 61/836,140, filed 6/17/13. U.S. Patent Application 14,307,09, filed 7/17/14. (Internal Tech ID M13-121L).

42. Forbes, S., and R. Curtiss III. *Citrobacter koseri* model and therapeutic. U.S. Provisional Application No. 61/914,124, filed 12/10/13. (Internal Tech ID M14-112L).

43. Roland, K., R. Curtiss III, P. Laniewski, and A. Mitra. Live *Salmonella* vaccine to prevent fowl typhoid. U.S. Provisional Application No. 61/987,820, filed 5/2/14. (Internal Tech ID M14-194L)

44. Curtiss, R. III, and Wei Sun. Genetically modified *Yersinia* as vaccines against *Yersinia* species. U.S. Provisional Application No. 62/048,845, filed 9/10/14. (Internal Tech ID M14-248L)

LICENSED VACCINES

1. Live attenuated *Salmonella choleraesuis* vaccine, Argus SC; APHIS registration 19A1.00., October 23, 1997. Marketed by Intervet. See references 154 and 226 in CV.
2. Live attenuated *Salmonella typhimurium* vaccine for broilers, Megan Vac 1; APHIS registration 19C1.01., November 25, 1998. Marketed by Lohmann Animal Health. See references 137, 139, 160, 164, 175, 177, 190, and 193 in CV.
3. Live attenuated *Salmonella typhimurium* vaccine for layers, Megan Egg; APHIS registration 19C1.02., November 4, 2003. Marketed by Lohmann Animal Health. See reference 214 in CV.

POSTDOCTORAL Scholars

Former Postdoctoral Fellows, Trainees, Scholars and Research Associates

Shamaila Ashraf, PhD (2006-2010) – Arizona State University
 Senior Scientist, ATCC, Manassas, VA
 PhD (Avian Virology), 2005, The Ohio State University, Wooster, OH, “Studies on infectious bursal disease virus”

- Keith Ameiss, PhD (2005-2009) – Washington University and Arizona State University
PhD (Poultry Sciences), 2005, Texas A&M University, College Station, TX, "Effects of Cytosine-Phosphate-Guanosine Oligodeoxynucleotides (CpG-ODNs) on Oral Immunization with Protein Antigen or Replicating Parasite"
- Yoshimitsu Abiko, PhD, DDS (1978-1980) - University of Alabama at Birmingham
Professor, School of Dentistry at Matsudo Department of Dentistry, Nihon University
PhD (Biochemistry), 1977, Nihon University, "Studies on Calcium-Stimulated Adenosine Triphosphatase in the Albino Rabbit Dental Pulp. Its Subcellular Distribution and Properties"
- W. James Alexander, MD (1977-1979) - University of Alabama at Birmingham
Senior Vice President, Clinical and Regulatory Operations and Chief Medical Officer, BioCryst Pharmaceuticals, Inc., Birmingham, AL
MD, 1974, University of Mississippi
- Iqbal Ibn Amin, MD, PhD, CMD (1993-1996) - Washington University
PhD (Microbiology), 1992, University of Birmingham, Birmingham, UK, "Studies on the invasiveness of *Salmonella typhimurium*"
- Chang Ho-Baek, PhD (2003-2008) – Washington University and Arizona State University
Staff Scientist, Life Technologies, Carlsbad, CA
PhD (Microbiology), 2003, Sogang University, Seoul, Korea – "Physiological and genetic analyses of the utilization of the opine, deoxyfructosyl flutamine, as a compound mediating relationships between agrobacterium and plant"
- John F. Barrett, PhD, (1982-1985) - University of Alabama at Birmingham and Washington University
(Deceased) Formerly, Executive Director, Anti-Infective Microbiology, Bristol-Myers Squibb, Pharmaceutical Research & Development Division, Wallingford, CT
PhD (Microbiology/Immunology), 1982, Temple University School of Medicine, "Kinetics and Mechanism of Hydrolysis of the N-acetylmuramal-hydrolase of *Streptococcus faecium* 9790"
- James R. Bonner, MD (1974-1976) - University of Alabama at Birmingham
Professor, Department of Pediatrics, Division of Allergy and Immunology, University of Alabama at Birmingham
MD, 1971, University of Michigan
- Jean-luc Boucaud, DVM (1988-1989) - Washington University
DVM (Veterinary Medicine), 1987, Ecoles Nationales Veterinaire de Lyon
- Christine Branger, PhD (2004-2008) – Washington University and Arizona State University
PhD (Biology), 2001, Nantes University, Nantes, France – "Protection against Leptospirosis: Studies of two genes of interest: *hap1* and *ompL1* encoding for respectively haemolysin and porine.
- Karen Brennehan, PhD (2007-2012) – Arizona State University
PhD (Microbiology) 2007, The Ohio State University, Columbus, OH, "Investigation and characterization of the enhanced humoral response following immunization with the lethal and edema toxins of *Bacillus anthracis*"
- Peter Brown, PhD (1992-1996) - Washington University
Centre for Immunology, St. Vincent's Hospital, Darlinghurst, New South Wales, Australia
PhD (Microbiology), 1992, University of Sydney, Australia, "Cloning and sequencing of the *rfb* gene cluster of a group C2 *Salmonella*: the evolutionary relationship with other serogroups"
- Lisa Burns-Keliher, PhD (1991-1998) - Washington University
Applications/Software Support Scientist, Bioinformatics Group, Monsanto Corporation, St. Louis, MO
PhD (Medical Microbiology), 1990, Texas Tech University Health Sciences Center, "Involvement of lipopolysaccharide in expression of the major outer membrane protein OmpF in *Escherichia coli* K-12"
- Josephine E. Clark-Curtiss, PhD (1973-1976) - University of Alabama at Birmingham
Professor, Arizona State University, School of Life Sciences and Biodesign Institute, Tempe, AZ

PhD (Microbiology), 1974, Medical College of Georgia, "A Molecular Characterization of the Genomes of the Compatible Mating Strains of *Nocardia erythropolis*"

Amiken Cohen, PhD (1966-1968) - Oak Ridge National Laboratory, TN

Professor Emeritus, Department of Microbiology, The Hebrew University of Jerusalem, Israel

PhD (Biochemistry), 1966, University of Pittsburgh, PA, "Biosynthesis of Complex Polysaccharides of the Yeast *Cryptococcus laurentii*"

Laurence Vincent Collins, PhD (1990-1994) - Washington University

Ingenieur de Recherche (PD), INSERM, Lyon, France

PhD (Microbial Pathogenesis), 1990, University of Adelaide, Australia, "The effect of mutations in lipopolysaccharide biosynthetic genes on the virulence of *Salmonella typhimurium* for the mouse"

Susan Cook, PhD (2003-2005) - Washington University

Assistant Director, Environmental Health and Safety and Biological Safety Officer, Washington University School of Medicine, St. Louis, MO

PhD (Molecular and Microbiology), 2003, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD – "Development of an in vivo imaging system to elucidate mechanisms of attenuation of Sindbis virus"

Rebecca C. Craven, PhD (1981-1984) - University of Alabama at Birmingham

Professor, Department of Microbiology & Immunology, The Pennsylvania State University, Hershey, Pennsylvania

PhD (Microbiology), 1981, University of Tennessee

France Daigle, PhD (1998-2001) – Washington University

Professor, Department of Microbiology and Immunology, University of Montreal

PhD (Microbiology & Immunology), 1996, University of Montreal, Montreal, Canada, "Genetic Studies of Virulence Factors Present in Extraintestinal *Escherichia coli* Strains"

Yakhya Dieye, PhD (2005-2008) – Arizona State University

PhD (Bacterial Genetics), 2002, Université Paris 11, Orsay, France, "Targeting of heterologous proteins in lactic acid bacteria: toward the use of *Lactococcus lactis* as delivery vehicle of useful molecules in gut of the host"

Teresa Ann Doggett, PhD (1989-1997) - Washington University

Dept. of Pharmacological and Physiological Sciences, St. Louis University School of Medicine, St. Louis, MO

PhD (Immunology), 1989, Plymouth Polytechnic, Devon, England, "Peripheral Blood, Intestinal Leucocytes and Antigen Absorption in the Gut of the Cichlid, *Oreochromis-mossambicus*"

Charles Dozois, PhD (1997-2001) – Washington University

Professor, INRS-Institut Armand-Frappier, Laval Québec

PhD (Microbiology & Immunology), 1995, University of Montreal, Montreal, Canada, "Phenotypic and Genetic Analyses of P and Type I Fimbriae of Pathogenic *Escherichia coli* from Poultry"

Joel Dworkin, M.D., Ph.D. (2001-2003) – Washington University

Ph.D. (Microbiology & Immunology), 1995, Vanderbilt University School of Medicine, Nashville, TN,

"Molecular Genetics of *Campylobacter* Fetus S-Layers: Studies of S-Layer Gene Organization, LPS-Binding Domains, and Expression"

M.D., 1997, Vanderbilt University School of Medicine, Medical Scientist Training Program (MTSB), Nashville, TN

Joseph O. Falkinham III, PhD (1972-1974) - University of Alabama at Birmingham

Professor of Biology, Virginia Polytechnic Institute & State University, Blacksburg, VA

PhD (Microbiology), 1969, University of California-Berkeley, "Analysis of Linkage Relationships in a Double Male Strain of *Escherichia coli* K-12"

Michael L. Fisher, PhD (2010-2014) - Arizona State University

Assistant Professor, Southern Connecticut State University, New Haven, CT

PhD (Molecular Microbiology), 2008, Tufts University, Boston, MA, "A role for bacterial virulence factors in a newly defined model of pneumonic yersiniosis"

- Anne Cornish Frazer, PhD (1970-1974) - Oak Ridge National Laboratory and University of Alabama at Birmingham
Senior Scientist, QC Technology Development, Bayer Healthcare Pharmaceuticals, Berkeley, CA
PhD (Microbiology/Immunology), 1970, Tulane University, "Regulatory Properties of Pyruvate Kinase and a Preliminary Study of Four Additional Enzymes from the Metabolic Routes Interlocking at 3-Phosphoglycerate in *Thiobacillus neapolitanus*"
- Jorge E. Galan, PhD, DVSc, DVM (1986-1989) - Washington University
Professor and Chairman, Section of Microbial Pathogenesis, Yale University School of Medicine
PhD (Bacteriology), 1986, Cornell University, "Studies on the Immune Response of the Horse to the M Protein of *Streptococcus equi*"
DVSc (Veterinary Science), 1982, National University of La Plata
DVM (Veterinary Medicine), 1980, National University of La Plata
- Claudia Gentry-Weeks, PhD (1985-1989) - Washington University
Associate Professor, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, CO
PhD (Microbiology), 1985, University of Oklahoma Health Science Center, "Cloning and Nucleotide Sequence of the Structural Gene for Type A Streptococcal exotoxin (erythrogenic toxin) from *Streptococcus pyogenes* Bacteriophage T12"
- Gurnam S. Gill, PhD (1976-1980) - University of Alabama at Birmingham
Research Scientist, The Upjohn Company, Kalamazoo, MI
PhD (Medical Biophysics), 1976, University of Toronto, Canada, "Studies on Chromosomal Organization and Transcription in the Bacteriophage T1"
- Louis Glatzer, PhD (1970-1972) - Oak Ridge National Laboratory
Professor Emeritus, University of Toledo, Toledo, OH
PhD (Zoology), 1970, University of Texas in Austin, "Studies on the Acetohydroxy Acid Synthetase of *Neurospora crassa* Mitochondria"
- Jon D. Goguen, PhD (1980-1982) - University of Alabama at Birmingham
Associate Professor of Molecular Genetics & Microbiology, University of Massachusetts Medical School, Worcester, MA
PhD (Zoology), 1980, University of Massachusetts, "Population Biology of a Conjugative Plasmid: Effects of Surface Populations of Bacteria"
- Raul M. Goldschmidt, PhD (1974-1976) - University of Alabama at Birmingham
R.W. Johnson Pharmaceutical Research Institute, Raritan, NJ
PhD (Biology), 1970, Columbia University, "Degradation of Polypeptides Synthesized by Nonsense Mutants of the *laeZ* gene in *Escherichia coli*"
- Paul A. Gulig, PhD (1985-1988) - Washington University
Professor, Department of Molecular Genetics and Microbiology, University of Florida, College of Medicine, Gainesville, FL
PhD (Microbiology), 1985, University of Texas Health Science Center-Dallas, "Studies of Outer Membrane Antigens of *Haemophilus influenzae* type b as Potential Vaccine Candidates"
- John H. Hanlin, PhD (1984-1985) - Washington University
Vice President of Public Health, Ecolab Inc.
PhD (Biology and Microbiology), 1984, Syracuse University, "The Mechanism of Heat Resistance of Bacterial Spores"
- Jeffrey B. Hansen, PhD (1978-1981) - University of Alabama at Birmingham
Formerly Senior Reporter, The Birmingham News, Birmingham, AL
PhD (Microbiology), 1978, University of Michigan, Ann Arbor MI, "Plasmids of *Pseudomonas*"
- Jubril Olugbenga Hassan, PhD (1989-1994) - Washington University

PhD (Immunology), 1989, University of Birmingham, England, "Some Aspects of Humoral and Cellular Immune Response to *Salmonella typhimurium* Infection in Chickens"

- Robert G. Holt, PhD (1978-1982) - University of Alabama at Birmingham
 Professor, Department of Microbiology, Meharry Medical College, Nashville, TN
 PhD (Biomedical Sciences), 1978, University of Tennessee-Knoxville, Graduate School of Biomedical Sciences, Oak Ridge National Laboratory, "Studies of the Ribonucleotide Reductase in *Pseudomonas stutzeri*"
- Allen L. Honeyman, PhD (1988-1991) - Washington University
 Associate Professor, Texas A & M Health Science Center, Baylor College of Dentistry, Dallas, TX
 PhD (Microbiology), 1987, University of Kansas, "Characterization of the *rodC* Locus of *Bacillus subtilis*"
- JeMin Charles Hsu, PhD (1975-1979) - University of Alabama at Birmingham
 (Deceased) Formerly, Senior Scientist, Rohm and Haas, Spring House, PA
 PhD (Microbiology), 1975, Clemson University, "Microbial Degradation of a Family of Herbicides 4-Hydroxy-3,5-Dihalogeno-4-hydroxybenzonitriles"
- Rui Huang, PhD (2001) – Washington University
 Professor and Director, School of Basic Medical Sciences and Life Sciences, Soochow University, Suzhou, Jiangsu, P. R. China
 PhD (Microbiology), 2000, Shanghai Medical University, Shanghai, P. R. China, "Study on the Biological Characteristics Mediated by Drug Resistant *Salmonella typhi* R Plasmid (pR_{ST98})"
- Michael C. Hudson, PhD (1987-1990) - Washington University
 (Deceased) Formerly, Professor of Biology, Department of Biology, University of North Carolina at Charlotte, Charlotte, NC
 PhD (Microbiology), 1987, University of Kansas, "Transcription Initiation in *Staphylococcus aureus*"
- Thomas A. Hughes, PhD (1981-1983) - University of Alabama at Birmingham
 Professor, Department of Biological Sciences, Clemson University, Clemson, SC
 PhD (Microbiology), 1981, North Carolina State University
- Richard A. Hull, PhD (1976-1978) - University of Alabama at Birmingham
 Formerly, Associate Professor of Microbiology, Baylor College of Medicine, Houston, TX
 PhD (Microbiology), 1976, University of Arizona, "Interference of Plasmids upon Bacteriophage Growth"
- Sheila I. Hull, PhD (1974-1978) - University of Alabama at Birmingham
 Formerly, Associate Professor of Microbiology, Baylor College of Medicine, Houston, TX
 PhD (Microbiology), 1975, University of Arizona, "Cell Division in *Bacillus subtilis*"
- Matsuhisa Inoue, PhD (1976-1978) - University of Alabama at Birmingham
 Chief Professor, Department of Microbiology, Kitasato University School of Medicine, Sagamihara, Japan
 PhD (Microbiology), 1976, Gunma University
- Elizbieta K. Jagusztyn-Krynicka, PhD (1979-1981) - University of Alabama at Birmingham
 Professor, Institute of Microbiology, Department of Bacterial Genetics, University of Warsaw, Warsaw, Poland
 PhD (Microbiology), 1979, Institute of Microbiology, University of Warsaw, "Repair of Damage in DNA Molecules Caused by Disintegration of Incorporated ³²P DNA Radiophosphorus Atoms"
- Maria Dolores Juarez-Rodriguez, PhD (2003-2005; 2006-2011) – Washington University and Arizona State University
 Postdoctoral Scholar, University of Louisville, Louisville, KY
 PhD (Biomedical Basic Research), 2002, Universidad Nacional Autónoma de México, Mexico City, Mexico, "Molecular characterization of the gene coding for the Rv2874 (DipZ) protein and its relationship with the mpt83-mpt70 locus of *Mycobacterium tuberculosis*"
- Ho Young Kang, PhD (1997-2002) - Washington University
 Assistant Professor, Division of Biological Sciences-Microbiology, Pusan National University, Pusan, Korea

PhD (Microbiology & Immunology), 1997, East Carolina University School of Medicine, Greenville, NC,
 "Identification and Characterization of the *Bordetella pertussis* Alcaligin Siderophore Biosynthesis Operon"

George G. Khachatourians, PhD, RM (CCM) (1971-1973) - University of Tennessee-Oak Ridge
 Professor, Department of Applied Microbiology and Food Science, College of Agriculture, University of
 Saskatchewan, Saskatoon, Canada
 PhD (Microbiology), 1971, University of British Columbia, "Pleiotrophic Effect of dnaA Gene on Initiation of DNA
 Replication and Cell Division in *Escherichia coli*"

Qingke Kong, PhD (2005-2009) - Arizona State University
 Assistant Research Professor, Biodesign Institute, Arizona State University, Tempe, AZ
 PhD (Microbiology), 2004, Nankai University, Tianjin, P.R. China, "Sequence of the *E. coli* O-antigen clusters and
 identification of sugar biosynthesis genes"

Wei Kong, PhD (2001-2007) – Washington University and Arizona State University
 Assistant Research Professor, Biodesign Institute, Arizona State University, Tempe, AZ
 PhD (Microbiology and Molecular Genetics), 2000, Kyushu University, Fukuoka, Japan, "A novel peroxiredoxin of the
 plant *Sedum lineare* is a homologue of *Escherichia coli* bacterioferritin co-migratory Protein (Bcp)"

Vjollca Konjufca, PhD (2002-2007) – Washington University and Arizona State University
 Assistant Professor, Southern Illinois University, Carbondale, IL
 PhD (Avian Immunology), 2002, University of Arkansas, Fayetteville, AR, "Modulation of immune system
 development and function in broilers by dietary vitamin E"

Marcel Koopman, PhD (1993-1994) - Washington University
 Research and Development Manager-Chiron Corporation, Europe
 PhD (Biology), 1992, Utrecht University, The Netherlands, "Characterization of *Serpulina hyodysenteriae* periplasmic
 flagella and hemolysin.

Wayne B. Lanier, Jr., PhD (1966-1967) - University of Tennessee-Oak Ridge
 PhD (Biophysics and Theoretical Biology), 1966, University of Chicago, "Recovery of Alleles of Specific Nutritional
 Markers in Sexual and Parasexual Crosses in *Aspergillus nidulans* as a Function of the Composition of the Recovery
 Medium"

Paweł ~~Wasi~~ski, PhD (2012-2015) - Arizona State University
 PhD (Biology), 2012, University of Warsaw, "Anti-*Campylobacter* immunoprophylaxis – construction of bacterial
 vaccine prototypes producing chickens cytokines and *Campylobacter* antigens"

In Soo Lee, PhD (2001-2002) - Washington University
 Associate Professor, Department of Microbiology, Han Nam University, Taejeon, South Korea
 PhD (Microbiology), 1993, Han Nam University, Taejeon, South Korea, "Distribution of Metal Ion-Tolerant Bacteria in
 Uranium Ores at Ogcheon Basin and Mechanisms of Detoxification for V₂O₅(V) in *Bacillus cereus* LP40"

Margie D. Lee, DVM, PhD (1990-1992) - Washington University
 Professor, Department of Population Health, University of Georgia, Athens, GA
 PhD (Microbiology), 1990, University of Georgia, "An Evaluation of the Virulence Relationship of Invasiveness,
 Endotoxin Release, and Complement Resistance of Avian Strains of *Pasteurella multocida*"
 DVM (Veterinary Medicine), 1986, Virginia Maryland Regional College of Veterinary Medicine

Tae Ho Lee, PhD (2001-2002) - Washington University
 Professor, Division of Biological Sciences-Microbiology, Pusan National University, Pusan, Korea
 PhD (Applied Microbiology), 1980, Osaka Prefecture University, Osaka, Japan, "Study on the Structure of Red Yeast
 Cell Wall"

Yuhua Li, MD (2005-2009) - Arizona State University
 Associate Professor, Hematology Department, Zhujiang Hospital, P.R. China
 MD (Internal Medicine), 2001, First Military Medical University, Guangzhou, P.R. China, "Effects of Ly49A transfected
 lymphocytes on experimental graft versus host disease post allogeneic bone marrow transplantation"

Xinyao Liu, PhD (2007-2011) - Arizona State University

Lead Scientist, Saudi Basic Industries Corporation (SABIC), Jeddah, Saudi Arabia

PhD (Biotechnology), 2007, Peking University, Beijing, P.R. China, "The characteristics of anticyanobacterial microorganisms: grazing amoeba W2 and cyanophage Pf-WMP3 and Pf-WMP"

Yingqin Luo, PhD (2008-2012) – Arizona State University

Software Developer, Research Informatics Core (RIC), Einstein-Montefiore Institute for Clinical and Translational Research (ICTR), Albert Einstein College of Medicine, New York

PhD (Bioinformatics) 2008, Beijing Normal University, Beijing, P.R. China, "Phylogenetic analysis of the prokaryotic genome evolution with genome-wide conservation of overlapping genes"

David L. MacLeod, PhD (1991-1993) - Washington University

PhD (Veterinary Microbiology), 1990, University of Guelph, "Shiga-like Toxin II Variant: Purification, Characterization, and Role in Edema Disease"

Francis L. Macrina, PhD (1972-1974) - University of Alabama at Birmingham

Vice President for Research, Virginia Commonwealth University, Richmond, VA

PhD (Molecular Biology), 1972, Syracuse University, "Genetic and Physical Characterization of Stable F/lac Plasmid"

Gregory G. Mahairas, PhD (1990-1993) - Washington University

President and Chief Scientific Officer, BEAT BioTherapeutics Corp. (BEATBio)

PhD (Immunobiology), 1989, Iowa State University, "Molecular Genetic Approaches to Studying *Mycoplasma pulmonis* Virulence"

John J. Maurer, PhD (1990-1993) – Washington University

Professor, Department of Population, The University of Georgia, Athens, GA

PhD (Microbiology), 1990, University of Texas Health Science Center at San Antonio, "Molecular Analysis of Lipoteichoic Acid from *Streptococcus agalactide*"

Melha Mellata, PhD (2004-2007) – Washington University and Arizona State University

Assistant Research Professor, Biodesign Institute, Arizona State University, Tempe, AZ

PhD (Microbiology and Immunology), 2004, Université de Montréal Faculté de Médecine Vétérinaire (GREMIP), PQ, Canada, "Role of virulence factors of avian pathogenic *Escherichia coli* in colibacillosis"

Arindam Mitra, PhD (2008-2012) – Arizona State University

Senior Assistant Professor, School of Chemical and Biotechnology, SASTRA University, Thanjavur Tamil Nadu, India

PhD (Animal Sciences), 2008, University of Maryland, College Park. "Regulation of factors contributing to virulence in *Escherichia coli*"

Brian Morrow, PhD (1994-1999) – Washington University

Senior Scientist, Infectious Diseases Drug Discovery, Johnson and Johnson Pharmaceutical Research and Development, San Diego, CA

PhD (Biology) 1994, University of Iowa, Iowa City, Iowa, "Cloning and characterization of two genes regulated with phenotype switching in the pathogene yeast *Candida albicans*"

Sathish Mundayoor, PhD (1986 -1989) – Washington University

Senior Scientist, Rajiv Gandhi Centre for Biotech, New Delhi, India

PhD (Microbiology/Immunology), 1984, All India Institute of Medical Sciences, "The Role of Macrophages in the Maintenance of *M. leprae* and in the Modulation of Immune Responses in Leprosy"

Maneesha Muralinath, PhD (2005-2009) – Arizona State University

Instructor, School of Life Sciences, Arizona State University, Tempe, AZ

PhD (Molecular and Cellular Biology), 2003, Arizona State University, Tempe, AZ, "The role of the amino terminus of E3L in vaccinia virus pathogenesis"

C. K. Krishnan Nair, PhD (1978-1979) - University of Alabama at Birmingham

Professor of Radiation Biology, Amala Cancer Research Centre, Trichur, Kerala

PhD (Biochemistry), 1977, University of Bombay, "Some Aspects of DNA Replication and Repair"

Yanlong Jiang, PhD (2010-2014) - Arizona State University

PhD (Preventive Veterinary Medicine), 2009, Northeast Agriculture University, Harbin, P.R. China, "Construction of cDNA and whole genome sequencing of Newcastle Disease Virus Strain V4"

Koji Nakayama, DDS, PhD (1986-1988) - Washington University

Professor, Department of Microbiology, School of Dentistry, Nagasaki University, Nagasaki, Japan

PhD (Microbiology), 1984, Kyushu University, "The Genetic Study of the Mechanism for Thymineless Death in *Escherichia coli*"

DDS (Dentistry), 1977, Kyushu University

Amiya R. Nayak, PhD (1991-1996) - Washington University

Consultant/Advisor - BioTEchNet

PhD (Immunology), 1989, Utkal University, Orissa, India, "Some Fascinating Problems on the Biochemistry and Immunology of the Mycobacteria"

Warren E. Nesbitt, PhD (1982-1985) - University of Alabama at Birmingham and Washington University

PhD (Microbiology and Immunology), 1982, University of Louisville, "Adherence of *Streptococcus sanguis*"

Cheryl A. Nickerson, PhD (1994-1998) - Washington University

Professor, School of Life Sciences and Biodesign Institute, Arizona State University, Tempe, AZ

PhD (Microbiology), 1994, Louisiana State University, Baton Rouge, LA, "Role of Curved DNA in Promoter Recognition with *Bacillus subtilis* and *Escherichia coli* RNA Polymerase"

Anjana Raina, PhD (1992-1994) - Washington University

PhD (Molecular Biology), 1991, Jawaharlal Nehru University, New Delhi, India, "Purification of seed storage proteins of *Amaranthus hypochondriacus* and cloning of the gene"

Michael Rozinov, PhD (1990-1991) - Washington University

PhD (Molecular Biology), 1980, Institute for Genetics and Selection of Industrial Microorganisms, "Cloning of the Threonin Operon Genes of *E. coli*"

Shigeno Saito, PhD (1980-1983) - University of Alabama at Birmingham

Assistant Professor, Department of Biochemistry, Nihon University School of Dentistry at Matsudo, Japan

PhD (Biochemistry), 1974, Tohoku University, Sendai, Japan, "Mucopolysaccharides of Rat Ascites Hepatoma Cells"

Federico Sebastiani, PhD (1992-1994) - Washington University

Assistant Professor, Universidad Nacional Agraria La Molina, Facultad de Ciencias, Departamento de Biología

PhD (Plant Biology), 1992, Washington University, St. Louis, MO, "Topological signals for sorting the conglycinin to seed protein bodies of soybean (*Glycine max*) using yeast as heterologous model system"

□ subuni

Shlomo Sela, PhD (1988-1991) - Washington University

Scientist, Food Science Agricultural Research Organization, Israeli Ministry of Agriculture, Jerusalem, Israel

PhD (Microbiology), 1986, Hebrew University, "Classification of *Eubacteria* at the Level of Genus/Family, Using Highly Conserved Genes"

Xiaoying Shen, PhD (2003-2004) – Washington University

Medical Instructor, Department of Medicine, Duke University, Durham, NC

PhD (Comparative Pathology), 2004, University of California, School of Veterinary Medicine, Davis, CA, "Evaluation of an FIV live-attenuated proviral DNA vaccine in newborn kittens"

Huoying Shi, PhD (2007-2010) - Arizona State University

Professor, College of Veterinary Medicine, Yangzhou University, P.R. China

PhD, 2005, College of Veterinary Medicine, Yangzhou University, P.R. China, "Molecular basis for spread of influenza A virus by reverse genetics"

Zhaoxing Shi, PhD (2005-2008) – Arizona State University

PhD (Genetics), 2002, Beijing Institute of Biotechnology, Beijing, P.R. China, "Interaction between HeLa cell and *Shigella flexneri* 2a"

Maria L. Smorawska, PhD (1977-1979) - University of Alabama at Birmingham
 Research Associate, Department of Microbiology, University of Warsaw, Poland
 PhD (Microbiology), 1976, University of Warsaw

Grace S. Spatafora, PhD (1988-1991) - Washington University
 Irene Heinz and John Laporte Given Professor in the Pre-medical Science, Department of Biology, Middlebury College, Middlebury, VT
 PhD, 1988, St. Louis University, "Characterization and Expression of Tubulin Genes During the Dimorphic Transitions of the Pathogenic Fungus, *Histoplasma capsulatum*"

Jay Srinivasan, PhD (1991-1996) - Washington University
 PhD (Life Sciences), 1991, Jawaharlal Nehru University, New Delhi, India, "Construction and Development of a Vaccinia Based Recombinant Antifertility Vaccine"

Christos Stathopoulos, PhD (1996-2000) - Washington University
 Associate Professor of Microbiology, Biological Sciences Department, California State Polytechnic University, Pomona, CA
 PhD (Biology & Microbiology), 1995, The University of Texas at Austin, "Export, topology, and biotechnological applications of *Escherichia coli* outer membrane proteins". 2001, University of Houston, Department of Biology and Biochemistry, Houston Science Center.

Sidney H. Stein, DMD, MS, PhD (1986-1987) - Washington University
 Chair, Associate Professor, Undergraduate Clinic Director, College of Dentistry, Periodontology, The University of Tennessee Health Science Center, Memphis, TN
 DMD, 1983, Washington University School of Dental Medicine

Gerald J. Stine, PhD (1963-1966) - Oak Ridge National Laboratory
 Park University of North Florida, Jacksonville, FL
 PhD (Biology), 1965, University of Delaware

Jin-Wu Sun, (1989-1997) - Washington University
 Genome Systems, St. Louis, MO
 BS/MS Biochemistry, Beijing University, Beijing, China

Wei Sun, PhD (2006-2010) - Arizona State University
 Assistant Research Professor, Biodesign Institute, Arizona State University
 PhD (Microbiology and Biochemical Pharmacy), 2004, Shanghai Institute of Pharmaceutical Industry, Shanghai, P.R. China, "Screening (-lactamase inhibitor with yeast two-hybrid system"

Rupinder Tewari, PhD (1989-1991) - Washington University
 Professor, Center for Microbial Biotechnology, Panjab University, Chandigarh, India
 PhD (Microbiology), 1986, London University, "Role of Colicin V Plasmids in the Virulence of *E. coli*"

Ascención Torres-Escobar, PhD (2004-2005; 2006-2007) – Washington University and Arizona State University
 Postdoctoral Scholar, University of Louisville, Louisville, KY
 PhD (Biomedical Basic Research), 2001, Universidad Nacional Autónoma de México, Mexico City, Mexico, "Molecular characterization of the gene coding the 38 kDa and the *Mycobacterium tuberculosis* regulon *pho* in *Mycobacterium smegmatis*"

Krishnan Thankavel, PhD (1993-1994) - Washington University
 Depts. of Microbiology and Pathology, Duke University Medical Center, Durham, NC
 PhD (Biochemistry), 1989, Annamalai University, India, "Larval development, yolk utilization and effect of starvation on the larval development of the estuarine crab *Thalamita crenata*"

Jelle Thole, PhD (1988-1989) - Washington University

Wageningen University and Research Centre, Animal Sciences Group, Lelystad, Netherlands
 PhD (Medicine), 1988, Amsterdam University, "A Major Immunogenic Mycobacterial Antigen: Its Molecular Characterization and its Implication in Adjuvant Arthritis"

Caihong Wang, DVM, PhD (2003-2004) - Washington University
 Staff Scientist, Department of Obstetrics and Gynecology, Washington University, St. Louis, MO
 PhD (Veterinary Pathology and Immunology), 1998, China Agricultural University, P.R. China – "Immune responses of head-associated lymphoid tissue to eye application of Newcastle disease vaccine in chicken."

Shifeng Wang, PhD (2003-2007) - Washington University and Arizona State University
 Assistant Research Professor, Biodesign Institute, Arizona State University, Tempe, AZ
 PhD (Microbiology and Immunology), 2003, Chinese Academy of Preventive Medicine, Beijing, P.R. China, "Characters of codon usage in viruses and its effect on gene expression"

Mary Wilmes-Riesenberg PhD (1991-1998) - Washington University
 Lead Business Analyst, bioMerieux, St. Louis, MO
 PhD 1991, Purdue University, West Lafayette, IN, "Investigating the Regulation of Bacterial Alkaline Phosphatase (BAP) synthesis in *phoR* mutants of *Escherichia coli*"

Wei Xin, PhD (2005-2009) - Arizona State University
 Assistant Research Scientist, School for Engineering of Matter, Transport and Energy, Arizona State University
 PhD (Microbiology and Immunology), 2004, National Institute for Viral Disease Control and Prevention, Beijing, P.R. China – "Expression of multi-antigen of HIV Botswana strain in vaccinia virus and immunogenicity study of HIV early-express protein in mice"

Bereket Zekarias, DVM, PhD (2004-2008) - Washington University and Arizona State University
 Project Leader Bacterial Vaccines, CEVA Biomune, Shawnee Mission, KS
 PhD (Animal Pathology), 2003, Utrecht University, Utrecht, The Netherlands, "Pathogenic factors in susceptibility differences to malabsorption syndrome and amyloid arthropathy in chickens"
 DVM (Veterinary Medicine), 1995, Addis Ababa University

Xiangmin Zhang, PhD (2006-2010) - Arizona State University
 PhD (Microbiology and Immunology), 2005, National Institute for Viral Disease Control and Prevention, Beijing, P.R. China, "The study of effect of codon bias on the gene expression efficiency in vaccinia virus vector"

Current Postdoctoral Scholars:

Stephen J. Forbes, PhD (2011-Present) - Arizona State University
 PhD (Biomedical Sciences), 2009, University at Albany, SUNY, Albany, NY, "Effect of Anti-Lipopolysaccharide IgA Antibodies on the Virulence and Physiology of *Salmonella enterica* and *Shigella flexneri*"

GRADUATE STUDENTS

Current Students

Rebecca Allen, Arizona State University, PhD Student
 Matthew Bellefleur, Arizona State University, PhD Student

Former Students

Raul Barletta, Professor, School of Veterinary Medicine and Biomedical Sciences, University of Nebraska, Lincoln, NE
 PhD, 1987 - University of Alabama at Birmingham - "Biochemistry, Genetics, and Role in Virulence of Glucosyltransferase A from *Streptococcus mutans*"

Claire M. Berg (Deceased) Formerly, Professor of Genetics, University of Connecticut, Storrs, CT
 PhD 1966, Columbia University, "Replication and Genetic Exchange in the Genome of *Escherichia coli* K-12"
 Research conducted in the Biology Division, Oak Ridge National Laboratory, Oak Ridge, TN

- Guy A. Cardineau, Director and Professor, Centro de Agrobiotecnología, Tec de Monterrey, Monterrey, Mexico
PhD, 1986, University of Alabama at Birmingham, "Characterization of the *Streptococcus mutans* Gene for Aspartate
□- semialdehyde Dehydrogenase: Identification of Sequences Involved in Gene Expression and Their Use in Vector
Construction"
- Raymond G. Fenwick, Jr., Formerly Associate Professor of Biochemistry, Dalhousie University, Halifax, Nova Scotia,
Canada
PhD, 1973, The University of Tennessee, "Conjugal DNA Replication by *Escherichia coli* K-12"
- Lingyu Guan, PhD 2012, East China University of Science and Technology, Shanghai, P.R. China
Co-Cultivation Doctoral Program, 2010-2012
- William R. Jacobs, Jr., Professor, Department of Microbiology and Immunology; Professor, Department of Molecular
Genetics, and Investigator, Howard Hughes Medical Institute, Albert Einstein College of Medicine, New York
PhD, 1985, University of Alabama at Birmingham, "Construction and Analyses of Genomic Libraries of
Mycobacterium leprae DNA"
- Randall T. Jones (Deceased)
PhD, 1969, The University of Tennessee, "Genetics of Bacteria in vivo as Related to Microbial Ecology"
Research conducted in the Biology Division, Oak Ridge National Laboratory, Oak Ridge, TN
- Hank A. Lockman, Principal Research Scientist, Battelle Memorial Institute Research, Columbus, OH
PhD, 1991, Washington University, "Motility and Adherence as *Salmonella typhimurium* Virulence Factors: The
Pathogenesis of *fla*, *mot*, and *fim* mutants in murine typhoid fever"
- Larry J. Maturin, Supervisory Microbiologist, Center for Food Safety and Applied Nutrition, Summit-Argo, IL
PhD, 1979, University of Alabama at Birmingham, "Role of RNA Synthesis in Conjugational Transfer of Chromosomal
and Plasmid DNA"
- Anthony T. Maurelli, Professor, Department of Microbiology, Uniformed Services University of the Health Sciences,
Bethesda, MD
PhD, 1983, University of Alabama at Birmingham, "Studies on the Genetics of Pathogenicity of *Shigella flexneri* 2a"
- Dennis A. Pereira, (Deceased) Formerly, Principal Research Investigator/Applied Biotechnology, Pfizer Research Center,
Groton, CT
PhD, 1979, University of Alabama at Birmingham, "Construction of Safer *Escherichia coli* for Use in Recombinant
DNA Experimentation"
- Stephen R. Petteway, Jr., Executive Vice President, Research and Development, Talecris Biotherapeutics, Clayton, NC
PhD, 1981, University of Alabama at Birmingham, "Cloning and Characterization of Procollagen cDNA"
- David L. Provence, Patent Attorney, Muetting & Raasch, Minneapolis, MN
PhD, 1994, Washington University, "Environmental Control, Genetic Basis, and Post-Translational Processing of a
Hemagglutinin Expressed by Avian Pathogenic *Escherichia coli*"
- James P. Robeson, Professor, Instituto de Biología, Universidad Católica de Valparaíso, Valparaíso, Chile
PhD, 1981, University of Alabama at Birmingham, "Expression of a *Streptococcus mutans* Glucosyltransferase in
Escherichia coli K-12"
- Kenneth J. Roozen, Formerly, Executive Director of the Medical University of South Carolina, Foundation for Research
Development
PhD, 1971, The University of Tennessee, "Studies Using Plasmid-Containing Minicells of *Escherichia coli* K-12"
- Javier Santander-Morales, Director, Nucleus for Interdisciplinary Biotechnology; Assistant Professor, Universidad Mayor,
Mayor, Chile
PhD, 2012, Arizona State University, "Evolutionary conserved genes of *Edwardsiella ictaluri* towards the
development of a live attenuated recombinant vaccine for the aquaculture industry"

Shihuan Shao

MSc, 2012, Arizona State University, "Effects of Cyclic Adenosine Monophosphate Independent Cyclic Adenosine Monophosphate Receptor Protein in Recombinant Attenuated *Salmonella* Vaccines"

Ronald J. Sheehy, Formerly, Assistant Vice President for Academic Affairs, Morehouse College, Atlanta, GA

PhD, 1972, The University of Tennessee, "Molecular Studies on *Escherichia coli* and *Salmonella typhimurium* Minicells"

Zhao Yang, PhD 2011, East China University of Science and Technology, Shanghai, P.R. China

Co-Cultivation Doctoral Program, 2008-2010

RESEARCH AND TRAINING SUPPORT

PAST SUPPORT - UNIVERSITY OF ALABAMA AT BIRMINGHAM (Only Direct Costs Listed):

NIH/NIDR DE02670 - Institute of Dental Research

Subproject: Extrachromosomal Elements in Streptococci

01	Jun. 1, 1972-May 31, 1973	\$25,000
02	Jun. 1, 1973-May 31, 1974	39,956
03	Jun. 1, 1974-May 31, 1975	36,331
04	Jun. 1, 1975-May 31, 1976	46,496
05	Jun. 1, 1976-May 31, 1977	53,849
06	Jun. 1, 1977-Mar. 29, 1978	44,969

Subproject: Genetic and Biochemical Bases for *S. mutans* Virulence

07	Mar. 30, 1978-Feb. 28, 1979	\$89,192
08	Mar. 1, 1979-Feb. 28, 1980	91,230
09	Mar. 1, 1980-Feb. 28, 1981	91,720
10	Mar. 1, 1981-Feb. 28, 1982	84,593
11	Mar. 1, 1982-Feb. 28, 1983	76,853
12	Mar. 1, 1983-Aug. 31, 1983	26,306

NSF GB-37546 - Mechanisms of Genetic Recombination in *Escherichia coli*

Mar. 15, 1973-Aug. 31, 1975	\$75,000
Jun. 1, 1975-Nov. 30, 1977	80,000

NSF GMS-73-06837 - Transmission of Genetic Information in *E. coli*

Jan. 15, 1978-Jun. 30, 1980	\$82,000
-----------------------------	----------

Merck & Co., Inc. #Q-0141 -Population Shifts in the Microbial Flora of the Oral Cavity as Affected by Alexidine

May 15, 1973-Dec. 15, 1973	\$26,921
----------------------------	----------

NIH/NIAID R01 AI11456 - Extrachromosomal Elements in Gram-negative Bacteria

01	Jun. 22, 1973-Apr. 30, 1974	\$27,195
01S	May 1, 1974-Oct. 31, 1974	3,000
02	May 1, 1974-Apr. 30, 1975	22,208
03	May 1, 1975-Apr. 30, 1976	23,318
04	May 1, 1976-Apr. 30, 1977	53,500
05	May 1, 1977-Apr. 30, 1978	40,900
06	May 1, 1978-Apr. 30, 1979	43,492
07	May 1, 1979-Apr. 30, 1980	46,291
08	May 1, 1980-Apr. 30, 1981	49,314

NIH/NIGMS T32 GM 07090 - Molecular, Cellular, and Medical Genetics

01	Jul. 1, 1975-Jun. 30, 1976	\$50,833
02	Jul. 1, 1976-Jun. 30, 1977	53,930
03	Jul. 1, 1977-Jun. 30, 1978	55,105
04	Jul. 1, 1978-Jun. 30, 1979	55,861

05	Jul. 1, 1979-Jun. 30, 1980	56,729
06	Jul. 1, 1980-Jun. 30, 1981	80,552
07	Jul. 1, 1981-Jun. 30, 1982	84,552
08	Jul. 1, 1982-Jun. 30, 1983	74,552
09	Jul. 1, 1983-Jun. 30, 1984	57,405
10	Jul. 1, 1984-Jun. 30, 1985	105,690

NIH/NIGMS T32 GM 07164 - Predoctoral Training in Molecular Cell Biology

01	Jul. 1, 1975-Jun. 30, 1976	\$63,781
02	Jul. 1, 1976-Jun. 30, 1977	59,945
03	Jul. 1, 1977-Jun. 30, 1978	82,190
04	Jul. 1, 1978-Jun. 30, 1979	86,026
05	Jul. 1, 1979-Jun. 30, 1980	86,026

NIH/NIAID N01 AI62508 - Construction of Safer *E. coli* Hosts for Phage and Plasmid Vectors

	Jun. 1, 1976-Dec. 29, 1977	\$178,124
	Dec. 30, 1977-Dec. 29, 1978	129,754

NIH/NIDR N01 DE62491 - Use of Mutants of Cariogenic Streptococci to Prevent Dental Caries

01	Jun. 28, 1976-Jun. 27, 1977	\$18,635
02	Jun. 28, 1977-Jun. 27, 1978	20,399
03	Jun. 28, 1978-Jun. 27, 1979	22,127
03S	Jan. 1, 1980-Mar. 31, 1980	5,649
04	Apr. 1, 1980-Mar. 31, 1981	40,681
05	Apr. 1, 1981-Mar. 31, 1982	32,735

NIH/NIAID T32 AI07041 - Infectious Diseases and Basic Microbiology Training

01	Jul. 1, 1976-Jun. 30, 1977	\$51,233
02	Jul. 1, 1977-Jun. 30, 1978	101,095
03	Jul. 1, 1978-Jun. 30, 1979	101,095
04	Jul. 1, 1979-Jun. 30, 1980	101,095
05	Jul. 1, 1980-Jun. 30, 1981	127,526
06	Jul. 1, 1982-Jun. 30, 1983	98,514
07	Jul. 1, 1983-Jun. 30, 1984	112,659
08	Jul. 1, 1984-Jun. 30, 1985	113,919
09	Jul. 1, 1985-Jun. 30, 1986	115,304
10	Jul. 1, 1986-Jun. 30, 1987	116,828

Damien Foundation - Genetic Analysis of *Mycobacterium leprae*

	Jun. 1, 1979-May 31, 1980	\$41,200
--	---------------------------	----------

WHO ID #790 403 - Genetic Analysis of *Mycobacterium leprae*

	Jun. 1, 1980-Jun. 30, 1981	\$54,400
	Jun. 1, 1981-May 31, 1982	76,000

WHO ID #790 403 - Genetic Analysis of *Mycobacterium leprae*

	Jul. 1, 1982-Jun. 30, 1983	\$73,700
--	----------------------------	----------

NIH/NIDR R01 DE06432 - Use of Mutants to Study *S. mutans* Pathogenicity

01	Aug. 1, 1982-Jul. 31, 1983	\$143,616
----	----------------------------	-----------

Cystic Fibrosis Foundation - Cystic Fibrosis Research Development Grant for CF Research Center

01	Oct. 1, 1982-Sep. 30, 1983	\$300,000
02	Oct. 1, 1983-Sep. 30, 1984	300,000
03	Oct. 1, 1984-Sep. 30, 1985	300,000
04	Oct. 1, 1985-Sep. 30, 1986	300,000
05	Oct. 1, 1986-Sep. 30, 1987	300,000

PAST SUPPORT - WASHINGTON UNIVERSITY (Only Direct Costs Listed):NIH R37 DE06673 - Genetic and Biochemical Bases for *S. mutans* Virulence

01	Aug. 1, 1983-Jul. 31, 1984	\$97,279
02	Aug. 1, 1984-Jul. 31, 1985	103,840
03	Aug. 1, 1985-Jul. 31, 1986	111,274
04	Aug. 1, 1986-Jul. 31, 1987	109,226
05	Aug. 1, 1987-Jul. 31, 1988	126,911
06	Aug. 1, 1988-Jul. 31, 1989	138,203
07	Aug. 1, 1989-Jul. 31, 1990	119,556
08	Aug. 1, 1990-Jul. 31, 1991	117,321
09	Aug. 1, 1991-Jul. 31, 1992	121,179
10	Aug. 1, 1992-Jul. 31, 1993	125,922
11	Aug. 1, 1993-Jul. 31, 1994	134,000
12	Aug. 1, 1994-Jul. 31, 1995	146,649
13	Aug. 1, 1995-Jul. 31, 1996	143,338
14	Aug. 1, 1996-Jul. 31, 1997	148,286
15	Aug. 1, 1997-Jul. 31, 1998	153,433

WHO ID #830 249 - Genetic Analysis of *Mycobacterium leprae*

Jul. 1, 1983-Jul. 31, 1984	\$36,811
Aug. 1, 1984-Jul. 31, 1985	39,500

WHO ID #830 100 - Genetic Analysis of *Mycobacterium leprae*

Jul. 1, 1983-Jun. 30, 1984	\$36,811
Jul. 1, 1984-Jun. 30, 1985	43,289
Sep. 1, 1985-Aug. 31, 1986	20,230

Molecular Engineering Associates, Inc. - Construction of Avirulent Mutants of Gram-negative Enteric Pathogens

01	Aug. 1, 1983-Jul. 31, 1984	\$67,175
02	Aug. 1, 1984-Jul. 31, 1985	98,083
03	Nov. 1, 1985-Oct. 31, 1986	88,733
04	Nov. 1, 1986-Aug. 31, 1987	34,841

NIH R01 DE06801 - Use of Mutants to Study *S. mutans* Pathogenicity

01	Aug. 1, 1983-Jul. 31, 1984	\$140,803
02	Aug. 1, 1984-Jul. 31, 1985	147,056
03	Aug. 1, 1985-Jul. 31, 1986	159,100
04	Aug. 1, 1986-Jul. 31, 1987	141,159
05	Aug. 1, 1987-Jul. 31, 1988	147,725
06	Aug. 1, 1988-Jul. 31, 1989	153,704
07	Aug. 1, 1989-Jul. 31, 1990	155,528

Procter and Gamble - Enhancement of the Secretory Immune System

01	Apr. 1, 1984-Mar. 31, 1985	\$89,903
02	Apr. 1, 1985-Mar. 31, 1986	65,555
03	Apr. 1, 1986-Mar. 31, 1987	67,319
04	Apr. 1, 1987-Mar. 31, 1988	70,733
05	Apr. 1, 1988-Mar. 31, 1989	78,769

NSF PCM 83-16440 - Spectrophotometer Facility for Genetic Research

01	Aug. 1, 1984-Jul. 31, 1985	\$32,000
----	----------------------------	----------

NIH R01 AI21548 - Protective Immunity to Pneumococcal Surface Proteins
(subcontract from UAB; Co-PI with David Briles)

01	Aug. 1, 1984-Jul. 31, 1985	\$32,065
02	Aug. 1, 1985-Jul. 31, 1986	35,945
03	Aug. 1, 1986-Jul. 31, 1987	33,307

NIH S10 RR 02424 - Fermentation Equipment		
01	Dec. 1, 1984-Nov. 30, 1986	\$87,065
USDA 86-CRSR-2-2854 - Genetic Analysis of Virulence of Avian Respiratory Bacterial Pathogens		
	Sep. 1, 1986-Aug. 31, 1987	\$30,810
	Sep. 1, 1987-Aug. 31, 1988	28,793
Sungene Technologies - Plant Biotechnology Collaborative Research		
01	Feb. 16, 1987-Feb. 15, 1988	\$35,762
02	Feb. 16, 1988-Feb. 15, 1989	33,962
03	Feb. 16, 1989-Aug. 15, 1989	18,801
NIH R22 AI26186 - Induction of Immunity to <i>Mycobacterium leprae</i> (Co-PI)		
01	Apr. 1, 1988-Mar. 31, 1989	\$83,444
02	Apr. 1, 1989-Mar. 31, 1990	74,508
03	Apr. 1, 1990-Mar. 31, 1991	88,898
NIH S10 RR04117-01 - Instrumentation for An Integrated DNA Chemistry Facility		
01	Apr. 11, 1988-Apr. 10, 1991	\$147,000
Markey Center Support for an Integrated DNA Chemistry Core Facility		
	Jun. 1, 1988-May 31, 1990	\$25,000
NSF BSR-8817467 - Workshop on Computerization of Data Bases for Genetic Stock Collections; Toronto, Canada		
01	Aug. 1, 1988-Jan. 31, 1989	\$15,169
NSF DIR-8714254 - Facilities Center for Resource Biotechnology		
01	Aug. 15, 1988-Jan. 31, 1991	\$460,000
USDA 88-34116-3792 - <i>Salmonella</i> Infection, Persistence and Prevention		
	Sep. 1, 1988-Aug. 31, 1989	\$24,587
	Sep. 1, 1989-Aug. 31, 1990	25,571
Center for Plant Science and Biotechnology - Genetically Modified Plants for Use as Oral Immunogens		
	Jan. 1, 1989-Jun. 30, 1989	\$14,306
	Jul. 1, 1989-Jun. 30, 1990	28,110
	Jul. 1, 1990-Jun. 30, 1991	28,400
	Jul. 1, 1991-Jun. 30, 1992	42,201
	Jul. 1, 1992-Jun. 30, 1993	33,592
	Jul. 1, 1993-Jun. 30, 1994	57,007
Agrigenetics - Plant Biotechnology Collaborative Research		
01	Aug. 16, 1989-Feb. 15, 1990	\$18,801
02	Feb. 16, 1990-Feb. 15, 1991	40,884
CONRAD CSA-90-071 - Development of Recombinant Avirulent <i>Salmonella</i> Antifertility Vaccines		
01	Feb. 1, 1990-Jan. 31, 1991	\$13,636
02	Feb. 1, 1991-Jan. 31, 1992	85,150
03	Feb. 1, 1992-Jan. 31, 1993	90,258
CONRAD CSA-94-129 - Development of Recombinant Avirulent <i>Salmonella</i> Antifertility Vaccines		
01	Dec. 1, 1993-Nov. 30, 1994	\$89,619
02	Dec. 1, 1994-Feb. 29, 1996	96,288
NIH R01 AI28487 - Genetic Analysis of <i>Bordetella avium</i> Virulence		
01	Apr. 1, 1990-Mar. 31, 1991	\$117,172
02	Apr. 1, 1991-Mar. 31, 1992	114,299

03	Apr. 1, 1992-Mar. 31, 1993	118,870
04	Apr. 1, 1993-Mar. 31, 1994	123,625
NIH 1S15 GM45467 - Small Instrumentation Grant		
01	Jun. 1, 1990-May 31, 1991	\$39,729
USDA GAM 9001702 - Analysis of <i>Salmonella enteritidis</i> Virulence in Chickens		
	Sep. 1, 1990-Aug. 31, 1991	\$77,936
	Sep. 1, 1991-Aug. 31, 1992	82,064
	Sep. 1, 1992-Aug. 31, 1993	91,617
	Sep. 1, 1993-Aug. 31, 1994	101,366
Bristol-Myers Squibb - Infectious Disease Research		
01	Apr. 1, 1991-Mar. 31, 1992	\$100,000
02	Apr. 1, 1992-Mar. 31, 1993	\$100,000
03	Apr. 1, 1993-Mar. 31, 1994	\$100,000
04	Apr. 1, 1994-Mar. 31, 1995	\$100,000
05	Apr. 1, 1995-Mar. 31, 1996	\$100,000
USDA 9102452 - Molecular Genetic Analysis of <i>Salmonella choleraesuis</i> Pathogenesis		
	Sep. 1, 1991-Aug. 31, 1992	\$77,150
	Sep. 1, 1992-Aug. 31, 1993	81,779
	Sep. 1, 1993-Aug. 31, 1994	86,685
NIH U54 HD29099 - Avirulent <i>Salmonella</i> SP10 Vaccine for Secretary Immunity		
01	Sep. 30, 1991-Sep. 29, 1992	\$ 72,899
02	Sep. 30, 1992-Sep. 29, 1993	73,784
NIH U54 HD29099 - Oral Recombinant <i>Salmonella</i> Antifertility Vaccines Core		
03	Sep. 1, 1993-Aug. 31, 1994	\$119,673
04	Sep. 1, 1994-Aug. 31, 1995	119,673
05	Sep. 1, 1995-Aug. 31, 1996	66,956
05A	Sep. 1, 1996-Feb. 28, 1997	47,256
Rockefeller Foundation Biotechnology Career Fellowship - Construction of a Recombinant Vaccine Strain of <i>Salmonella</i> Expressing Immunogenic and Protective Surface Antigen		
	May 1, 1994-Apr. 30, 1997	\$59,900
NSF BIR-9317842 - Instrumentation for Computer-Based Detection and Imaging of Biological Samples		
	May 1, 1994-Oct. 31, 1996	\$56,673
USDA 94-02102-1091 - Genetic Analysis of Avian <i>E. coli</i> Virulence		
	Sep. 1, 1994-Aug. 31, 1995	\$51,348
	Sep. 1, 1995-Mar. 31, 1997	53,915
	Sep. 15, 1997-Sep. 30, 1998	73,960
	Oct. 1, 1998-Sep. 30, 1999	77,400
	Oct. 1, 1999-Sep. 30, 2000	80,840
NIH R41 AI36585 - Avirulent <i>Salmonella</i> Host-Vector Human Vaccine Systems		
01	Sep. 1, 1994-Nov. 30, 1995	\$ 76,779
02	May 1, 1997-Apr. 30, 1998	247,014
03	May 1, 1998-Apr. 30, 1999	250,952
USDA 97-35204-4512 - Genetic Analysis of Avian <i>E. coli</i> Virulence		
04	Sep. 15, 1997-Sep. 30, 1998	\$73,960
05	Oct. 1, 1998-Sep. 30, 1999	77,400
06	Oct. 1, 1999-Sep. 30, 2000	80,840

VION Pharmaceuticals, Inc. - Collaborative Research Endeavor

	Jul. 1, 1997-Jun. 30, 1998	\$50,000
--	----------------------------	----------

USDA 97-02552 - Adhesins for Colonization of Chickens & Their Use in Prevention of Salmonellosis

01	Oct. 1, 1997-Sep. 30, 1998	\$43,000
02	Oct. 1, 1998-Sep. 30, 1999	44,720
03	Oct. 1, 1999-Sep. 30, 2000	46,400

STTR IR41-AI38599 - Biological Containment of Live Bacterial Vaccines

01	Sep. 1, 1995-Aug. 31, 1996	\$ 68,838
02	Sep. 15, 1999-Aug. 31, 2000	146,064
03	Sep. 1, 2000-Aug. 31, 2001	147,617

USDA 99-35204-8572 - Attenuated *Salmonella* Antigen and DNA Vaccine Delivery Vaccines Against *Eimeria*

	Sep. 1, 1999-Aug. 31, 2000	\$76,611
	Sep. 1, 2000-Aug. 31, 2002	91,062

USDA 00-35204-9224 – Genetic Analysis of Avian *E. coli* Virulence

07	Sep. 1, 2000-Aug. 31, 2001	\$73,056
08	Sep. 1, 2001-Aug. 31, 2002	76,100
09	Sep. 1, 2002-Aug. 31, 2003	79,144

USDA 2001-02994 – Induction of Cross Protective Immunity to *Salmonella* in Chickens

01	Oct. 1, 2001-Sep. 30, 2002	\$79,326
02	Oct. 1, 2002-Sep. 30, 2003	82,790
03	Oct. 1, 2003-Jun. 15, 2004	

NIH R01 DE06669 - Antigen Delivery System Design for Host Defense Analysis

01	Apr. 1, 1983-Mar. 31, 1984	\$189,524
02	Apr. 1, 1984-Mar. 31, 1985	160,545
03	Apr. 1, 1985-Mar. 31, 1986	203,903
04	Apr. 1, 1986-Mar. 31, 1988	210,309
05	Apr. 1, 1988-Mar. 31, 1989	117,048
06	Apr. 1, 1989-Mar. 31, 1990	105,248
07	Apr. 1, 1990-Mar. 31, 1991	104,004
08	Mar. 1, 1992-Feb. 28, 1993	140,000
09	Mar. 1, 1993-Feb. 28, 1994	135,281
10	Mar. 1, 1994-Feb. 28, 1995	141,237
11	Mar. 1, 1995-Feb. 29, 1996	146,885
12	Mar. 1, 1996-Feb. 28, 1997	152,724
13	May 1, 2000-Apr. 30, 2001	212,500
14	May 1, 2001-Apr. 30, 2002	212,500
15	May 1, 2002-Apr. 30, 2003	212,500
16	May 1, 2003-Apr. 30, 2004	212,500
17	May 1, 2004-Apr. 30, 2005	212,500

PAST SUPPORT—WASHINGTON UNIVERSITY AND ARIZONA STATE UNIVERSITY (Only Direct Costs Listed)USDA 03-35204-13748 - Attenuated *Salmonella* Antigen and DNA Vaccine Delivery Vaccines Against *Eimeria*

	Aug. 1, 2003-Jul. 31, 2006	\$218,800
--	----------------------------	-----------

NIH R01 AI24533 - Molecular Genetic Analysis of *Salmonella* Pathogenicity

01	Apr. 1, 1987-Mar. 31, 1988	\$74,189
02	Apr. 1, 1988-Mar. 31, 1989	65,526
03	Apr. 1, 1989-Mar. 31, 1990	65,865
04	Apr. 1, 1990-Mar. 31, 1991	181,148
05	Apr. 1, 1991-Mar. 31, 1992	191,531
06	Apr. 1, 1992-Mar. 31, 1993	161,563

07	Apr. 1, 1993-Mar. 31, 1994	162,336
08	Apr. 1, 1994-Mar. 31, 1995	163,071
09	Sep. 1, 1996-Mar. 31, 1997	179,378
09	Apr. 1, 1997-Mar. 31, 1998	61,530
10	Apr. 1, 1998-Mar. 31, 1999	159,330
11	Apr. 1, 1999-Mar. 31, 2000	164,110
12	Apr. 1, 2000-Mar. 31, 2001	169,033
13	Jun. 15, 2002-May 31, 2003	250,000
14	Jun. 1, 2003-May 31, 2004	225,000
15	Jun. 1, 2004-May 31, 2005	225,000
16	Jun. 1, 2005-May 31, 2006	225,000
17	Jun. 1, 2006-May 31, 2007	225,000

Ellison Medical Foundation ID-SS-0520-03 – Providing an economic benefit to using a vaccine to enhance food safety and to reduce antibiotic use in agriculture

01	Sept. 1, 2003-Oct. 31, 2004	\$149,976
02	Nov. 1, 2004-Oct. 31, 2005	149,976
03	Nov. 1, 2005-Oct. 31, 2006	149,976
04	Nov. 1, 2006-Oct. 31, 2007	149,976

AERAS Collaborative Research Proposal

01	Feb 1, 2008-Jan. 31, 2009	\$167,205
----	---------------------------	-----------

NIH R01 AI065779 – *Salmonella* Anti-Influenza DNA and Antigen Delivery Vaccine

01	Aug. 16, 2005-Jan. 31, 2006	\$201,616
02	Feb. 1, 2006-Jan. 31, 2007	486,055
03	Feb. 1, 2007-Jan. 31, 2008	494,119
04	Feb. 1, 2008-Jan. 31, 2009	467,762
05	Feb. 1, 2008-Jan. 31, 2010	no-cost extension

USDA 2007-35201-18519

Food Safety Vaccine of Economic Benefit to Poultry Producers to Prevent *Salmonella* and APEC Infections and Foodborne Transmission to Humans

01	Aug. 15, 2007-Aug. 14, 2008	\$103,248
02	Aug. 15, 2008-Aug. 14, 2009	106,612
03	Aug. 15, 2009-Aug. 14, 2010	110,090
04	Aug. 15, 2010-Aug. 14, 2011	no-cost extension

US Department of Energy ARPA-E – Cyanobacteria designed for solar-powered highly efficient production of biofuels (Willem Vermaas, PI; Roy Curtiss, Co-PI)

01	Jan. 1, 2010-Dec. 31, 2010	\$418,909
02	Jan. 1, 2011-Dec. 31, 2011	411,353

Bill and Melinda Gates Fdn 37863 – A Live Recombinant Attenuated *Salmonella* Anti-Pneumococcal Vaccine for Newborns

01	Jul. 1, 2005-Jun. 30, 2006	\$1,108,518
02	Jul. 1, 2006-Jun. 30, 2007	1,347,594
03	Jul. 1, 2007-Jun. 30, 2008	2,740,951
04	Jul. 1, 2008-Jun. 30, 2009	4,341,943
05	Jul. 1, 2009-Jun. 30, 2010	3,294,722
06	Jul. 1, 2010-Jun. 30, 2011	no-cost extension
07	Jul. 1, 2011-July 31, 2012	no-cost extension

Bill and Melinda Gates Fdn Supplemental Funding – A Live Recombinant Attenuated *Salmonella* Anti-Pneumococcal Vaccine for Newborns

	Jul. 25, 2007-Jun. 30, 2010	\$630,706
	Jul. 1, 2010-July 31, 2012	no-cost extension

NIH R21 CA152456 - Engineered Self-destructing *Salmonella* as a Colorectal Cancer Cure
(Wei Kong, PI; Roy Curtiss, Co-Investigator)

01	Jun. 1, 2010-May 31, 2011	\$108,750
02	Jun. 1, 2011-May 31, 2012	126,585
03	Jun. 1, 2012-May 31, 2013	no-cost extension

USDA 2009-65119-05703 – Bath/Oral Live Recombinant *Edwardsiella* Vaccine for the Aquaculture Industry

01	Sept. 1, 2009-Aug. 31, 2010	\$105,733
02	Sept 1, 2010-Aug. 31, 2011	98,121
03	Sept 1, 2011-Aug. 31, 2012	101,064
04	Sept 1, 2012-Aug. 31, 2013	no-cost extension

NSF 0965511- BREAD- Investigation of Attenuation Strategies to Enable Development of a Live Fowl Typhoid Vaccine
(Kenneth Roland, PI; Roy Curtiss, Co-Investigator)

01	Apr. 15, 2010-Mar. 31, 2011	\$139,417
02	Apr. 1, 2011-Mar. 31, 2012	133,401
03	Apr. 1, 2012-Mar. 31, 2013	147,104
04	Apr. 1, 2013-Mar. 31, 2014	no-cost extension

CURRENT SUPPORT - ARIZONA STATE UNIVERSITY (Only Direct Costs Listed):

NIH R01 AI056289 – Recombinant Attenuated *Salmonella* Vaccines for Humans

01	Jul. 1, 2003-Dec. 31, 2003	\$149,337
02	Jan. 1, 2004-Dec. 31, 2004	250,000
03	Jan. 1, 2005-Dec. 31, 2005	250,000
04	Jan. 1, 2006-Dec. 31, 2006	250,000
05	Jan. 1, 2007-Dec. 31, 2007	250,000
06	Jan. 1, 2007-Dec. 31, 2007	250,000
07	Jun. 1, 2008-May 31, 2009	250,000
08	Jun. 1, 2009-May 31, 2010	250,000
09	Jun. 1, 2010-May 31, 2011	250,000
10	Jun. 1, 2011-May 31, 2012	245,025
11	Jun. 1, 2012-May 31, 2013	245,025
	Jun. 1, 2013-May 31, 2014	no-cost extension
12	Jun. 15, 2014-May 31, 2015	294,031

NIH R01 AI60557 - *S. typhimurium* Vaccine Against Bacterial Enteropathogens

01	Sept. 30, 2003-March 31, 2004	\$152,254
02	April 1, 2004-Mar. 31, 2005	200,918
03	April 1, 2005-Mar. 31, 2006	206,327
04	April 1, 2006-Mar. 31, 2007	211,898
05	April 1, 2007-Mar. 31, 2008	217,636
06	April 1, 2008-Mar. 31, 2009	no-cost extension
07	Feb. 4, 2010-Jan. 31, 2011	340,055
08	Feb. 1, 2011-Jan. 31, 2012	286,743
09	Feb. 1, 2012-Jan. 31, 2013	292,454
10	Feb. 1, 2013-Jan. 31, 2014	298,315
11	Feb. 1, 2014-Jan. 31, 2015	304,262
12	Feb. 1, 2015-Jan. 31, 2016	no-cost extension

NIH R01 AI057885 – Attenuated Live and Recombinant *Yersinia pestis* Vaccines

01	Jan. 1, 2004-Dec. 31, 2004	\$437,263
02	Jan. 1, 2005-Dec. 31, 2005	398,601
03	Jan. 1, 2006-Dec. 31, 2006	409,922
04	Jan. 1, 2007-Dec. 31, 2007	421,582
05	Jan. 1, 2008-Dec. 31, 2008	463,961
06	Jan. 1, 2009-Dec. 31, 2009	no-cost extension
07	Jun. 1, 2010-May 31, 2011	250,000

08	Jun. 1, 2011-May 31, 2012	250,000
09	Jun. 1, 2012-May 31, 2013	250,000
10	Jun. 1, 2013-May 31, 2014	232,650
11	Jun. 1, 2014-May 31, 2015	247,500

USDA 2011-67005-30182

Advancing the understanding of the zoonotic risk of ExPECs and evaluation of a vaccine to control these contaminants in poultry production

01	Mar. 15, 2011-Mar. 14, 2012	\$233,615
02	Mar. 15, 2012-Mar. 14, 2013	233,499
03	Mar. 15, 2012-Mar. 14, 2014	233,359
04	Mar. 15, 2014-Mar. 14, 2015	226,969
05	Mar. 15, 2015-Mar. 14, 2016	233,778

NIH R01 AI093348 – Recombinant Attenuated Bacterial Vaccines Against Biodefense Agents

01	May 1, 2011-Apr. 30, 2012	\$673,374
02	May 1, 2012-Apr. 30, 2013	672,580
03	May 1, 2013-Apr. 30, 2014	605,322
04	May 1, 2014-Apr. 30, 2015	605,322

CURRENT SUPPORT – University of Florida (Only Direct Costs Listed):

NIH R01 AI056289 – Recombinant Attenuated *Salmonella* Vaccines for Humans Co-PI; Josephine Clark-Curtiss Co-PI

13	Jun. 1, 2015-May 31, 2016	296,455
14	Jun. 1, 2016-May 31, 2017	296,455
15	Jun. 1, 2017-May 31, 2018	296,455
16	Jun. 1, 2018-May 31, 2019	296,455

NIH R01 AI093348 – Recombinant Attenuated Bacterial Vaccines Against Biodefense Agents PI

05	May 1, 2015-Apr. 30, 2016	605,322
----	---------------------------	---------